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1 INTRODUCTION 
Diabetes mellitus has reached epidemic extents worldwide (Zimmet 2017). The current global 
diabetes estimates exceeded all prior extrapolations, revealing that 463 million people were 
suffering from diabetes in 2019 with an expected increase of 25% and 51% for 2030 and 2045 
(Saeedi, Petersohn et al. 2019). The alarming prevalence shows the urgency to find new 
approaches to prevention and treatment of diabetes mellitus. Fundamental research in diabetes 
was predominantly conducted in animals especially in mice and rats (Aigner, Rathkolb et al. 
2008) but rodents have limitations in translational research. Therefore, more appropriate animal 
models for preclinical trials are needed that can mimic the human diabetic patient and are still 
feasible within limitations set by the laboratory or the project conditions. The pig is an 
auspicious large animal model for diabetes research. Unlike mice, pigs show a similar fat 
metabolism, β-cell architecture and β-cell content to humans. Moreover, their human-like size 
and physiology of their organs and their lifespan enable testing of β-cell replacement therapies 
and investigation of chronic hyperglycemia on different organs and organ crosstalk. Defined 
by their mode of disease onset, animal models can be divided in spontaneous or induced models 
(reviewed in (Brito-Casillas, Melian et al. 2016)). Recently, genetically-modified pig models 
have moved into focus, tailor-made they can resemble human disease mechanisms with great 
translational potential (Renner, Blutke et al. 2020). Existing genetically engineered diabetic pig 
models, like the INSC94Y transgenic domestic pig, have shown advantages compared to porcine 
diabetes models generated by other methods than genetic modification, i.e., pancreatectomy or 
chemical β-cell destruction. The method is non-invasive and the pigs develop a consistent overt 
diabetic phenotype, independent of other factors and lacking unintended side-effects due to diet, 
chemicals or drugs (Renner, Braun-Reichhart et al. 2013, Renner, Blutke et al. 2020).  
The aim of this study was the development and characterization of a size-reduced pig model 
expressing the well-known INSC94Y mutation to compare them to the INSC94Y transgenic 
domestic pig model. Crossbreeding of a minipig background caused the size reduction and 
enabled the use of the distinct advantages of a smaller pig strain. To optimize laboratory pig 
models they have to become as light and small as possible to facilitate daily handling, 
experimental procedures and to make them more cost-effective.  
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Nowadays, further long-scale, efficiency and safety studies are required for diabetes research 
to test new pharmacotherapies and to investigate their potential beneficial effect on pathological 
alterations in secondary organs associated with prolonged disease duration. Therefore, more 
suitable animal models are desired, combining a moderate body weight and size without lacking 
translational properties. 
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2 REVIEW OF THE LITERATURE 
2.1 Diabetes mellitus 
2.1.1 Definition, history and status quo 
Diabetes is a chronic metabolic disease of multifactorial origin (ADA 2020). Hyperglycemia, 
i.e., an increased blood glucose concentration is the hallmark of diabetes. High levels of blood 
glucose cause typical clinical symptoms as polydipsia, polyuria, and blurred vision. In severe 
cases hyperglycemia can lead to ketoacidosis or a non-ketotic hyperosmolar syndrome turning 
into a life-threatening state (IDF 2019). Diabetes can result in long-term damages in multiple 
organs due to microvascular complications like nephropathy, retinopathy and neuropathy and 
macrovascular complications including ischemic heart disease, stroke and peripheral vascular 
disease (Forouhi and Wareham 2014, IDF 2019). Undiagnosed or untreated diabetes increases 
the risk for these long-term effects and turns faster into a severe, health-threatening condition. 
Diabetes has a long history of awareness all over the world. Descriptions of symptoms and 
treatments have already been mentioned in Egyptian papyri dated back to 1500 before Christ 
(BC) (Lakhtakia 2013) as well as in ancient Chinese medical manuscripts (Karamanou, 
Protogerou et al. 2016). The Indian Surgeon Sushruta defined diabetes around 500 BC, using 
the name “Madhumeha” which means sweet urine disease, after he discovered the attraction of 
ants to the urine (Karamanou, Protogerou et al. 2016). Two hundred BC the ancient Hellenistic 
Demetrius of Apamea coined the word “diabetes” which indicates the excessive urination (Gale 
2014), a term his later colleague Aretaeus of Cappadocia used to give the first accurate 
description of the disease but falsely considered the stomach or the kidney as the underlying 
cause (Gale 2015). It took some more centuries to recognize that the sweetness derives from 
glucose and to discover the high glucose levels in the blood (inter alia, Chevreul, Dobson, 
Bernard, beginning-middle of 19th century) (Gale 2014). By the end of the same century, islets 
of Langerhans were characterized in the thesis of Paul Langerhans who underestimated the 
importance of his own discovery at that time (Gale 2015). Unintentionally, the first induced 
diabetes was described by Minkowski and von Mering after removal of the pancreas of a dog. 
In 1921 insulin was discovered by Banting et al. and soon thereafter in 1923 commercialized 
for the benefit of millions of lives (Karamanou, Protogerou et al. 2016).  
Thus, many milestones already have been set in the history of diabetes mellitus and nowadays 
various successful strategies exist to identify and treat the distinct types of this disease, based 
on results gathered from long-term studies as the Diabetes Control and Complications Trial 
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(DCCT) (Nathan, Genuth et al. 1993), United Kingdom Prospective Diabetes Study (UKPDS) 
(Turner, Holman et al. 1991) or The Environmental Determinants of Diabetes in the Young 
(TEDDY) (Krischer 2007). However, there is still no cure for diabetes available and it remains 
a worldwide problem. Whereas in the past diabetes prevalence increased parallel to improved 
living conditions and public wealth of industrial states, at present the diabetes burden increases 
most in emerging economies (Cho, Shaw et al. 2018, Saeedi, Petersohn et al. 2019). Within 
these countries the prevalence is lower in rural areas compared to urbanized areas where 
multiple ethnic groups have adopted to a less active, sedentary western lifestyle (IDF 2019, 
Saeedi, Petersohn et al. 2019). An inadequate education including unhealthy diets and 
insufficient exercise is culpable for highly increased obesity rates frequently associated with 
diabetes mellitus (Forouhi and Wareham 2014). The impact of a rising prevalence on low and 
middle-income countries is deeper than on wealthier nations with a functional healthcare. 
Patients from these affected regions have a higher risk to stay undiagnosed, fall ill earlier, have 
a more severe progression and finally die sooner (Cho, Shaw et al. 2018). Presently, Africa 
shows the highest proportion of early deaths (under 60 years of age) by far (73%), followed by 
Middle East/North Africa (53%) and South East Asia (52%) (IDF 2019). 
Currently, 463 million people are estimated suffering from diabetes worldwide (Saeedi, 
Petersohn et al. 2019). For 2045 an increase of 51% up to a total number of 700 million affected 
people is predicted (Saeedi, Petersohn et al. 2019). These numbers do still not include a further 
374 million people with impaired glucose tolerance (IGT), a condition which is thought to be a 
precursor of diabetes mellitus (Santaguida, Balion et al. 2005, Saeedi, Petersohn et al. 2019). A 
statistical estimation of the IDF on the prevalence of diabetes worldwide in 2019 (Figure 1 A) 
places the highest rates in the Western Pacific area with 35% (163 million) and South East Asia 
with 19% (88 million). In these areas, in particular China (116 million) and India (77 million) 
report an excessive number of people suffering from diabetes. In 2019 Europe made up for 13% 
(59 million) of the proportion of the global diabetic population, however with a decreasing 
global trend the prevalence for Europe in 2045 is estimated to be 10% with 68 million people 
being affected (Figure 1 B). In the next 25 years the main focus may drift to Africa and Middle 
East/North Africa trusting the current extrapolations from the IDF. In this time period the 
number of diabetic patients in these two regions may increase by 143% (47 million) and 96% 
(108 million), respectively. For 2019 globally estimated 4.2 million deaths (people aged 
between 20–79 years) and a healthcare expenditure of more than USD 845 billion were ascribed 
to diabetes (IDF 2019).  
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Figure 1: Diabetes worldwide and per region in 2019 and 2045.  
Global prevalence of diabetes in 2019 (A) and 2045 (B). Data and figures adapted from the 
International Diabetes Federation (IDF) Atlas 9th edition 2019 (IDF 2019). 
2.1.2 Classification  
The World Health Organization (WHO) has started to publish the first guidelines for a common 
nomenclature for the different types of diabetes mellitus in 1965, followed by a revision in the 
late 1970s and an update in 1997 by the American Diabetes Association (ADA). This latter 
update included the important correction in which insulin dependence is not a criterion for 
classification anymore. Nowadays three main types of diabetes mellitus, type 1 diabetes 
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mellitus (T1D), type 2 diabetes mellitus (T2D), gestational diabetes mellitus (GDM) and a 
fourth category, summarizing specific types of diabetes due to various other causes, are widely 
recognized (ADA 2020).  
2.1.2.1 Type 1 diabetes 
Type 1 diabetes (T1D) has a minor incidence of less than 10% of all diabetes cases (Roden 
2016) and occurs predominantly in young people with European descent (Gillespie 2006). T1D 
can be further divided into two subgroups, an immune-mediated form and a very rare idiopathic 
form (ADA 2020).  
A genetic susceptibility with a strong association to the human leukocyte antigen (HLA) and 
yet undefined environmental factors are related to T1D (Gillespie 2006, Rewers, Hyoty et al. 
2018). These various factors trigger the pathomechanism characterizing T1D: autoimmune 
pancreatic β-cell destruction that usually leads to an absolute insulin deficiency and finally to 
the onset of diabetes (Yoon and Jun 2005, Mujtaba, Fridell et al. 2015, Petersmann, Nauck et 
al. 2018). In most cases it is a cellular-mediated autoimmune destruction due to the presence of 
one or more types of auto-antibodies (ADA 2020).  
Due to the massive β-cell loss, insulin secretion is highly decreased. Therefore, patients with 
clinical type 1 diabetes are dependent on insulin therapy (Roden 2016). Nowadays there is still 
no cure for T1D. Clinical symptoms mostly occur when 80% of β-cell mass is lost (Gillespie 
2006). For this reasons the goal of diabetes research is to establish strategies to predict, prevent 
or reverse a manifestation of T1D.  
2.1.2.2 Type 2 diabetes 
Type 2 diabetes (T2D) is responsible for more than 90% of all diabetic cases and mostly occurs 
at an advanced age (Roden 2016, Petersmann, Nauck et al. 2018). The incidence is higher in 
some ethnical groups like African Americans, American Indians, Hispanics/Latinos and Asian 
Americans. The etiology is multifactorial. Factors as a high caloric diet, insufficient physical 
activity and a genetic predisposition foster the development of T2D. T2D is characterized by a 
combination of peripheral insulin resistance and dysfunction of β-cells (Kaneto 2015) leading 
to a relative insulin deficiency that causes hyperglycemia (Petersmann, Nauck et al. 2018). 
Before T2D manifests a condition named prediabetes is present. Prediabetes is characterized 
by blood glucose levels above the normal range but still below the thresholds diagnostic for 
diabetes and can be defined by the presence of impaired glucose tolerance (IGT) and/or 
impaired fasting glucose (IFG) and/or elevated glycosylated hemoglobin (HbA1c) (ADA 2020). 
The manifestation of T2D is gradual (Petersmann, Nauck et al. 2018) and functional impairment 
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exists long before first clinical signs are present (Roden 2016). Plasma insulin and C-peptide 
levels can be elevated at an earlier stage due to insulin resistance, before their concentrations 
decrease due to a secretion deficit (Petersmann, Nauck et al. 2018). Thus, for standard diagnosis 
elevated levels of: fasting plasma glucose (FPG) (≥126 mg/dl) or random plasma glucose (≥200 
mg/dl) or glucose tolerance (2-h plasma glucose ≥200 mg/dl) or glycosylated hemoglobin 
(HbA1c) (≥6.5%) are defined for diabetes (ADA 2020). There are different therapeutic options 
depending on the cause, the stage and the clinical manifestation of the disease. Therapeutic 
strategies begin with a change of the unhealthy lifestyle, followed by various antidiabetics to 
lower the blood glucose level which may be used in conjunction. They differ in their substance 
group and mode of action. For example, a class of drugs called sensitizers like metformin or 
pioglitazone lowers the insulin resistance of target organs (Erdmann, Dormandy et al. 2007, 
Eurich, McAlister et al. 2007). Another group are secretagogues, which increase the insulin 
secretion from the pancreas, e.g., sulfonylureas or meglitinides (Rendell, Glazer et al. 2003). A 
third group, α-glucosidase inhibitors, lowers the absorption of glucose from the gastrointestinal 
tract (Ji, Xiao et al. 2010). Another class of medications are incretin mimetics with the main 
task to stimulate insulin release like the intestinal peptides glucose-dependent insulinotropic 
polypeptide (also known as gastric inhibitory peptide) (GIP) and glucagon-like peptide-1 (GLP-
1) (Meier and Nauck 2005, Drucker and Nauck 2006). Another class of drugs are sodium-
glucose transport protein 2 (SGLT2) inhibitors also called gliflozin, they lower the blood sugar 
level by inhibiting the reabsorption of glucose in the renal tubules (Scheen 2014). Vanadium 
salts, in particular vanadyl sulfate are used as component of antidiabetic drugs and diet 
supplement. Vanadyl sulfate shows insulin-like effects and it is suggested that it improves 
insulin sensitivity (Crans, Schoeberl et al. 2011, Crans, Henry et al. 2019). The majority of 
antidiabetics are orally administrated. Medication of T2D can comprise a combination of drug 
therapy and insulin therapy choosing from a variety of rapid to long acting insulin, usually 
injected subcutaneously (Raskin, Rendell et al. 2001). To determine individualized therapies 
and to improve future classification schemes, a better characterization of the underlying β-cell 
disorder of T2D is required (Skyler, Bakris et al. 2017).  
2.1.2.3 Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) defines an impaired glucose tolerance leading to 
hyperglycemia, which primary manifests during the second or third trimester of pregnancy 
(ADA 2020) or according to other references, after the 19th week of pregnancy (Roden 2016). 
Parallel to T2D and obesity, GDM is on the rise (Alfadhli 2015) with highest prevalence in the 
south East Asia region (Cho, Shaw et al. 2018), GDM accounts with 75–90% for most of the 
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cases of hyperglycemia in pregnancy (Yuen, Saeedi et al. 2019). A diagnosis before the above 
mentioned stage in most of the cases indicates an undiagnosed pre-existing pregestational 
diabetes (mainly T2D). GDM usually manifests only during gestation and women completely 
regenerate after delivery but should be maintained well monitored during and after pregnancy 
due to an increased risk to develop T2D later in life (ADA 2020).  
The pathophysiology of GDM is still poorly understood. It is claimed that elevated 
concentrations of pregnancy hormones lead to decreased insulin sensitivity by disturbing the 
insulin receptor signaling beyond the normal extent as reduction of insulin sensitivity during 
pregnancy is part of the physiological adaption processes. Additionally, altered levels of 
cytokines support the development of insulin resistance and dysfunction of insulin secretion 
(Mao, Chen et al. 2017). 
2.1.2.4 Specific types of diabetes due to other causes 
Monogenic forms of diabetes and secondary diabetes constitute the two major groups of this 
section. Monogenic diabetes accounts for 1–5% of all diabetes cases (IDF 2019). Currently, 
more than 30 genes are associated to monogenic diabetes (Yang and Chan 2016) causing either 
β-cell dysfunction or severe insulin resistance, both resulting in hyperglycemia (Klupa, Skupien 
et al. 2012). The most common forms are maturity onset diabetes of the young (MODY) 
(Letourneau, Carmody et al. 2018) and neonatal diabetes mellitus (NDM). The underlying gene 
mutations affect either transcription factors or endocrine pancreas function (Yang and Chan 
2016). MODY and NDM are divided in subgroups based on the respective gene mutation. They 
differ in the age of onset, manner of inheritance and clinical phenotype (ADA 2020). Even the 
same MODY type can result in substantial differences in its clinical manifestation in individual 
patients. This heterogeneity is probably based on the mutations impact on protein function and 
modifying environmental factors (Fajans and Bell 2011). 
MODY was the first monogenic form of diabetes discovered. As the name indicates it is 
characterized by an onset at an early stage of life (<25 years) (ADA 2020). The mode of 
inheritance is autosomal dominant and up to date 14 genes have been identified which are 
classified as MODY type 1–14 (Flannick, Johansson et al. 2016). The most common types 
consist of mutations in genes expressed by the β-cells, as the glucokinase gene (GCK-
MODY/MODY2) and the transcription factor hepatocyte nuclear factor 1α gene (HNF1A-
MODY/MODY3). They account for 30–50% and 30–65% of all MODY types, respectively, 
followed by mutations in the hepatocyte nuclear factor 4α gene (HNF4A-MODY/MODY1) and 
the hepatocyte nuclear factor 1β gene (HNF1B-MODY/MODY5) with an incidence of 5–10% 
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and <5% of all cases, respectively. The ten other genes associated with the remaining types 
account for approximately 20% of all MODY types, including insulin gene (INS)-MODY 
(MODY10), which is caused by variants of insulin gene mutations (reviewed in (Naylor, Knight 
Johnson et al. 1993, Liu, Sun et al. 2015)). The common types show a mild and stable fasting 
hyperglycemia. Usually patients either do not need therapy or respond well to low dose 
sulfonylureas (Shepherd, Pearson et al. 2003). 
In contrast to MODY, NDM occurs usually within the first six months of age and can be of 
transient (TNDM) or of permanent (PNDM) nature. Both forms are mostly inherited 
dominantly. TNDM patients can experience a total recovery during childhood but up to 50% of 
them show recurrence later in life, usually during adolescence (Greeley, Naylor et al. 2011). 
The most common reason for TNDM is an overexpression of paternally imprinted genes 
hydatidiform mole associated and imprinted gene (HYMAI) or pleiomorphic adenoma gene-like 
1 gene (PLAGL1) on chromosome 6q24 due to uniparental disomy (Mackay and Temple 2010) 
Approximately half of the cases of PNDM result from mutations in potassium inwardly 
rectifying channel subfamily J member 11 gene (KCNJ11) or ATP-binding cassette sub-family 
C member 8 gene (ABCC8). These genes encode for the two subunits of the ATP-sensitive 
potassium channel (KATP) in β-cells. The affected KATP channels are involved in the regulation 
of insulin secretion (Gloyn, Pearson et al. 2004). The second most common cause of PNDM 
are heterozygous mutations in the INS gene itself (Stoy, Edghill et al. 2007). The expression of 
a misfolded mutant proinsulin causes an insulin-deficient diabetes that can be diagnosed 
predominantly in the neonatal but definitely within the infancy phase (<1 year) and is therefore 
referred to as mutant INS gene induced diabetes of youth (MIDY) (Liu, Haataja et al. 2010, 
Stoy, Steiner et al. 2010, Wolf, Braun-Reichhart et al. 2014). The treatment for the majority of 
TNDM or PNDM cases consists of oral sulfonylureas or insulin injection (Pearson, Flechtner 
et al. 2006, Stoy, Greeley et al. 2008, Schimmel 2009). 
Other forms of monogenic diabetes result from defects in insulin action. They cause severe 
insulin resistance and are associated with mutations in the insulin receptor gene (INSR) (Longo, 
Langley et al. 1992) or the high mobility group AT-hook 1 gene (HMGA1) that encodes for a 
transcription factor that binds the promoter of INSR gene (Foti, Chiefari et al. 2005). The genetic 
syndromes are referred to as type A insulin resistance (Musso, Cochran et al. 2004), Donohue 
syndrome (Donohue and Uchida 1954), Rabson-Mendenhall syndrome (Rabson and 
Mendenhall 1956) and lipoatrophic diabetes (Parker and Semple 2013). 
Secondary diabetes is another less common condition, whereby diabetes occurs as a 
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consequence of 
- diseases of the exocrine pancreas (e.g., pancreatitis, cystic fibrosis, traumata, pancreatectomy, 
neoplasms, hemochromatosis, fibrocalculous pancreopathy) 
- diseases of the endocrine system (e.g., Cushing syndrome, acromegaly, hyperthyreosis, 
pheochromocytoma, somatostatinoma, aldosteronoma, glucagonoma) 
- drug- or chemical-induced diabetes (e.g., glucocorticoids, neuroleptics, interferon alpha, 
pentamidine, vacor, niacin, thyroid hormones, diazoxide, thiazide, β agonists, phenytoin, 
treatment of HIV/AIDS, post transplantation diabetes mellitus) 
- infections (e.g., congenital rubella infection, cytomegalovirus) 
- rare forms of autoimmune-mediated diabetes (e.g., “Stiff-man” syndrome, Anti-insulin 
receptor antibodies) 
- other genetic syndromes (e.g., Down-, Klinefelter-, Turner-Syndrome).  
(Roden 2016, Petersmann, Nauck et al. 2018, ADA 2020). 
2.1.3 Mutations in the insulin gene causing disorders of glucose homeostasis 
More than 50 different mutations of the insulin gene have been identified as a reason for 
diabetes in the last decades. INS mutations can cause distinct metabolic consequences whereby 
the impact on glucose homeostasis varies in the associated pathomechanism, the severity and 
the phenotypic expression (Stoy 2014). Insulin gene mutations are predominantly associated 
with PNDM (Stoy, Steiner et al. 2010). To date, 26 different INS mutations are related to forms 
of MIDY, a rare syndrome of insulin-deficient diabetes with early onset  
(<1 year) (Liu, Haataja et al. 2010, Wolf, Braun-Reichhart et al. 2014). Other INS mutations 
are associated to types of MODY and idiopathic type 1 diabetes mellitus have a later onset and 
appear even more seldom (Edghill, Flanagan et al. 2008). Other rare disorders of glucose 
homeostasis induced by insulin gene mutations are hyperproinsulinemia and hyperinsulinemia, 
that only lead to a mild diabetes in adults when insulin resistance is additionally present (Stoy, 
Steiner et al. 2010). 
The next chapter will present and describe the distinct insulin gene mutations and their effects 
in detail. 
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2.2 Impact of insulin mutations on insulin biosynthesis, insulin bioactivity 
and insulin processing in pancreatic β-cells 
2.2.1 INS-gene mutations affecting relevant steps of insulin biosynthesis 
The biosynthesis of the proteohormone insulin takes place in the pancreatic β-cells with 
duration of 30–150 minutes for the termination of a mature and bioactive molecule (Alarcon, 
Leahy et al. 1995, Steiner, Park et al. 2009). One gene on chromosome 11 encodes for the 
human insulin mRNA, that is subsequently translated into the amino acid sequence of 
preproinsulin. The human insulin precursor contains 110 amino acids in a single chain, arranged 
as four functional domains, including signal peptide (SP), insulin B-chain, C-peptide and 
insulin A-chain (Steiner 2011). Preproinsulin is predominantly translocated across the 
endoplasmic reticulum (ER) by the signal recognition particle (SRP)-dependent co-translational 
or by the SRP-independent posttranslational route (Lakkaraju, Thankappan et al. 2012). While 
SRP interacts with the SP of preproinsulin and the SRP membrane receptor in targeting the 
novel molecule to the Sec61 translocon in the ER, SRP-independent translocation is still not 
fully understood but may work as a kind of backup mechanism for the translocation of small 
secretory proteins like preproinsulin (Lakkaraju, Thankappan et al. 2012, Johnson, Powis et al. 
2013). In the ER lumen, SP is processed by proteolytic cleavage forming proinsulin that 
undergoes oxidative folding (reviewed in (Liu, Wright et al. 2014)). Thereby three disulfide 
bonds are formed by connecting the cysteine residues A6–A11, A7–B7 and A20–B19, an 
essential step as it is suggested that impaired foldability of proinsulin has a selective effect on 
insulin evolution (Weiss 2009). In its stable tertiary structure, proinsulin exits from the ER and 
is delivered to the Golgi apparatus and subsequently collected into immature secretory granules. 
Proteolytic cleavage is processed by enzymatic co-action of prohormone convertases PC1/3 
and PC2 and carboxypeptidase E (Alarcon, Leahy et al. 1995, Steiner 2011). Finally, active 
insulin and C-peptide emerge and are concentrated in equal amounts in mature insulin secretory 
granules of the β-cell (Steiner, Park et al. 2009, Liu, Wright et al. 2014).  
Mutations of the insulin gene can affect any of the former described biosynthetic steps and 
therefore they can be assigned to four different groups: 
1) Insulin gene mutations affecting insulin gene transcription or translation 
So far, 12 recessively inherited INS-gene mutations were discovered (Garin, Edghill et al. 
2010). This group contains deletions within the INS promoter region or disruption of 
transcription factor binding sites resulting in a decreased insulin promoter activity of up to 90% 
(Garin, Edghill et al. 2010). The deletion (c.-366_-343del) eliminates so called elements C1 
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and E1, i.e., binding sites for transcription factors MAFA or NEUROD1, respectively. Further, 
the nonsense mutation c.-218A>C leads to the disruption of a binding site of the transcription 
enhancer element CRE3. Other nonsense mutations that cause an impaired transcription are c.-
331(C>G, C>A) and c.-332C>G (Garin, Edghill et al. 2010). The translational start site for 
preproinsulin is affected by the missense mutations c.3G>A, c.3G>T and a null mutation caused 
by a multiexon deletion, that besides exon 1 and 2 abolishes the majority of the coding region 
of the gene (Garin, Edghill et al. 2010). Another nonsense mutation (c.*59A>G) produces an 
instable mRNA that interferes with the translation process (Fred and Welsh 2009, Garin, 
Edghill et al. 2010).  
Recently a dominant mutation, c.212dupG in exon 3, was detected. This duplication mutation 
leads to a frameshift (Gly73fs) and consequently results in an impaired translation due to the 
loss of the original stop codon. The synthesised preproinsulin has a prolonged C-peptide by 
additional 27 amino acids (Xiao, Liu et al. 2019). 
2) Insulin gene mutations affecting endoplasmic reticulum targeting and translocation of 
preproinsulin are located at the signal peptide of the preproinsulin. The spectrum of the 
associated phenotypes ranges from mild maturity-onset (R6C, R6H) to severe early-onset forms 
of clinical diabetes (L13R, A24D) (reviewed in (Liu, Sun et al. 2015)). The heterozygous 
mutation A24D results in either an impaired cleavage of the signal peptide or produces an 
abnormal proinsulin (Stoy, Edghill et al. 2007, Liu, Lara-Lemus et al. 2012) with the 
consequence of misfolding in the ER, leading to β-cell failure (Guo, Xiong et al. 2014). The 
mutation L13R is located in the h-region of the signal peptide. It interferes with the hydrophobic 
property of this region by amino acid substitution and therefore affects ER targeting and 
translocation of preproinsulin, resulting in β-cell failure (Hussain, Mohd Ali et al. 2013). 
Mutations R6C and R6H lead to a loss of positive charge in the n-region of the signal peptide 
and thus complicate the entry of the precursor into the ER (Edghill, Flanagan et al. 2008, 
Boesgaard, Pruhova et al. 2010). 
3) Insulin gene mutations affecting the folding pathway of proinsulin in the ER represent the 
majority of all insulin gene mutations, accounting for more than 70% (reviewed in (Liu, Sun et 
al. 2015)). Proinsulin mutations provoke misfolding caused by distinct amino acid substitutions 
in different sites of the molecule and thus trigger a cascade of blocked ER export and 
accumulation of aberrant proinsulin leading to an ER response, β-cell apoptosis (Wang, 
Takeuchi et al. 1999, Zuber, Fan et al. 2004, Colombo, Porzio et al. 2008) and furthermore a 
decreased production and secretion of co-expressed wild-type insulin (Hodish, Liu et al. 2010). 
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These heterozygous missense mutations predominantly lead to the onset of MIDY with 
decreased insulin secretion and reduced β-cell mass (Stoy, Edghill et al. 2007, Liu, Haataja et 
al. 2010).  
Probably the best investigated mutation in this group is the INSC96Y mutation (Stoy, Edghill et 
al. 2007).The spontaneous C96Y mutation disrupts the interchain disulfide bond C31(B7)-
C96(A7) by substitution of a cysteine residue by a tyrosine residue at position 96 (Wang, 
Takeuchi et al. 1999). Another well-studied mutation belonging to this group is INS2C95S. The 
C95S mutation disrupts the intrachain disulfide bond C95(A6)-C100(A7) by cysteine exchange 
in amino acid position 95 (Herbach, Rathkolb et al. 2007).  
Additionally, there are 16 proinsulin mutations described generating unpaired cysteine residues 
by affecting either native cysteine or creating new cysteine residues. All unpaired cysteine 
mutations interfere with the maturation of disulfide bonds (Liu, Li et al. 2005). Furthermore, 
12 mutations cause misfolded proinsulin by non-cysteine amino acid exchanges, mainly located 
at the B-chain of the insulin. The pathomechanism of these mutations on proinsulin folding is 
still not fully understood but it is suggested that they all indirectly disturb maturation or pairing 
of disulfide bonds (Hua, Mayer et al. 2006, Liu, Wright et al. 2014). 
A novel heterozygous mutation c.125 T>G (p.Val42Gly) in exon 2 impairs the synthesis of 
insulin. The thymine-to-guanine substitution probably provokes proinsulin misfolding of the 
disulfide bond, resulting in NDM with low levels of insulin secretion (Sun, Du et al. 2018). 
4) Insulin gene mutations affecting trafficking and processing of proinsulin are located at the 
junction between the B-chain and the C-peptide, consisting of two arginine residues and the 
junction between the C-peptide and the A-chain, consisting of one lysine and one arginine 
residue (Stoy 2014). These junctions are the cleavage sites for proteolytic enzymes, i.e., 
prohormone convertase (PC)1/3 (B-chain/C-peptide) and PC2 (C-peptide/A-chain). 
Substitutions of the distinct amino acids at the cleavage sites lead to extremely varying 
phenotypes. For example, an exchange of arginine by cysteine located at the first junction (R55) 
results in a severe form of MODY (Stoy, Edghill et al. 2007, Colombo, Porzio et al. 2008), 
whereas substitutions of arginine by other amino acids (leucine, histidine, proline) at the second 
junction (R89) result in asymptomatic or mild forms of hyperproinsulinemia and glucose 
intolerance (Steiner, Tager et al. 1990). Patients affected by the latter mutations show high 
concentrations of proinsulin-like molecules due to an improper cleavage process (Stoy 2014). 
Another substitution of arginine by cysteine is located at the cleavage site (R89) leading to a 
severe form of MIDY. Due to proinsulin misfolding and retention in the ER no proinsulin-like 
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molecules are secreted. This suggests that pathomechanisms are not necessarily depending on 
the locus of the mutation (Colombo, Porzio et al. 2008). Another mutation (H34D) reforces this 
assumption. It affects the sorting of proinsulin and leads to hyperproinsulinemia due to secretion 
of unprocessed proinsulin by an unregulated pathway, but is located at the B-chain instead of 
one of the cleavage sites. Furthermore, studies on mutant H34D suggest that native proinsulin 
carries structural information that is relevant for the proper processing of the precursor in the 
β-cell (Chan, Seino et al. 1987). 
2.2.2 INS-gene mutations affecting insulin bioactivity 
There are three known rare missense mutations that cause insulinopathies, originating from a 
substitution of a single amino acid residue in the B- or A-chain: F48S, F49L, and V92L (Given, 
Mako et al. 1980). The resulting abnormal insulin is less efficient in binding to its corresponding 
insulin receptor due to reduced receptor affinity and therefore the bioactivity of mutant insulin 
varies from 14–0.2% compared to wild-type insulin (Assoian, Thomas et al. 1982). Another 
consequence of this reduction is an impaired physiological degradation of insulin that depends 
on receptor-mediated endocytosis (Steiner, Tager et al. 1990). The mutant insulin accumulates, 
leading to an elevated concentration in the circulation and an altered insulin-C-peptide ratio 
(Steiner, Tager et al. 1990). Phenotypic characteristics are glucose intolerance and 
hyperinsulinemia in patients but diabetes only arises in adults with concomitant insulin 
resistance (Stoy 2014). 
Besides the decreased insulin-receptor-binding potency, mutant proinsulin F48S shows an 
abnormal intracellular condition, caused by impaired disulfide pairing of B19–A20. The 
exchange of the phenylalanine residue at position 24 of the B-chain provokes instable side 
chains that result in insufficient disulfide bond (Hua, Mayer et al. 2006). Therefore, the 
mutation expresses an intermediate phenotype that is different from other mutants like F49L, 
V92L or the MIDY mutants. It combines impaired insulin-receptor-binding with other 
abnormalities like misfolding of proinsulin in the ER and ER stress response, a decreased 
secretion of mutant proinsulin and a negative interaction with co-expressed wild-type proinsulin 
(Liu, Hodish et al. 2010).  
2.2.3 Consequences of INS-gene mutations on processes in the β-cell 
The majority of the dominant INS-gene mutations described in 2.2.1 promote pathomechanisms 
that lead to β-cell failure, predominantly due to an ER stress response. Insulin mutations 
associated with MIDY express misfolded proinsulin that retains within the ER and leads to its 
dilation and impaired function. Such ER stress triggered by misfolded proinsulin is recognized 
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by ER-chaperones, e.g., binding immunoglobulin protein (Bip). Chaperones support the 
activation of the unfolded protein response (UPR) that consists of three known transmembrane 
proteins: the ribonuclease inositol-requiring protein–1 (IRE-1), the PERK kinase homologue 
PEK-1 and activating transcription factor–6 (ATF-6). These proteins in turn try to attenuate ER 
stress by rebalancing ER homeostasis (Henis-Korenblit, Zhang et al. 2010). Collectively, they 
serve as a stress receptor of the cell. They detect and subsequently transduce the ER stress signal 
to the nucleus and to the translational apparatus to adjust transcription and protein synthesis. 
Thereby translation of new arriving proteins decreases and due to increased lipid synthesis in 
the ER membrane an expansion of the ER is possible (Cox, Chapman et al. 1997). These 
mechanisms improve the capacity of the ER to process the misfolded proinsulin. Furthermore, 
the degradation of misfolded proinsulin increases by retro-translocation of abnormal proteins 
to the cytosol and due to autophagy by the lysosome (reviewed in (Ron and Walter 2007)). The 
translation of ER-resident chaperones increases as well, which enhances the UPR (Chang-Chen, 
Mullur et al. 2008). If these UPR initiated processes cannot alleviate ER stress, as a last step 
the UPR triggers a cascade ending in β-cell apoptosis (Eizirik, Cardozo et al. 2008). Besides 
ER stress, cytoplasmic stress induced by mutant preproinsulin is another pathomechanism 
promoting β-cell failure (Guo, Xiong et al. 2014). Untranslocated preproinsulin generated by 
mutant R6C/H accumulates intracellularly in a juxtanuclear compartment and thereby activates 
a cytosolic chaperon (HSP70) that provokes a cellular stress response (Kaganovich, Kopito et 
al. 2008). 
The accumulation of misfolded proinsulin in the ER results in an impaired insulin secretion 
before ER or cytoplasmic stress-mediated β-cell failure arises. Animal models, as the transgenic 
pig line expressing mutant insulin C94Y, showed that decreased plasma insulin concentrations 
and hyperglycemia precede the decrease of β-cell mass (Renner, Braun-Reichhart et al. 2013). 
This indicates that processing of native insulin is disturbed before it gets reduced by β-cell 
apoptosis. As the mutation is heterozygous, mutant as well as wild-type proinsulin is expressed, 
but not all wild-type proinsulin is processed to active insulin (Liu, Hodish et al. 2007). 
Furthermore, it has been proved in the Akita mutant mouse expressing INSC96Y that native 
proinsulin gets misfolded and sorted out like its mutant equivalent and this may be because of 
a direct interaction of mutant and co-expressed wild-type proinsulin (Liu, Hodish et al. 2007). 
A dominant-negative blockade of wild-type proinsulin by misfolded mutants is described due 
to intermolecular disulfide bonds build between the cysteine residues of both kinds of 
proinsulin. Thereby, wild-type proinsulin that forms such a disulfide-linked complex retains in 
the ER and cannot be exported (Hodish, Liu et al. 2010, Liu, Hodish et al. 2010). Furthermore, 
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this blockade is suggested to be dose-dependent and complies with the ratio of co-expressed 
mutant proinsulin to the wild-type proinsulin, as demonstrated in transgenic mice and pigs 
expressing C96Y and C49Y mutant proinsulin, respectively (Hodish, Absood et al. 2011, 
Renner, Braun-Reichhart et al. 2013). Recent studies have investigated that the effect between 
mutant and wild-type proinsulin might be even bidirectional. It is claimed that native proinsulin 
has a rescue effect on co-expressed mutant proinsulin by provision of ER oxidoreductin-1alpha 
(Ero1alpha). This protein normally supports native proinsulin to fold and exit the ER. Upon 
increased expression of Ero1alpha some mutant proteins can be directly rescued from 
misfolding and withhold in the ER. Besides the increase of exported proinsulin, Ero1alpha 
reduces ER stress and further β-cell failure by enhancing oxidative folding of proinsulin 
(Wright, Birk et al. 2013).  
2.3 Animal models with insulin gene mutations 
Since decades, a broad range of distinct animal models for diabetes research exists. In vivo 
studies contributed important results to understand the different pathomechanisms of this 
multifactorial disease and nowadays animal models are still indispensable for the establishment 
of efficient and safe novel pharmacotherapies, new surgical methods and various other 
scientific questions (Aigner, Klymiuk et al. 2010, Zhang, Wu et al. 2018, Cooper, Hara et al. 
2019). Nowadays, translational medicine has a particular importance, with the objective to 
translate results from basic research to clinical administration to provide successful treatments 
for patients (Aigner, Renner et al. 2010). Therefore, appropriate animal models are warranted 
that are based on well conducted preclinical research to reduce translational failure (Bolker 
2017, Leenaars, Kouwenaar et al. 2019). The range of animal models reaches from non-
mammalian models and rodent models to large animal, e.g., dog, pig or non-human primate 
models and therefore from low cost and high throughput towards high cost and improved 
translational value, respectively (reviewed in (Dalgaard 2015, Kleinert, Clemmensen et al. 
2018)). Currently, companion animals are also used more frequently as a resource for 
translational medicine, bridging the discoveries derived from laboratory animals to clinical 
applications (Kol, Arzi et al. 2015). Based on their etiology, laboratory animal models can be 
divided into spontaneous or induced models. Spontaneous animal models have been inbred in 
laboratories for many generations by selecting for desired phenotypic characteristics e.g., for 
hyperglycemia (Rees and Alcolado 2005). A major advantage compared to induced models is 
the assumption that they share pathomechanisms of the human disease more closely (Roep and 
Atkinson 2004, King 2012). Induced models are used more often in diabetes research due to 
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the fact that they are easier to generate than spontaneous models. These models have their focus 
more on the symptoms characteristic for diabetes like hyperglycemia but not on the underlying 
process of the disease itself (reviewed in (Brito-Casillas, Melian et al. 2016)). Induced models 
can be generated by surgical methods like partial or total pancreatectomy (Jawerbaum and 
White 2010) or by non-surgical methods. Non-surgical models can either be generated by the 
administration of toxic chemicals or drugs (i.e., alloxan, streptozotocin, vacor) (Rees and 
Alcolado 2005, Lenzen 2008), hypercaloric nutrition (Lai, Chandrasekera et al. 2014), viral 
infection (e.g., Coxsackie B virus) (Jun and Yoon 2001) or by genetic modification (Wolf, 
Braun-Reichhart et al. 2014). 
The following chapter will present the most relevant spontaneous or genetically modified 
rodent and pig models for diabetes research with mutations in the insulin gene. 
2.3.1 Rodent models 
Rodents, especially mice, still represent the leading animal model used for preclinical diabetes 
research. Besides the advantages shared with non-mammalian models, like low maintenance 
costs, a short and efficient reproductive cycle and the availability of different species and strains 
provided by various suppliers, mouse and rat models are more relevant to human physiology 
compared to non-mammalians (reviewed in (Kleinert, Clemmensen et al. 2018)). Rodent 
models are very valuable for basic research but their translational value, e.g., for the evaluation 
of efficacy and safety of novel therapeutic strategies targeting metabolic diseases is limited. 
However, the genome of the mouse is completely encoded and various tools and techniques are 
available for genetic manipulation and engineering of tailored models (Rees and Alcolado 
2005) that can represent characteristics of diabetes or its comorbidities and complications. 
Nevertheless, rodents show discrepancies to human physiology and anatomy that are relevant 
for diabetic studies, such as a different lipometabolism or pancreatic islet architecture (see 
chapter 2.3.1.1). An important difference to the genetic background of humans, in which one 
insulin gene (INS) exists, is the presence of two INS genes in mouse and rat (Ins1 and Ins2 
gene), probably evolved by retrotransposition (Deltour, Vandamme et al. 2004). Most rodent 
models used are inbred strains. This provides the advantage of a homogenous background with 
less variation between the individuals, allowing lower animal numbers but lacking the aspect 
of human heterogeneity (reviewed in (Brito-Casillas, Melian et al. 2016)). 
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The most common mouse models with insulin gene mutations are described in the following 
chapters. 
2.3.1.1 Ins2C96Y mutant (Akita) mouse model 
The nonobese Ins2C96Y mutant mouse model represents the best investigated insulin gene 
mutation. It derived from a C57BL/6 colony in Akita (Japan) (Yoshioka, Kayo et al. 1997) and 
contains an autosomal dominant spontaneous C96Y mutation in one of the two Ins2 alleles that 
exhibits a G → A transversion in exon 3. The consequence is the substitution of a cysteine 
residue by a tyrosine residue at position 96 of the Ins2 gene that leads to a disruption of a 
disulfide bond between the A and B chain and therefore to essential alterations in proinsulin 
folding in the ER (Wang, Takeuchi et al. 1999). The described mutation also exists in humans 
causing a permanent neonatal diabetes termed mutant INS gene induced diabetes of youth 
(MIDY) (Liu, Haataja et al. 2010) The mutation triggers the retention of misfolded proinsulin 
in the ER that leads to an ER stress response and subsequent β-cell loss (see chapter 2.2.1) and 
a dose-dependent blockade of co-expressed wild-type proinsulin by mutant proinsulin (see 
chapter 2.2.3). Heterozygous Akita mice developed severe clinical diabetes shortly after 
weaning (3–4 weeks), characterized by hypoinsulinemia, hyperglycemia, polyuria and 
polydipsia. The diabetic phenotype was more pronounced in male mice. The mean morning 
blood glucose level was 492 mg/dl in male diabetic mice and 245 mg/dl in female diabetic mice. 
Homozygous animals die in the perinatal period (Yoshioka, Kayo et al. 1997, Kayo and 
Koizumi 1998, Zhou, Pridgen et al. 2011). The Akita mouse is an excellent model to investigate 
pancreatic β-cell dysfunction and to find potential agents to mitigate ER stress (Chen, Zheng et 
al. 2011). Furthermore, microvascular and macrovascular diseases can be investigated. The 
Akita model resembles frequently observed microvascular complications, such as retinopathy 
(Barber, Antonetti et al. 2005), neuropathy (Choeiri, Hewitt et al. 2005), and nephropathy 
(Susztak, Raff et al. 2006). Macrovascular complications such as accelerated atherosclerosis 
and dilated cardiomyopathy are difficult to investigate in mouse models. Vascular and cardiac 
complications are very rare in mice as they lack an atherogenic lipoprotein profile due to their 
naturally efficient lipoprotein clearance (Breslow 1996). To induce atherosclerosis in mice, they 
need to be genetically modified (Hsueh, Abel et al. 2007). Nevertheless, Akita mice lacking the 
low-density lipoprotein receptor have been generated to study diabetic macrovascular disease 
(Zhou, Pridgen et al. 2011). Additionally, they are a good choice for β-cell replacement 
therapies (reviewed in (King 2012)). Ins2C96Y mice develop an insulin-dependent diabetes 
without the appearance of autoimmune components leading to β-cell destruction (Yoshioka, 
Kayo et al. 1997), thus they serve well to evaluate the reaction to pancreatic islet grafts without 
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the interference of pre-existing inflammatory processes due to β-cell autoantibodies. 
Furthermore, due to the spontaneous developed diabetes no interference of toxic side effects 
are expected, as it can occur in models using chemicals to induce a diabetic state (Mathews, 
Langley et al. 2002). 
2.3.1.2 Munich Ins2C95S mouse model 
This nonobese diabetic mouse model derived from the Munich ENU mouse mutagenesis project 
(Herbach, Rathkolb et al. 2007). The large-scale project used the alkylating agent N-ethyl-N-
nitrosourea (ENU) for random chemical mutagenesis in mice and screened subsequently for 
hyperglycemia, which served as the clinically relevant parameter for diabetes in this project 
(Aigner, Rathkolb et al. 2008). Thus, various novel mouse lines for diabetes research have been 
established resulting in a hyperglycemic phenotype. The Munich Ins2C95S mutant mouse model 
has the genetic background of the inbred strain C3HeB/FeJ. The C95S mutant exhibits a T → 
A transversion in the insulin 2 gene in exon 3, which disrupts the intrachain disulfide bond 
C95(A6)-C100(A7) by an amino acid exchange from cysteine to serine in position 95. 
Consequently, Ins2C95S mutants developed a diabetic phenotype (Herbach, Rathkolb et al. 
2007). The C95S mutation in the mouse homologue is similar to the human mutation in the 
insulin gene (C95Y) causing the MIDY syndrome (Stoy, Steiner et al. 2010). Herbach et al. 
described heterozygous Munich Ins2C95S mice of both genders presenting hyperglycemia at the 
age of one month. At three month of age, heterozygous male mutant mice showed decreased 
body weight compared to sex-matched control. Fasted and postprandial blood glucose levels as 
well as glucose tolerance in an oral glucose tolerance test (OGTT) were significantly elevated 
compared to controls, respectively. Blood glucose levels of male mutant mice were generally 
higher than levels of female mutants which showed only mild hyperglycemia. Ins2C95S mutants 
reached almost and. Serum insulin levels of male and female Ins2C95S mutants were reduced 10 
minutes after glucose challenge compared to their controls, respectively. The insulin tolerance 
test showed a decreased response of blood glucose levels 10 minutes after insulin injection in 
Ins2C95S mutant mice compared to wild-type mice. Accordingly, the homeostasis model 
assessment (HOMA) of β-cell function index was remarkably reduced and the HOMA insulin 
resistance index significantly increased in Ins2C95S mutant mice compared to controls. 
Additionally, pancreatic insulin content was decreased in both sexes of Ins2C95S mutant mice. 
These results were indicative for an impaired insulin secretion, disturbed β-cell function and 
insulin resistance in Munich Ins2C95S mutants. The appearance of exocrine pancreas and 
pancreas volume remained unchanged in six-month-old mutant mice compared to wild-type 
mice. Immunohistochemical staining showed alterations in the composition and organization 
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of pancreatic islets of Ins2C95S mutant mice, consisting of reduced and weaker insulin positive 
staining of β-cells and instead increased proportions of glucagon expressing α-cells in 
comparison to control mice. Munich Ins2C95S mutant males had significantly decreased 
calculated total volume of β-cells (-81%) and reduced volume density of β-cells compared to 
control. In contrast, volume density of α-cells in the islet was remarkably higher in mutant 
males compared to wild-type males. Munich Ins2C95S mutant females did not reveal remarkable 
changes in the calculated total volume and volume density of β-cells compared to sex-matched 
controls, but the volume density and total volume of α-cells in the islets of mutant females were 
significantly higher compared to wild-type females. Electron microscopic evaluation of β-cells 
showed ultrastructural alterations in heterozygous Munich Ins2C95S mutant mice, such as a 
dilated ER, mitochondrial swelling and a severe reduction of insulin secretory granules with 
dense cores and only a thin or missing surrounding halo. Ultrastructural changes in female 
Ins2C95S mutants were less pronounced. In homozygous Munich Ins2C95S mutants diabetes 
occurred earlier and more severe in male and female mice, revealing glycosuria, hyperglycemia 
and growth retardation. Homozygous mutant mice revealed random blood glucose levels of 400 
mg/dl for males and 394 mg/dl for female mutant mice at the age of three weeks. Male 
homozygous Ins2C95S mutants died earlier than females with a mean age of 46 days versus 52 
days, respectively (Herbach, Rathkolb et al. 2007). Therefore, the Munich mouse is another 
rodent model to investigate cellular defects, pathophysiology of β-cell dysfunction and β-cell 
death caused by ER stress (reviewed in (Liu, Sun et al. 2015)). 
2.3.1.3 Transgenic mouse expressing proinsulin-H34D 
Another transgenic mouse model is the H34D mutant mouse carrying a mutation that exhibits 
a C → G transversion in the codon for residue 10 of proinsulin leading to a replacement of the 
histidine residue for aspartic acid at position B10 (Gruppuso, Gorden et al. 1984, Chan, Seino 
et al. 1987, Carroll, Hammer et al. 1988). The substitution of the amino acid inhibits the 
association of (ASP10)proinsulin to hexamers in the presence of zinc (Blundell, Cutfield et al. 
1972). The region of the mutation is analogous to the coding region of a human insulin allele 
(Carroll, Hammer et al. 1988). In humans, proteolytic processing of mutant proinsulin to insulin 
is impaired and leads to hyperproinsulinemia and mild glucose intolerance (Gruppuso, Gorden 
et al. 1984). H34D transgenic mice were generated by deoxyribonucleic acid (DNA) 
microinjection (Brinster, Chen et al. 1985). For further evaluation mice containing about 100 
copies of the mutant gene were chosen. They showed normal blood glucose levels but increased 
levels of proinsulin compared to controls. About 65% of the proinsulin synthesized in H34D 
transgenic mice was of the mutant form (Carroll, Hammer et al. 1988). Besides normal mouse 
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proinsulin that was processed via a regulated secretory pathway, 15% of the mutant proinsulin 
was secreted via an unregulated pathway without being processed proteolytically and about 
20% of mutant proinsulin was degraded in the β-cells of the transgenic mice. These results 
indicated that selective secretion of (ASP10)proinsulin leads to hyperproinsulinemia (Carroll, 
Hammer et al. 1988). Furthermore, studies on mutant H34D suggest that native proinsulin 
carries structural information that is relevant for the proper sorting of proinsulin (Chan, Seino 
et al. 1987). 
2.3.2 Porcine Models  
Pigs are the most auspicious model to bridge the gap between preclinical and clinical studies 
for diabetes research (Larsen and Rolin 2004, Aigner, Renner et al. 2010). While basic 
preclinical trials can be implemented in non-mammalian or rodent models differences in 
anatomy, physiology and pharmacokinetics of these species aggravates further translational 
research (Bolker 2017). Pigs have explicit advantages compared to other rodent or nonrodent 
species due to their similarities to the human organism in term of anatomy, physiology, 
biochemistry, genetics, lifespan and size. Their cardiovascular system is almost identical to 
humans regarding the size, the distribution of the blood supply or the pattern in which collateral 
circulation develops after ischemia as well as a similar cardiac electrophysiology (reviewed in 
(Kassab and Fung 1994, Clauss, Bleyer et al. 2019)). Also the digestive tract and urinary system 
are comparable to humans (Laven, Orvieto et al. 2004, Smith and Swindle 2006). Thus, organ 
development and disease progression are considered to be very equal to humans as well. Most 
importantly for diabetic studies, morphology and functionality of the pancreas and its islets are 
very similar to humans (Lunney 2007, Swindle, Makin et al. 2012). Pigs show the same 
predisposition to certain metabolic disorders associated to diabetes, like obesity or metabolic 
syndrome for instance (Renner, Blutke et al. 2018). The size of pigs makes scanning or imaging 
of body structures, organs or vessels easier and surgical procedures can be performed using 
standard human equipment (Lunney 2007). These are important facts, as the pig is a promising 
donor for islet replacement therapies (Zhu, Zhang et al. 2018). Additionally, permanent 
cannulation of vessels is easier to perform and easier to maintain compared to rodents. The 
genome of swine has high sequence and chromosome structure homology with humans and due 
to its complete sequencing a wide range of tools can be used for genetic manipulation and 
analysis (Lunney 2007, Walters, Wolf et al. 2012). The porcine model fulfils most of the needed 
requirements for translational research, in particular genetically engineered pig models. In 
recent years the usage of genetically modified pigs for translational research has increased. 
These models aroused the interest by providing discoveries of human diseases and results for 
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appropriate treatments that could not be acquired by existing animal models (Walters, Wolf et 
al. 2012, Prather, Lorson et al. 2013). Distinct tailored pig models are available showing 
characteristics of diabetes comparable to humans (reviewed in (Wolf, Braun-Reichhart et al. 
2014, Renner, Blutke et al. 2020)). In contrast to non-human primates, pigs are easier to 
maintain and have higher fertility with a shorter reproductive cycle and a larger litter size. This 
facilitates multigenerational studies and using piglets from the same litter decreases the 
biological variance. To conclude, they are less cost intensive and do not raise the same public 
ethical concern when compared to primate or dog models. Additionally, there are more 
accredited laboratories and suppliers available for pigs than for primates, an important aspect 
that needs to be considered while planning a long-scale in vivo study. 
To date the following genetically engineered pig models with mutations in the insulin gene or 
insulin gene knockout are available and are described in the following chapters. 
2.3.2.1 The INSC93S transgenic pig model 
The INSC93S transgenic pig line corresponds to the Munich Ins2C95S mutant mouse model 
described in 2.3.1.2 and is similar to the human mutation INSC95Y that triggers the MIDY 
syndrome (Stoy, Steiner et al. 2010). The mutation in the pig exhibits a transition (T → A) and 
leads to an amino acid exchange (Cys → Ser) and subsequently to a disruption of the disulfide 
bond (A6–A11). In humans the mutation exhibits a different transition (G → A) and amino acid 
exchange (Cys → Tyr). As a consequence misfolded proinsulin gets retained in the ER, native 
insulin processing and secretion is impaired which initiates ER stress and finally β-cell death 
(Herbach, Rathkolb et al. 2007, Colombo, Porzio et al. 2008, Hodish, Liu et al. 2010). INSC93S 
transgenic pigs with a Landrace-Swabian Hall background were generated by SCNT and 
laparoscopic embryo transfer (Kurome, Kessler et al. 2015). At three to four months of age 
male and female INSC93S transgenic animals showed increased mean fasting blood glucose 
levels of 121 mg/dl and reduced glucose tolerance and insulin secretion compared to control 
animals (Renner, Martins et al. 2019). After reaching sexual maturity at seven months of age, 
transgenic animals showed decreased fasting plasma insulin levels in comparison to wild-type 
littermates. The reduction of glucose tolerance and insulin secretion in INSC93S transgenic pigs 
had deteriorated and was more pronounced in female pigs compared to age-matched males. 
One-year-old INSC93S transgenic pigs showed a tendency of decreased volume density and total 
volume of β-cells in the pancreas compared to controls. None of the transgenic animals 
presented growth retardation (Renner, Martins et al. 2019). Furthermore, female INSC93S 
transgenic pigs were mated to evaluate the impact of maternal diabetes on glucose metabolism 
and the metabolome of the offspring at the day of birth. During the third trimester INSC93S 
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transgenic sows revealed mild fasting hyperglycemia, impaired glucose tolerance and insulin 
resistance compared to non-pregnant wild-type sows. Before first colostrum uptake, non-
transgenic neonatal offspring of hyperglycemic sows presented already impaired glucose 
tolerance and insulin resistance compared to wild-type piglets from normoglycemic sows. 
Additionally, targeted metabolomics showed changes in their profile (Renner, Martins et al. 
2019). The benefit of the INSC93S transgenic porcine model is that hyperglycemic effects can be 
evaluated without interfering influences of obesity, such as in diet-induced obese models 
(Thompson, Valleau et al. 2017). Furthermore, foetal maturation during pregnancy and maturity 
stage of piglets at birth is very similar to humans and is a good comparison to human offspring 
(Litten-Brown, Corson et al. 2010). 
2.3.2.2 The INSC94Y transgenic domestic pig (DP) model  
The INSC94Y transgenic line is the corresponding porcine model to the Akita mouse model 
described in 2.3.1.1. The porcine mutation INSC94Y is the homologue to the human mutation 
INSC96Y with the difference that the C-peptide is two amino acids shorter in the pig. The 
mutation contains a G → A transition in the INS gene that promotes a substitution of amino 
acids in position 94 and induces the disruption of a disulfide bond between the A and B chain. 
As in the Akita mouse model, the mutation leads to the production of misfolded proinsulin with 
the same pathological consequences for the β-cell (see chapter 2.2.1) that  may consist of the 
formation of molecular complexes containing co-expressed native and mutant proinsulin in the 
pig (see chapter 2.2.3) (Hodish, Liu et al. 2010, Renner, Braun-Reichhart et al. 2013). The pig 
line was generated by somatic cell nuclear transfer (SCNT) and embryo transfer (Klymiuk, 
Bocker et al. 2012), resulting in animals with a PNDM (Renner, Braun-Reichhart et al. 2013, 
Wolf, Braun-Reichhart et al. 2014). The INSC94Y transgenic DP model was characterized by 
Renner et al. (Renner, Braun-Reichhart et al. 2013); they exhibited a persistent diabetic 
phenotype comprising increased blood glucose levels shortly after birth compared to their wild-
type littermates, respectively. At this early stage INSC94Y transgenic piglets did not show 
reduced β-cell mass. Instead, an impaired insulin secretion due to the negative blockade of 
native proinsulin is assumed to be the initial reason for hyperglycemia in these first days of life. 
At 4.5 months of age INSC94Y transgenic pigs revealed significantly elevated mean fasting blood 
glucose levels of more than 300 mg/dl and remarkably lower fasting insulin levels compared to 
non-transgenic littermates. HOMA of β-cell function index was remarkably reduced and 
HOMA of insulin resistance index significantly increased, indicating reduced β-cell function 
and insulin resistance in INSC94Y transgenic pigs. Qualitative histological evaluation of 
endogenous pancreas of 4.5-month-old transgenic pigs showed alterations of the cell 
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composition with reduced and less intense immunostained insulin positive cells compared to 
control pigs. Quantitative histological analysis of 4.5-month-old INSC94Y transgenic pigs 
showed a decrease of the volume density and the total volume of β-cells and the total volume 
of β-cells related to body weight by 54%, 72% and 53% compared to controls, respectively. 
Electron microscopic evaluation of β-cells presented severely dilated ER of 4.5-month-old 
transgenic pigs compared to wild-type littermates (Renner, Braun-Reichhart et al. 2013). The 
development of a persistent clinical phenotype without major external interferences is an 
important advantage of genetically engineered diabetes models compared to other methods 
inducing the disease. Other methods are either more invasive, need repeated administration of 
chemicals or drugs or trigger adverse side effects like obesity that can have an interfering 
influence. Moreover, animals can respond differently to chemicals and drugs and can carry a 
predisposition for diabetes, which induces unwanted variability (Dufrane, van Steenberghe et 
al. 2006). In addition to its use for basic investigation of β-cell impairment and its consequences, 
this large animal model complements the rodent model regarding translational objectives. Islet 
transplantation is a promising approach for treating severe diabetes that is difficult to adjust 
with insulin treatment. This can be addressed using INSC94Y transgenic pigs for the preclinical 
assessment of immunosuppressants and to further evaluate suitability of e.g., transplantation 
devices (Sakata, Yoshimatsu et al. 2012). Questions of preconceptional diabetes mellitus 
(PCDM) and their effects on the descendants can be reasonably investigated since mating with 
INSC94Y transgenic sows makes a multigenerational study possible (Wolf, Braun-Reichhart et 
al. 2014). In 4.5-month-old INSC94Y transgenic animals diabetes-related secondary alterations, 
such as significant growth retardation with reduced body weight by 41% compared to the 
control animals were observed. Concordantly, most organ weights were proportionally reduced. 
Except the kidneys that revealed an increased relative organ weight and increased relative 
glomerular volume to body weight compared to wild-type littermates. However, there were 
neither histological alterations indicative for diabetic kidney disease in 4.5-month-old 
transgenic pigs or 1-year-old cloned transgenic pigs nor alterations indicative for diabetic 
neuropathy in 4.5-month-old transgenic pigs compared to wild-type littermates. In contrast, a 
progressive cataract was observed in INSC94Y transgenic animals starting at eight days of age 
(Renner, Braun-Reichhart et al. 2013). Long-scale studies could lead to the development of 
more secondary lesions. Also, a biobank was established (Munich MIDY Pig Biobank) 
containing a broad collection of paraffin, plastic and Epon-resin embedded or cryopreserved 
samples. The sample collection consists of tissue and body fluids of two-year-old female 
INSC94Y transgenic and non-transgenic animals (Blutke, Renner et al. 2017). In a current study, 
liver and blood samples from the Munich MIDY Pig Biobank were used for the first multi-
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omics study in a diabetic large animal model to investigate functional alterations of the liver 
(Backman, Flenkenthaler et al. 2019). Currently, more size-reduced pig models would be 
desirable in particular for testing of new developed pharmaceuticals and therefore novel 
genetically modified pigs with an INSC94Y mutation need to be reared. An example is the INSC94Y 
transgenic MPH model that was generated and is the subject of this investigation. Therefore, 
common minipig models that play a role in biomedical research are further described for 
comparison.  
2.4 The minipig as an animal model for biomedical research 
Since the 1940s pigs were more and more often used as a large animal model for biomedical 
research and soon scientists started to develop and establish pig lines smaller in size that were 
named minipigs. Apart from the reduced requirements of food and space, minipigs are much 
easier to handle, for example during transportation due to a lower body weight compared to 
DPs. Another advantage is the lower amount of test compound needed due to the lower body 
weight of minipigs which is of special value in early drug testing. As early development studies 
for new pharmaceuticals are often limited by the amount and cost of their drug prototype. One 
of the main breeding goals for all minipig lines was to generate a pig with a calm and docile 
character that is sociable towards conspecifics and tolerates manipulation by humans as stress 
free as possible.  
A broad variety of breeds were used to generate new minipig lines with specific properties. 
Therefore, crossbreeding of distinct existing minipig breeds with each other, with feral 
miniature pigs, domestic pigs or wild boars through numerous generations were performed. A 
few strains kept their native origin and are continuously used for preclinical studies without any 
hybridization as certain investigations need a small gene pool as objective criterion. 
The following overview contains the current minipig breeds used in biomedical research, 
introduced in chronological order according to their year of establishment and are grouped by 
crossbred or native origin. 
2.4.1 Crossbred minipig models 
2.4.1.1 Sinclair miniature swine (Minnesota miniature) 
The Sinclair miniature swine, one of the first minipig lines bred for biomedical research, was 
generated in 1949 by the Hormel Institute at the University of Minnesota (Dettmers and Rempel 
1968). The Sinclair minipig descended from four different feral and domestic pig lines that 
were crossbred over the decades; Guinea Hog, Catalina wild boar, Piney-Woods and Ras-n-
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lansa. Later on the breed was crossbred with Yorkshire as white skin is desired for numerous 
questions in biomedical research (Dettmers, Rempel et al. 1971). The Sinclair miniature swine 
represented a fundamental genetic background for the development of later minipig models 
(e.g., Göttingen minipig) (Glodek and Oldigs 1981). Currently, there is one population in the 
United States that is kept as outbred strain named Sinclair S-1 miniature swine (Sinclair-Bio-
Resources 2019). The phenotype shows a wide variety of hair coats, from single- to tricolored. 
Newborn piglets have a mean body weight of 590 gram. Adults gain a mean body weight of 
55–70 kilogram and have a medium body size compared to other minipigs. They are lighter and 
smaller than Westran (chapter 2.4.2.3), Hanford (chapter 2.4.1.2) or Yucatan (chapter 2.4.2.1) 
but heavier and larger than Göttingen minipigs (see chapter 2.4.1.3) (Ganderup, Harvey et al. 
2012). Males and females reach sexual maturity at an age of approximately three to four and 
four to five months, respectively. Sows have an average litter size of six piglets. The animals 
show a calm and social temper (Ganderup, Harvey et al. 2012, McAnulty 2012). In the past the 
Sinclair miniature swine was mainly used for human alcoholism studies (Preston, Tumbleson 
et al. 1972, Foudin, Tumbleson et al. 1984, Wood, Gorka et al. 1991). Nowadays this breed is 
further used as a model for diseases of various organ systems, especially for the cardiovascular 
system and its interaction with metabolic disorders like diabetes (reviewed in (Bellinger, 
Merricks et al. 2006)). Sinclair minipigs have been used to generate e.g., atherosclerotic swine 
models (Sinclair-Bio-Resources 2019). After a few weeks of feeding a high-fat, high-
cholesterol diet Sinclair piglets developed aortic strokes and after feeding the same diet for 
months atherosclerotic lesions leading to arterial occlusions were found in these minipigs. To 
accelerate the manifestation of atherosclerosis the arterial intima can be mechanically irritated, 
injured or metabolic disorders like diabetes can be induced in parallel (Sinclair-Bio-Resources 
2019). For atherogenic studies a diabetic state and associated obesity was induced and 
maintained in pigs by intravenous alloxan treatment (175 mg/kg) combined with a high-fat diet 
for about 12 weeks. Under this protocol Sinclair minipigs exhibited hyperglycemia, 
dyslipidemia and atherosclerotic alterations in peripheral vascular and coronary arteries, similar 
to humans (Dixon, Stoops et al. 1999, Roberts, Sturek et al. 2001). The Sinclair miniature pig 
is also a suitable large animal model for osteoporosis (Sinclair-Bio-Resources 2019). 
Ovariectomized minipigs fed a calcium-restricted diet revealed alterations in bone similar to 
those seen in patients of postmenopausal osteoporosis (Mosekilde, Weisbrode et al. 1993). 
Based on this protocol, Sinclair minipigs can be used for safety and efficacy studies of novel 
drug therapies, to analyse their effect on bone content and architecture (Borah, Dufresne et al. 
2002). Finally, Sinclair miniature pigs can exhibit a spontaneously cutaneous malignant 
melanoma very similar to human melanoma (Gomez-Raya, Amoss et al. 2009) and are therefore 
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an important source for dermatology and oncology research (Manning, Millikan et al. 1974, 
Misfeldt and Grimm 1994, Sinclair-Bio-Resources 2019).  
2.4.1.2 Hanford miniature swine 
In 1958 Hanford Laboratories in the United States developed the Hanford miniature swine by 
crossbreeding domestic Palouse sows with a Pitman-Moore boar. Later, feral Swamp pig was 
introduced for body size reduction followed by the incorporation of Yucatan miniature swine 
in the 1960s (Bustad and McClellan 1966). Since 2002 a closed herd of Hanford miniature 
swine is kept at Sinclair Bio Resources in Columbia (Sinclair-Bio-Resources 2019). 
Furthermore, Hanford minipigs served as background for the development of the later minipig 
models, such as FDA Hormel-Hanford or Munich minipig (McAnulty 2012). The newborn 
Hanford miniature swine has a mean body weight of 700 gram while the adult reaches a mean 
body weight of 80–95 kilogram and is therefore one of the largest minipig breeds, together with 
the Westran minipig (see chapter 2.4.2.3). Males and females reach sexual maturity within an 
age of approximately three to four and four to five months, respectively (Ganderup, Harvey et 
al. 2012). Their average litter size is 6.7 piglets (McAnulty 2012). The breed presents 
characteristics like a uniform white skin with a spare hair coat and low subcutaneous fat content 
compared to other minipig lines (McAnulty 2012). These features make them perfectly suitable 
for dermal studies (reviewed in (Stricker-Krongrad, Shoemake et al. 2017)), e.g., as transdermal 
drug delivery model (Panchagnula, Stemmer et al. 1997) and more frequently as a model for 
regulatory dermal toxicity studies (Stricker-Krongrad, Shoemake et al. 2016, Sinclair-Bio-
Resources 2019). The lower fat content makes the Hanford minipig also an attractive model for 
surgical investigations (Sinclair-Bio-Resources 2019). A unique advantage of Hanford 
minipigs over other minipig lines is the development of human-sized organs and structures 
(Friedman, Gaines et al. 1994, Swindle, Makin et al. 2012). The similar collateral blood flow 
and heart size to human made them a preferred model for cardiovascular disease (Marshall, 
Kott et al. 1977, Eisele, Griffey et al. 1993, Sinclair-Bio-Resources 2019). 
2.4.1.3 Göttingen minipig 
The Göttingen minipig was the first minipig line developed in Europe, in the University of 
Göttingen, Germany in the1960s (Kohn, Sharifi et al. 2007). Initially, it was a crossbred of 
Vietnamese Potbelly pig and Minnesota miniature swine with the objective of a high fertility 
rate and a docile behaviour. Later the German Landrace was introduced to obtain a uniform 
white skin color and thus a first population of a white strain of Göttingen minipigs was founded 
(Glodek and Oldigs 1981). Meanwhile, specific pathogen free (SPF) animals have become 
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available. In 1992 Ellegaard Denmark acquired the exclusive right to breed and sell Göttingen 
minipigs but a base population is kept in a farm near Göttingen where the genetic management 
for the whole breeding population is done. In the last decades Ellegaard expanded its 
distribution and signed into licensing agreements with other breeding facilities to ensure a 
worldwide availability. Since 2003 the minipigs are bred and distributed in the United States 
and since 2010 and 2013 they are available in Japan and Korea, respectively (EGM 2019). 
Newborn piglets have a mean body weight of 450 gram while adults reach a mean body weight 
of 30–40 kilogram. (Ganderup, Harvey et al. 2012) They are considered the smallest minipig 
breed, reaching an average body height of 44–48 cm (S.L.A-Research 2000, Swindle, Makin et 
al. 2012). Male and female Göttingen minipigs reach sexual maturity within an age of 
approximately three to four and four to five months, respectively. Sows have an average litter 
size of six and a half piglets (Ganderup, Harvey et al. 2012, McAnulty 2012). The Göttingen 
minipig can be used for a broad range of scientific questions and is therefore one of the most 
popular breeds in biomedical research and for regulatory toxicity testing (Swindle, Makin et al. 
2012). They are especially valuable for cardiovascular and diabetes studies (reviewed in 
(Bellinger, Merricks et al. 2006)). After administration of nicotinamide (NIA) and 
streptozotocin (STZ) or alloxan the Göttingen minipigs develop a reduced β-cell mass, impaired 
insulin secretion and hyperglycemia (Kjems, Kirby et al. 2001, Larsen, Rolin et al. 2007). Under 
a protocol of double low-dose administration of STZ (40 mg/kg) within an 11-day interval, 
minipigs showed diabetic characteristics including β-cell mass reduction and the presence of 
glutamic acid decarboxylase autoantibodies but without developing insulin autoantibodies 
(Rolandsson, Haney et al. 2002). To establish a model for type 2 diabetes or insulin resistance, 
Göttingen minipigs were fed a high-fat high-energy diet for three months (Larsen, Rolin et al. 
2002) with or without additional treatment with STZ alone (maximum of 125 mg/kg) and in 
combination of a pretreatment with NIA (maximum of 230 mg/kg) (Larsen, Wilken et al. 2002). 
In a different study a combined protocol of slow infusion of STZ (130 mg/kg) with a low-fat 
diet was used to induce hyperglycemia and reduce insulin secretion (Koopmans, Mroz et al. 
2006). Additionally, Göttingen minipigs are used to test novel drug therapies for diabetes 
(Ribel, Larsen et al. 2002, Knudsen 2010). When fed an obesity-inducing diet, Göttingen 
minipigs serve as a model for the metabolic syndrome (Johansen, Hansen et al. 2001, 
Christoffersen, Golozoubova et al. 2013, Pedersen, Ingerslev et al. 2013, Zhang and Lerman 
2016, Renner, Blutke et al. 2018). Furthermore, pancreatectomy can be performed in Göttingen 
minipigs to study new therapeutic drugs or the efficacy of medical devices for glucose 
monitoring (Strauss, Tiurbe et al. 2008). The Göttingen minipig is also an excellent model for 
oral surgery, e.g., for dental implantation healing (Coelho, Pippenger et al. 2018) Finally, the 
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uniform white skin color offers opportunities for dermatology and radiology research, which 
demand unpigmented animals for their studies (Mahl, Vogel et al. 2006). 
2.4.1.4 Panepinto micropig 
The Panepinto micropig was founded in the 1990s with the goal to use the breed for biomedical 
research as well as in petting zoos (McAnulty 2012). Selected pigs from the Micro-Yucatan 
line from a herd of the Colorado State University were crossbred with Vietnamese miniature 
pigs. After further steps of selective breeding for smaller size, the modern Panepinto micropig 
background consists of 90% Yucatan and 10% Vietnamese miniature pig (Schook and 
Tumbleson 2013). The micropigs have a grey to black skin color, large ears and wattles. The 
newborn piglet has a mean body weight of 500–800 g, while the adult reaches a mean body 
weight of 25–30 kilogram and is therefore smaller in body size than other mini- or micropigs. 
Animals become sexually mature with four to six months of age and the average number of 
piglets per litter is seven to eight (McAnulty 2012, Schook and Tumbleson 2013). The 
Panepinto miniature pig is only bred in the United States and is mainly used for cardiovascular 
or diabetes studies (McAnulty 2012, Gutierrez, Dicks et al. 2015). 
2.4.2 Native minipig models 
2.4.2.1 Yucatan miniature swine and Micro-Yucatan miniature swine 
The Yucatan miniature swine derived from 25 animals imported to the US from the Mexican 
Peninsula Yucatan in 1960 and was generated at Colorado State University (Panepinto and 
Phillips 1986). It has a native origin initially derived from one gene pool and is kept as an 
outbred strain for biomedical research. The average birth weight ranges from 500–900 gram 
and the adult body weight range is 70–80 kilogram. Yucatan minipigs have a medium body 
size, reaching an average body height of 57 cm and body length of 76 cm (Panepinto, Phillips 
et al. 1978). Thus, it is larger than the Göttingen (see chapter 2.4.1.3) or Sinclair (see chapter 
2.4.1.1) but smaller than the Hanford (see chapter 2.4.1.2) minipig. Males and females reach 
sexual maturity within an age of approximately three to four and four to five months, 
respectively. The average number of piglets per litter is six. Animals are slate-grey and hairless 
(Panepinto, Phillips et al. 1978, Ganderup, Harvey et al. 2012, McAnulty 2012). In the 1970s 
two lines were generated by selective breeding, “low K” with impaired glucose tolerance and 
“high K” with an enhanced glucose tolerance (Phillips, Panepinto et al. 1982). The impaired 
glucose tolerance in the “low K” line resulted from a decreased peripheral insulin level. The 
decrease of insulin concentrations was the consequence of reduced insulin secretion due to a 
modified pancreatic receptor or postreceptor response. Morphometric analysis of the pancreas 
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of pigs of this strain confirmed normal synthesis and storage of insulin and a normal number of 
islets and β-cells. Therefore, “low K” pigs were not able to secrete an appropriate insulin 
amount due to an insufficient glucose stimulus. The secretory response of insulin to a glucose 
stimulus was reduced compared to other secretagogues like isoproterenol (Phillips, Panepinto 
et al. 1982, Panepinto and Phillips 1986). Females revealed a propensity for obesity and 
developed diabetes with hyperglycemia and hyperinsulinemia during gestation and lactation. 
Until the 7th generation the characteristic of glucose intolerance got lost and the “low K” line is 
not available anymore (Hand, Surwit et al. 1987). Currently, the Yucatan minipig is used as a 
model for diabetes and dyslipidemia by inducing diabetes through STZ or alloxan and 
additionally obesity can be induced by feeding a high-fat diet. Besides hyperglycemia, these 
minipigs exhibited elevated cholesterol and triglyceride levels and obtained a normal to obese 
body shape. The acquired glycemic control and the body shape of these minipigs depended on 
the long-term insulin and food maintenance algorithm that was given to prevent diabetes-
induced body wasting (Boullion, Mokelke et al. 2003). Furthermore, alloxan-induced diabetic 
male Yucatan pigs fed an atherogenic diet developed atherosclerosis and altered collagen depots 
in arteries (Hill, Dixon et al. 2001). Alloxan-induced diabetic animals showed retinal capillary 
changes, therefore it is a useful model for diabetes-associated microvascular alterations 
(Hainsworth, Katz et al. 2002). The Yucatan minipig is also a common model for exercise 
physiology and its effect on vascular function or lipoproteins (Mokelke, Dietz et al. 2005, 
Richardson, Lai et al. 2009). Yucatan models with a modified low-density lipoprotein receptor 
(LDLR) gene were generated, exhibiting hypercholesterolemia and a progressive 
atherosclerosis with formation of macrovascular lesions, especially when fed a high-fat diet 
(Davis, Wang et al. 2014, Amuzie, Swart et al. 2016). Selective breeding brought forth a 
Yucatan model with ventricular septal defect (VSD) (Sinclair-Bio-Resources 2019). The defect 
is very similar to the most common form of VSD in humans and some pigs additionally 
developed pulmonary hypertension and a patent foramen ovale (Swindle, Thompson et al. 
1990). Furthermore, the Yucatan minipig is used in numerous fields of biomedical research, 
e.g., as a model of cystic fibrosis (Welsh, Rogers et al. 2009, Cooney, Abou Alaiwa et al. 2016), 
tumorigenesis (Sieren, Meyerholz et al. 2014) or neurological disorders (White, Swier et al. 
2018).  
The Micro-Yucatan miniature swine derived from the Yucatan miniature swine by introducing 
a small Yucatan boar into the Colorado State University breeding program. Subsequently, 
selective breeding for smaller than average size and weight was performed (Panepinto and 
Phillips 1981). In 1985 Charles River Laboratories established a Micro-Yucatan breeding 
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program and since 2002 Sinclair Bio Resources acquired the herd (McAnulty 2012, Sinclair-
Bio-Resources 2019). Micro-Yucatan pigs have similar characteristics compared to Yucatan 
minipigs. They are interchangeable and practically only differ in size, reaching a body weight 
of 55–70 kilogram (Ganderup, Harvey et al. 2012). Like Yucatan minipigs, Micro-Yucatans 
are a used as a model for cardiovascular diseases, obesity and diabetes (Lee, Xu et al. 2010, 
Sinclair-Bio-Resources 2019) and a special model exhibits as well VSD (Johnson, Fyfe et al. 
1993, Sinclair-Bio-Resources 2019, Sinclair-Bio-Resources 2019). It should be considered that 
variations in cardiovascular parameters exist between the Yucatan minipig and Micro-Yucatan 
(Smith, Spinale et al. 1990). As the Micro-Yucatans are also a useful model of human 
menopause they offer the opportunity to evaluate the effects on cardiovascular and reproductive 
tissues in sexually mature and in ovariectomized micropigs under postmenopausal oestrogen 
therapy (Goodrich, Clarkson et al. 2003).  
2.4.2.2 Chinese Guizhou minipig 
The Chinese Guizhou minipig is one of various minipig strains from China and is used for 
biomedical research since the 1990s. The genetic homozygosity and stable phenotype of this 
naturally evolved minipig can have significant benefits for biomedical researches (Min, Pan et 
al. 2014). Currently, they are used as a model for atherosclerosis, T2D or novel drug testing. 
When fed a high-fat high-sucrose diet this minipig breed developed a mild dyslipidemia with 
obesity, hyperglycemia, insulin resistance, impaired insulin secretion, reduced β-cell mass and 
atherosclerotic lesions in the aorta (Xi, Yin et al. 2004). By treating Chinese Guizhou minipigs 
fed a high-fat high-sucrose diet with a synthetic lipoprotein lipase activator, obesity was 
inhibited, insulin response and high-density lipoprotein (HDL) cholesterol were increased and 
total cholesterol was reduced (Yin, Liao et al. 2004). 
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2.4.2.3 Westran minipig 
The Westran strain is one of the minipig lines that is kept highly inbred. The poor gene diversity 
makes this strain especially interesting for transplantation research. Their well-characterized 
homozygous major histocompatibility complex (MHC) makes tolerance induction and 
immunosuppression easier compared to other strains (Lee, Simond et al. 2005). This enhances 
the use of inbred Westran pigs for xenotransplantation studies in which a low genetic variation 
is essential (Cooper, Gollackner et al. 2002, O'Connell, Hawthorne et al. 2005). The animals 
are descendants of feral pigs from Kangaroo Island, originated from just one breeding pair of 
pigs that were released on the Island in 1803. The Westran (Westmead Hospital transplantation) 
line was established in 1993 in the Westmead hospital in Sydney with the goal to generate 
potential donators for non-human organs and tissues (O'Connell, Hawthorne et al. 2005). 
Westran pigs appear white, partly with black spots. Newborn piglets have a mean body weight 
of 930 gram while adults gain a mean body weight of 80–93 kilogram and therefore reach a 
comparably large body size compared to other minipig lines. Animals become sexually mature 
with six to seven months of age and the average number of piglets per litter is 4.6 (O'Connell, 
Hawthorne et al. 2005, McAnulty 2012). As already mentioned, the biggest benefit of this pure 
blood strain is the maintenance of relevant characteristics in between the population like the 
same blood group type 0 or a similar MHC, providing a transplant model for allo- or 
xenotransplantation studies with improved rejection properties (Hawthorne, Cachia et al. 2000, 
Lee, Simond et al. 2005). Finally, Westran minipigs have also been used for pancreatic islet 
transplantation as a treatment strategy for T1D (Hawthorne, Simond et al. 2011).  
2.4.2.4 Ossabaw minipig 
Ossabaw minipigs have a unique genetic history. It is assumed that they originate from a 
Spanish strain brought to the US. Some of these animals escaped and lived isolated on the 
Ossabaw Island where they developed a “thrifty genotype„ due to the extreme conditions of the 
habitat with alternate periods of abundant food and starvation that provoked an adaptation of 
the lipometabolism (Dyson, Alloosh et al. 2006). The average body weight of a 10 to 12 
months-old Ossabaw minipig is 88 kilogram. It is a slow growing strain for the reason of lower 
plasma growth hormone in comparison to other strains (Kasser, Martin et al. 1981). When 
Ossabaw minipigs are fed ad libitum in captivity they acquire obesity, insulin resistance, 
glucose intolerance, hypertension and dyslipidemia. Consequently, an ad libitum diet increases 
the risk of developing T2D, metabolic syndrome and coronary heart disease (Dyson, Alloosh 
et al. 2006). Thus, this strain is an excellent model for these types of metabolic disorders and 
their consequences (Edwards, Alloosh et al. 2008, Pedersen, Ingerslev et al. 2013). Ossabaw 
Review of the literature 48 
minipigs develop the above mentioned phenotype of metabolic syndrome within a shorter time 
period compared to other minipig strains, when fed a high-fat high-cholesterol diet and without 
the need of a chemical or surgical diabetes induction (Neeb, Edwards et al. 2010). When the 
Ossabaw minipig model of metabolic syndrome additionally was injected with Alloxan, even 
more severe coronary atherosclerosis was observed (Badin, Kole et al. 2018). Juvenile female 
Ossabaw pigs fed a western-style diet (high-fat, high-fructose and high-cholesterol) for 16 
weeks developed not only dyslipidemia, obesity and insulin resistance but also microbiota 
dysbiosis and nonalcoholic steatohepatitis (NASH) (Panasevich, Meers et al. 2018). In dietary 
restriction studies Ossabaw minipigs showed only a slight decrease in adipose tissue mass and 
no loss in muscle mass or amount of adipocytes (Etherton and Kris-Etherton 1980). 
Furthermore, this strain is used as experimental model for bladder dysfunctions (Mattern, Lloyd 
et al. 2007, Edwards, Alloosh et al. 2008). 
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3 ANIMALS, MATERIALS AND METHODS 
3.1 Animals 
All animals which were part of the present study were hemizygous female and male transgenic 
or non-transgenic domestic pig-minipig hybrids (MPHs) and age-matched female and male 
non-transgenic domestic pigs (DPs). MPHs were generated by mating transgenic German 
Landrace-Swabian-Hall crossbred sows expressing the mutant insulin (INS) C94Y with a black 
minipig boar. Animals were maintained under controlled species-appropriate conditions, i.e., 
small groups with their littermates. Pens were planar-fixed with straw bedding. Animals were 
fed once daily with an appropriate pig diet produced by the Livestock Centre of the Veterinary 
Faculty of the Ludwig-Maximilians-University displayed in Table 1. Water was offered ad 
libitum. To reduce animal distress to a minimum, all pigs were used to the staff and trained for 
the planned procedures. All animal experiments were performed in compliance with the 
German Animal Welfare Act and were approved by the local animal welfare authority 
(Regierung von Oberbayern, Munich, AZ 55.2-1-54-2532-163-2014 and 55.2-1-54-2532-70-
2012). 
Table 1: Composition of porcine diets used 
  
Ingredient                      
Laktationsfutter Sauen 
(lactating sows)
Ferkelkorn                            
(piglets 6.5 kg up to 40 kg)
MJ ME/kg  12.3 13
Dry matter % 88.9 89.4
Crude ash %  5.9 5.7
Crude protein %  19.1 19.4
Crude fiber % 6.6 5
Crude fat %  2.9 2.9
Starch % 38.5 41.4
Sugar %  3.8 2.7
Calcium %  0.71 0.82
Phosphorus %  0.48 0.52
Sodium %  0.16 0.22
Magnesium %  0.19 0.28
Potassium %  0.91 1.19
Copper %  0.0243 0.1574
Zinc %  0.12 0.129
Manganese %  0.072 0.065
ME= metabolizable energy; MJ= Mega joule; Indicated data refer to 1 kg food
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3.2 Materials 
3.2.1 Apparatuses 
Accu-jet® pro pipette controller     Brand, Wertheim, DE 
Agarose gel electrophoresis chamber    WG-Biotech, Ebersberg, DE 
Agarose gel electrophoresis chamber    OWL Inc., USA 
AU480 autoanalyzer      Beckman-Coulter, Krefeld, DE 
Benchtop 96 tube working rack     Stratagene, La Jolla, USA 
Electrophoresis Power Supply EPS 500/400  GE Healthcare GmbH, Munich, DE 
EM 10 transmission electron microscope   Carl Zeiss AG, Oberkochen, DE 
GE Lunar iDXA scanner      GE Healthcare GmbH, Solingen, DE 
Gel documentation system      Bio Rad, Munich, DE 
HM 315 microtome       Microm, Walldorf, DE 
HM 360 microtome       Microm, Walldorf, DE 
Incubator         Memmert, Schwabach, DE 
LB 2111 γ-counter       Berthold, Bad Wildbach, DE 
Microprocessor pH meter      WTW, Weilheim, DE 
Microscope digital camera (DP72, Olympus)  Olympus, Hamburg, DE 
Microwave        Siemens, Munich, DE 
MS1 minishaker        IKA, Staufen, DE 
Multipette® plus        Eppendorf, Hamburg, DE 
Object micrometer       Carl Zeiss AG, Oberkochen, DE 
Pipettes (1000 µl, 200 µl, 20 µl, 10 µl, 2 µl)   Gilson Inc, USA 
Precision® Xceed glucometer     Abbott, Wiesbaden, DE 
Reichert-Jung TM60 milling maschine  Leica Microsystems GmbH, Wetzlar, 
DE 
Reichert-Jung Ultracut E microtome   Leica Microsystems GmbH, Wetzlar, 
DE 
RH Basic heating plate with magnetic stirrer  IKA, Staufen, DE 
Scanning stage       Märzhäuser, Wetzlar, DE 
Shandon Citadel tissue processor 1000   Thermo Fisher Scientific, GmbH, 
Schwerte, DE 
Stemi SV11 stereomicroscope     Carl Zeiss AG, Oberkochen, DE 
Staining box according to Schifferdecker   Carl Roth GmbH & Co. KG, Karlsruhe, 
DE 
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Systemic microscope (BX41, Olympus)   Olympus, Hamburg, DE 
Thermomixer 5436       Eppendorf, Hamburg, DE 
Varioklav 400 autoclave   H + P Labortechnik, Oberschleißheim, 
DE 
WB 6 water bath       Firmengruppe Preiss-Daimler, DE 
Centrifuges: 
Biofuge pico        Heraeus, Munich, DE 
Megafuge 1.0 R        Heraeus, Munich, DE 
Rotanta 96         Hettich, Tuttlingen, DE 
Eppendorf centrifuge 5810R      Eppendorf, Hamburg, DE 
Eppendorf centrifuge 5430R      Eppendorf, Hamburg, DE 
Thermocycler: 
Biometra Uno Thermoblock      Biometra,Göttingen, DE 
Biometra T Professional      Biometra,Göttingen, DE 
Mastercycler® gradient      Eppendorf, Hamburg, DE 
Scales: 
Analytical balance       Sartorius, Göttingen, DE 
Bizerba (inclination scale)     August Sauter KG, Ebingen, DE 
F. Star 125 large animal scale    Meier-Brakenberg, Exertal, DE 
Kern EOB 15K5        Kern GmbH, Barlingen-Frommern, DE 
Mettler PM 6000       Mettler-Toledo GmbH, Gießen, DE 
3.2.2 Consumables 
Blood lancets        Henry Schein® Vet GmbH, Hamburg DE 
Cellstar® cell culture plates (12 well)    Greiner Bio-One GmbH, Solingen, DE 
Cover slips for histology   VWR International GmbH, Darmstadt, 
DE 
Culture tubes with caps (12 ml, 50 ml)   Falcon® Becton Dickinson, Heidelberg, 
DE 
Disposable plastic pipettes   Falcon®, Becton Dickinson, Heidelberg, 
DE 
DryEase® Mini cellophane   Life TechnologiesTM GmbH, 
Darmstadt,  DE 
1000 eco Lab pipette tips (200 µl, 1000 µl)  neoLAB® Migge Laborbedarf-Vertriebs   
GmbH, Heidelberg, DE 
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Freestyle Precision Xtra Plus     Abbott, Wiesbaden, DE 
blood glucose stripes 
Gelatine epon embedding capsules    Plano, DE 
Hypodermic needles (18 G/20 G)   Henry Schein® Vet GmbH, Hamburg, DE 
Latex Powder-Free sempercare gloves    Satra Technology Center, Nordhamshire 
Microscope slides Star Frost®     Engelbrecht, Edermünde, DE 
Monovette® blood collection system   Sarstedt, Nümbrecht, DE 
(Serum, EDTA) 
Multi Guard Barrier Tips SorensonTM Bioscience Inc., Utah,  
(10 µl, 20 µl, 200 µl, 1000 µl)  USA 
NexttecTM cleanColumns     Nexttec GmbH, Leverkusen, DE 
Parafilm®M   American Can Company, Greenwich, 
USA 
PCR reaction tubes (0.2 ml)      Braun, Wertheim, DE 
Quali-PCR tubes (0.2 ml) and capstrips    G. Kisker Biotech GbR, Steinfurt, DE 
Rotilabo® weighing bowls (20 ml, 330 ml)   Carl Roth GmbH & Co. KG, Karlsruhe, 
DE 
Safe-Lock 1.5 ml Eppendorf Tubes®    Eppendorf, Hamburg, DE 
Sempercare® nitrile gloves   Satra Technology Center, 
Northamptonshire, UK 
Single-use syringes (2.5 ml, 10 ml, 20 ml)   Henry Schein®Vet GmbH, Hamburg, DE 
Sterican® cannulas (18 G, 20 G)     B. Braun, Melsungen, DE 
Tissue culture dishes (60 x 15 mm)    Sarstedt, Nümbrecht, DE 
Uni-Link embedding cassettes     Engelbrecht, Edermünde, DE 
Vascocan® indwelling venous     B. Braun, Melsungen, DE 
catheters and stylets 
3.2.3 Chemicals 
Chemicals were used according to requirements such as safety, handling and analytical purity 
unless described otherwise. 
Acetic acid (glacial acetic acid, Rotipuran®)   Carl Roth GmbH & Co KG, Karlsruhe, 
DE 
Acetone  neoLAB® Migge Laborbedarf-Vertriebs 
GmbH, Heidelberg, DE 
Agarose UltraPureTM Electrophoresis grade   InvitrogenTM, Karlsruhe, DE 
Benzoylperoxide  Merck KGaA, Darmstadt, DE 
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Bromophenolblue       Merck KGaA, Darmstadt, DE 
3,3´Diaminobenzidine tetrahydrochloride  KemEnTec, Copenhagen, Denmark 
(DAB) 
5,5´Diethylbarbituric acid sodium salt   Merck KGaA, Darmstadt, DE 
1,4-Dithiothreitol (DTT)   Biomol Feinchemikalien GmbH, 
Hamburg, DE 
Dodecenylsuccinic acid anhydride pract. (DDSA) Serva Electrophoresis GmbH, 
Heidelberg, DE 
Eosin  Merck KGaA, Darmstadt, DE 
Ethanol         Merck KGaA, Darmstadt, DE 
Ethidiumbromide (1 mg/ml)      Merck KGaA, Darmstadt, DE 
Ethylenediaminetetraacetic acid     Merck KGaA, Darmstadt, DE 
(EDTA, Titriplex®III) 
Ethylene glycol monobutyl ether     Merck KGaA, Darmstadt, DE 
Ethylmercury thiosalicylic acid sodium salt   Serva Electrophoresis GmbH, 
Heidelberg, DE 
Formaldehyde solution (Roti®-Histofix 4%)  Carl Roth GmbH & Co KG, Karlsruhe, 
DE 
Formaldehyde solution (Rotipuran® 37%)  Merck KGaA, Darmstadt, DE 
Glutaraldehyde   Serva Electrophoresis GmbH, 
Heidelberg, DE 
Glycerol (Rotipuran®)   Carl Roth GmbH & Co. KG, Karlsruhe, 
DE 
Glycidether 100   Serva Electrophoresis GmbH, 
Heidelberg, DE 
Hydrochloric acid (25%)   neoLAB® Migge Laborbedarf-Vertriebs 
GmbH, Heidelberg, DE 
Hydrogen peroxide (35%)  neoLAB® Migge Laborbedarf-Vertriebs 
GmbH, Heidelberg, DE 
2-Hydroxyethyl methacrylate Sigma-Aldrich Chemie GmbH, DE 
(HEMA)  
Lead nitrate solution, Pb(NO3)2 (1 M)    Merck KGaA, Darmstadt, DE 
Magnesium chloride       Qiagen GmbH, Hilden, DE 
Mayer`s Hemalum solution      Applichem GmbH, Darmstadt, DE 
Methyl methacrylate (MMA)     Sigma-Aldrich Chemie GmbH, DE 
Methylnadic anhydride (MNA)  Serva Electrophoresis GmbH, 
Heidelberg, DE 
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Monopotassium phosphate (KH2PO4)  neoLAB
® Migge Laborbedarf-Vertriebs 
GmbH, Heidelberg, DE 
Osmium tetroxide (OsO4)      chemPUR®, Karlsruhe, DE 
Phenylmethylsulfanylfluoride (PMSF)   Sigma-Aldrich Chemie GmbH, DE 
Polyethylene glycol 400      Merck KGaA, Darmstadt, DE 
Phosphoric acid (H3PO4) (Emprove®)    Merck KGaA, Darmstadt, DE 
Potassium chloride       Merck KGaA, Darmstadt, DE 
Potassium hydrogen phosphate     Merck KGaA, Darmstadt, DE 
Potassium hydroxide pellets      Merck KGaA, Darmstadt, DE 
D(+)-saccharose   neoLAB® Migge Laborbedarf-Vertriebs 
GmbH, Heidelberg, DE 
Saccharose        Merck KGaA, Darmstadt, DE 
Safranin O   Chroma Technology GmbH, Olching, DE 
Sodium acetate (C2H3NaO2)     Merck KGaA, Darmstadt, DE 
Sodium carbonate (Suprapur®)     Merck KGaA, Darmstadt, DE 
Sodium chloride (Ensure®)      Merck K G aA, Darmstadt, DE 
Sodium citrate solution (1 M)     Merck KGaA, Darmstadt, DE 
Sodium hydroxide (NaOH)   VWR International GmbH, Darmstadt, 
DE 
Sodium hydroxide solution (2 M)   VWR International GmbH, Darmstadt, 
DE 
Sodium-orthovanadate (Na3VO4)     Sigma-Aldrich Chemie GmbH, DE 
Sodium phosphate dibasic dehydrate neoLAB® Migge GmbH, DE 
(Na2HPO4 x 2 H2O) 
2-Sodium tetraborate (Borax)     Merck KGaA, Darmstadt, DE 
2, 4, 6-Tris-(dimethylamino-Methyl)phenol Serva Electrophoresis GmbH,  
(DMP 30)  Heidelberg, DE 
Toluidine blue O Roth, DE 
Uranyl acetate        Merck KGaA, Darmstadt, DE 
Xylene         Applichem GmbH, Darmstadt, DE 
3.2.4 Antibodies, drugs, enzymes, oligonucleotides, standards 
3.2.4.1  Antibodies 
Polyclonal guinea pig anti-porcine insulin   Dako cytomation, Hamburg, DE 
Polyclonal rabbit anti-human glucagon    Dako cytomation, Hamburg, DE 
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HRP-conjugated rabbit anti-guinea pig IgG   Dako cytomation, Hamburg, DE 
HRP-conjugated goat anti-rabbit IgG   Dako cytomation, Hamburg, DE 
3.2.4.2 Drugs 
Altrenogest (Regumate®)      Serumwerke Bernburg, Bernburg, DE 
Azaperon (Stresnil®)       Janssen Pharmaceutica, Beerse, Belgium 
Human Chorionic Gonadotropin (hCG, Ovogest®)  Intervet, Unterschleißheim, DE 
Embutramide, Mebezonium iodide,    Intervet, Unterschleißheim, DE 
Tetracaine hydrochloride (T61®)  
Pregnant Mare Serum Gonadotropin   Intervet, Unterschleißheim, DE 
(PMSG, Intergonan®)    
Sodium chloride solution (0.9%)    B. Braun, Melsungen, DE 
Ketamine hydrochloride (Ursotamin®)    Serumwerke Bernburg, Bernburg, DE 
Xylazine (Xylazin 2%)      WDT, Garbsen, DE 
3.2.4.3 Enzymes 
Taq DNA Polymerase (5 U/ml)     Qiagen GmbH, Hilden, DE 
3.2.4.4 Oligonucleotides 
All oligonucleotides were designed manually and manufactured by Thermo Fisher 
Scientific, USA. 
ACTB (sense)  5 ´ TGGACTTCGAGCAGAGATGG 3´ 
ACTB (antisense)  5 ´ CACCGTGTTGGCGTAGAGG 3´ 
neoPf (sense)  5 ´ CAGCTGTGCTCGACGTTGTC 3´ 
neoSr (antisense)  5 ´ GAGTCAACTAGTCCTCAGAAGAACTCGTCAAG 3´ 
3.2.5 Buffers, media and solutions 
For preparation of buffers, media or solutions aqua bidestillata (aqua bidest.) was used as a 
solvent if not described otherwise. For this, water was deionized with a water purification 
system (EASYpure® II, pure Aqua, Schnaitsee, DE). 
3.2.5.1 Buffers and solutions for electron microscopy 
3.2.5.1.1 Soerensen´s phosphate buffer 
192 ml   Solution A 
808 ml   Solution B 
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3.2.5.1.1.1 Solution A 
4.5 g    KH2PO4 
ad 500 ml   Aqua bidest. 
3.2.5.1.1.2 Solution B 
11.9 g   Na2HPO4 x 2 H2O 
ad 1000 ml  Aqua bidest. 
3.2.5.1.2 Soerensen´s washing solution 
6.8 g    D(+)-saccharose 
100 ml   Soerensen´s phosphate buffer 
1%    Merthiolate solution 
3.2.5.1.2.1 Merthiolate solution 
1%    Ethylmercury thiosalicylic acid sodium salt 
3.2.5.1.3 Fixation solution for glycidether embedding 
6.84 g   D(+)-saccharose 
1 ml   Aqua bidest. 
2 ml    HCl, 0.1 M 
2 ml    Veronal-acetate buffer 
5 ml    2% Osmium tetroxide solution 
1g   Osmium tetroxide 
3.2.5.1.3.1 Veronal-acetate buffer 
1.5 g    5,5´Diethylbarbituric acid sodium salt 
1 g    Sodium acetate 
ad 50 ml   Aqua bidest.adjusted to pH 10.3 
3.2.5.1.4 Glycidether embedding mixture 
41.2 g  Solution A 
75 g    Solution B 
1.5 ml   2,4,6-Tris-(dimethylaminomethyl) phenol 
3.2.5.1.4.1 Solution A 
38.32 g   Glycidether 100 
45.30 g   2-Dodecenyl succinic acid anhydride 
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3.2.5.1.4.2 Solution B 
61.8 g   Glycidether 100 
56.34 g   Methyl nadic anhydride 
3.2.5.1.5 Toluidine blue staining solution 
1 g    2-Sodiumtetraborate (Borax) 
0.8 g    Toluidine blue O 
ad 100 ml   Aqua bidest. 
Borax was dissolved in aqua bidest, Toluidine blue O was added and afterwards the solution 
was stirred on a magnetic stirrer for two hours. Prior to use the staining solution was filtered. 
3.2.5.1.6 Safranin O staining solution 
1 g    2-Sodiumtetraborate (Borax) 
1 g    Safranin O 
40 g    Saccharose 
2–3 drops  Formaldehyde 37% 
ad 100 ml   Aqua bidest. 
After dissolving borax in aqua bidest., Safranin O and saccharose were added and the staining 
solution was stirred for two hours and stored at room temperature until further processing. Prior 
to use, 2–3 drops of formaldehyde (37%) were added and the solution was finally filtrated. 
3.2.5.1.7 Uranyl acetate contrasting solution 
1 g    Uranyl acetate 
ad 50 ml   Aqua bidest. 
Solution was carefully stirred and filtered prior to use. 
3.2.5.1.8 Lead acetate contrasting solution 
6 ml    Sodium citrate 
4 ml    Lead nitrate solution (1 M) 
8 ml    NaOH (1 M) 
ad 50 ml   Aqua bidest. 
Sodium citrate was dissolved in aqua bidest. while stirring. Then, lead nitrate solution was 
added dropwise followed by precipitation. NaOH was administered until the solution returned 
clear. Filtration was required before use. 
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3.2.5.2 Buffers for agarose gel electrophoresis 
3.2.5.2.1 TAE buffer (50x) 
242 g   Tris 
57.1 ml   Glacial acetic acid 
100 ml   EDTA 0.5 M (pH 8.0) 
ad 1000 ml  Aqua bidest. 
Buffer was diluted to single concentration with aqua bidest. prior to use. 
3.2.5.2.2 TAE running buffer (1x) 
20 ml   50 x TAE buffer 
ad 1000 ml  Aqua bidest. 
3.2.5.2.3 Loading buffer for DNA (6x) 
3 ml    Glycerol 
7 ml    Aqua bidest. 
Tip of a spatula  bromophenolblue 
Buffer was aliquoted and stored at 4°C until usage. 
3.2.5.3 Buffers and solutions for tissue preparation and immunhistochemical stainings 
3.2.5.3.1 DAB solution 
According to safety instructions, aliquotes were prepared by dissolving one tablet DAB in 10 
ml aqua bidest. Followed by filtration and storage at -20°C protected from light. Prior to use, 
aliquots were thawed in the dark and 2 µl H2O2 per 1 ml DAB solution was added. 
3.2.5.3.2 PBS 
0.25 g  Potassium hydrogen phosphate 
8.0 g   Sodium chloride 
1.46 g  Sodium phosphate dibasic dehydrate 
1 l    Aqua bidest. 
3.2.5.3.3 TBS (10x) (pH 7.6) 
90 g    NaCl 
60.5 g   Tris 
ad 1000 ml  Aqua bidest. 
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Concentrated stock buffer was autoclaved and diluted to single concentration with aqua bidest. 
prior to use. 
3.2.5.3.4 100 mM Tris/HCl (pH 8.5) 
100 mM   Tris 
Accurate adjustment of pH 8.5 is required for the desired staining intensity. 
3.2.5.4 Solutions for hematoxylin and eosin staining 
3.2.5.4.1 HCL-ethyl alcohol stock solution 
7000 ml  Alcohol 96% 
2500 ml  Aqua bidest. 
100 ml  Hydrochloric acid 25% 
3.2.5.4.2 HCL-ethyl alcohol working solution 
100 ml  HCL-ethyl alcohol stock solution 
100 ml  Alcohol 70% 
3.2.5.4.3 1% eosin solution 
10 g   Eosin 
1000 ml  Aqua bidest. 
1.5 ml  Glacial acetic acid 
Eosin was diluted in hot aqua bidest. and cooled down before glacial acetic acid was added. 
3.2.6 Kits 
NexttecTM Genomic DNA Isolation Kit    Nexttec GmbH, Leverkusen, DE 
Porcine C-peptide ELISA     Mercodia AB, Uppsala, Sweden 
Porcine Insulin Radioimmunoassay (RIA) Kit   MilliporeTM, Billerica, USA 
3.2.7 Other reagents 
Bode Sterilium® hand sanitizer     Bode Chemie, Hamburg, DE 
Goat serum        MP Biomedicals, Illkirch, France 
Histokitt         Engelbrecht, DE 
PCR buffer        Qiagen GmbH, Hilden, DE 
Porcine serum        MP Biomedicals, Illkirch, France 
Q-solution         Qiagen GmbH, Hilden, DE 
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Rabbit serum       MP Biomedicals, Illkirch, France 
Vet-Sept® solution (10%)      A. Albrecht, Aulendorf, DE 
3.2.8 DNA molecular weight markers  
Gene RulerTM (1kb DNA Ladder)    MBI Fermentas, St. Leon Roth, DE 
3.2.9 Software 
GE Lunar analysis software version 4.7e   GE Healthcare GmbH, Solingen, DE 
GraphPad Prism® version 5.0     GraphPad Software Inc., La Jolla, USA 
Microsoft Paint       Microsoft Corporation, Redmond, USA 
NewCASTTM stereology acquisition and    Visiopharm, Hoersholm, Denmark  
analyses system 
Olympus VisiomorphTM image analyses    Visiopharm, Hoersholm, Denmark 
SAS (version 8.2)       SAS Institut Inc., USA 
3.3 Methods 
3.3.1 Generation of INSC94Y transgenic and non-transgenic MPHs 
Previously, INSC94Y transgenic pigs were generated by somatic cell nuclear transfer (SCNT) on 
a DP background (Renner, 2013). For the generation of MPHs oestrus synchronized INSC94Y 
transgenic sows (#1605 and #1611) were artificially inseminated using semen of a non-
transgenic black minipig boar (#MP10). For oestrus synchronization altrenogest (Regumate®) 
was given orally for 17 days to the sows. Forty-eight hours post application of the last 
altrenogest portion, 750 IU of pregnant mare serum gonadotropin (PMSG, Intergonan®) were 
injected intramuscularly (i.m.) followed by an injection of 750 IU of human chorionic 
gonadotropin (hCG, Ovogest®, Intervet, Unterschleißheim, DE) i.m. 80 hours after PMSG 
administration (Kurome, Ueda et al. 2006). Twenty-four hours post hCG injection artificial 
insemination was performed on two consecutive days. 
3.3.2 Identification of INSC94Y transgenic and non-transgenic MPHs 
To discriminate INSC94Y transgenic piglets from wild-type animals, a genotype-specific PCR 
was performed on tissue samples from tail biopsies of each newborn piglet. 
Genotyping of INSC94Y transgenic MPHs and non-transgenic controls was kindly performed by 
Ana Sofia Martins (Chair for Molecular Animal Breeding and Biotechnology, LMU Munich). 
3.3.2.1 Isolation of genomic DNA from tail biopsy 
Tissue for DNA isolation was obtained from tail biopsies of newborn piglets and stored at -20°C 
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until further processing. A NexttecTM Genomic DNA Isolation Kit (Nexttec GmbH, Leverkusen, 
DE) was used for isolation of genomic DNA from tissue samples according to the 
manufacturer’s instruction. The different steps of the procedure were performed at room 
temperature unless stated otherwise. First, the tissue sample was minced and transferred into 
1.5 ml reaction tubes. Lysis buffer (containing 3 µl DTT) was added and the sample was 
incubated for tissue digestion overnight at 60°C. The next day DNA was purified by transferring 
120 µl of the lysate to NexttecTM Clean Columns followed by an incubation step of three 
minutes and subsequent centrifugation for one minute at 700 x g. The eluate including the 
purified DNA was either immediately used for genotyping PCR or stored at 4°C until further 
processing. 
3.3.2.2 Polymerase chain reaction (PCR) 
To identify INSC94Y transgenic pigs genotyping PCR was performed. As the neomycin 
resistance cassette was linked to the INSC94Y expression cassette, neomycin resistance cassette 
specific primers A and B were used as displayed in Table 2. 
To verify the integrity of genomic DNA the house-keeping gene β-actin (ACTB) was amplified 
additionally. Due to its constant expression at high levels in all relevant cell types, it was used 
as a loading control. For ACTB PCR specific primers C and D were used  
(Table 2). 
Table 2: Primers used for PCR 
Primer C ACTB  (sense) 5 -́TGGACTTCGAGCAGAGATGG-3´
Primer D ACTB  (antisense) 5 -́CACCGTGTTGGCGTAGAGG-3´
Primer Base sequence
Primer A neoPf (sense) 5 -́ CAGCTGTGCTCGACGTTGTC-3´
Primer B neoSr (antisense) 5 -́ GAGTCAACTAGTCCTCAGAAGAACTCGTCAAG-3´
 
All reaction components (Table 3) were set up in an area separate from that used for DNA 
preparation or further analyses of amplified DNA. Tips containing hydrophobic filters to 
minimize crosscontamination were used. After thawing all components were mixed (excluding 
template DNA) on ice in 0.2 ml reaction tubes to a total volume of 25 µl or 20 µl respectively. 
Finally, the template DNA was added and the composition was mixed gently by pipetting up 
and down. PCR tubes were kept on ice before being placed into the thermocycler.  
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Table 3: Reaction compositions for neoPf/neoSr and ACTB PCR 
2.5 µl 2 µl
2.5 µl 1.25 µl
2.5 µl 4 µl
0.4 µl 2 µl
0.4 µl 0.4 µl
0.2 µl 0.4 µl
15.5 µl 0.2 µl
1 µl 8.75 µl
1 µl
25 µl 20 µl
Aqua bidest.
Primer B (10 µM) Primer C (10 µM)
Q-solution (Qiagen)
dNTPs (2 mM)
Primer D (10 µM)
ACTB  sense/antisenseneo Pf/neo Sr
Taq DNA polymerase (5 U/µl)
Total volume
10 x PCR buffer (Qiagen)
MgCl2 (15 mM) (Qiagen)
dNTPs (2 mM)
Primer A (10 µM)
10 x PCR buffer (Qiagen)
MgCl2 (25 mM) (Qiagen)
DNA template Aqua bidest.
DNA template
Total volume
Taq DNA polymerase (5 U/µl)
 
The cycling program shown in Table 4 was used to perform PCR. 
Table 4:  Thermocycler conditions 
95°C 1 x
95°C
62°C
72°C
72°C 1 x
Program for Neo and ACTB PCR
35 xAnnealing 30 sec
Elongation 45 sec
Final Elongation 10 min.
Denaturation 4 min.
Denaturation 30 sec
 
To stop the reaction, the temperature of the thermocycler was cooled down to 4°C. After 
amplification the samples were stored overnight at 2–8°C or for longer storage at -20°C until 
further processing. To proof the validity of the processed PCR a positive and negative control 
were used, containing DNA from a previously genotyped INSC94Ytransgenic and non-transgenic 
pig respectively. Aqua bidest. served as non-template control. 
3.3.2.3 Agarose gel electrophoresis 
After the completion of the PCR program, amplified DNA fragments were separated by agarose 
gel electrophoresis which separates DNA fragments according to their size. For this reason a 
2% agarose solution was prepared with TAE buffer. The mixture was heated up by a microwave 
until the agarose was melted. Afterwards ethidium bromide (0.5 µg/ml) was added which 
intercalates into the DNA. Due to its fluorescent properties DNA strands can be visualized 
under UV-light. The gel mixture was filled into an electrophoresis chamber with a special comb. 
When the gel was hardened TAE running buffer was added to the chamber and the comb was 
removed. In the next step 6x DNA loading dye was added to PCR samples that afterwards were 
loaded into the gel slots, together with a DNA molecular weight standard (Gene RulerTM 1kb, 
MBI Fermentas, St. Leon Roth, DE) as a standard for fragment size. The electrophoresis 
chamber was connected to an anode and a cathode. Due to the negatively charged DNA, 
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fragments were moving through the gel towards the anode. Smaller ones moved faster than 
larger ones so that after a certain time DNA fragments differing in size were separated in the 
chamber and could be visualized by UV-light irradiation. 
3.3.3 Physiological characterization of INSC94Y transgenic and non-transgenic MPHs 
3.3.3.1 Analyses of body weight gain and body measurements 
3.3.3.1.1 Body weight gain 
Body weight of all INSC94Y transgenic MPHs, non-transgenic littermates as well as of age-
matched non-transgenic DPs was determined in regular intervals from the day of birth prior to 
colostrum uptake until day 178 of age. In addition, birth weight of wild-type DPs born to 
INSC94Y transgenic domestic sows was determined. Standard large animal scales (Kern, Meier-
Brakenberg, DE) were used with an inaccuracy of ± 5 gram up to a body weight of 10 kilogram 
and ± 100 gram for a body weight above 10 kilogram. 
3.3.3.1.2 Growth parameters 
Growth parameters of INSC94Y transgenic and non-transgenic MPHs and age-matched non-
transgenic DPs were measured in centimeters using a measuring tape, caliper or ruler. In total, 
five measurements starting with the day of birth and subsequently on day 14, 28, 63 and 153 
were performed. The following growth parameters were determined: occipito-nasal length, 
biparietal diameter, crown-rump length, height and width of the shoulder, circumference of the 
forearm, thorax, abdomen and shank as well as height and width of the hip. The landmarks of 
each parameter were kept constant during all measurements and were defined as shown in 
Table 5. 
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Table 5: Measurement of growth parameters 
Growth Parameter Landmarks Measuring tool
Occipito-nasal length Occiput at the base of the head – tip of the nose Measuring tape
Biparietal diameter At the level caudal of the eyes Caliper
Crown-rump length Base of the head (occiput) to base of the tail Measuring tape
Shoulder height
Highest point of the shoulders; animals ≤40 kg 
were in a hanging position; animals ≥40 kg were 
standing on the ground Ruler and rod
Shoulder width Widest point of shoulder (processus caracoideus) Caliper
Forearm circumference 2 cm above the carpal joint Measuring tape
Thorax circumference Right next to the front legs Measuring tape
Abdomen circumference At the level of the umbilicus Measuring tape
Shank circumference 2 cm above the tuberculum tarsi Measuring tape
Hip height
Highest point of the hipss; animals ≤40 kg were in 
a hanging position; animals ≥40 kg were standing 
on the ground Ruler and rod
Hip width Widest point of the hip (tuber coxae) Caliper  
3.3.3.2 Body composition by Dual-energy X-ray absorptiometry (DXA) 
Body composition of INSC94Y transgenic and non-transgenic MPHs as well as of age-matched 
wild-type DPs was analysed in duplicate at an age of six months by Dual-energy X-ray 
absorptiometry (DXA) using a GE Lunar iDXA scanner (GE Healthcare GmbH, Solingen, DE). 
Subsequently, the mean value of the respective data generated on these two measurements was 
calculated.  
DXA measurements were performed under anaesthesia. Anaesthesia was induced by 
intramuscular injection of azaperone (2 mg/kg BW) and ketamine hydrochloride (20 mg/kg 
BW) and maintained by intravenous application of ketamine hydrochloride (20 mg/kg BW) and 
xylazine (1 mg/kg BW) if necessary. Under anaesthesia, animals were positioned in prone 
position with the front legs outstretched in caudal direction for the scanning process. The whole 
body mode „adult normal“ was used and each animal was scanned from rostral to caudal 
direction. Data were generated and recorded with the GE Lunar analyses software (version 
4.7e). 
The principle of DXA measurements is based on the unequal absorption capacity for different 
body tissues scanned by two X-ray beams with different energy levels. On the basis of these 
differences, body composition can be determined. The following parameters were determined: 
total tissue corresponding to body weight, bone mineral content, fat mass and lean mass 
expressed in gram. The bone mineral density was expressed in g/cm². Additionally, the ratio of 
each parameter to total tissue was calculated in percent except for bone mineral density. 
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3.3.3.3 Determination of blood parameters 
3.3.3.3.1 Blood glucose levels 
To monitor glucose homeostasis of INSC94Y transgenic MPHs and their wild-type littermates, 
random blood glucose levels were determined in regular intervals starting at day four of age 
until five weeks of age, i.e., the time point of weaning. Thereafter, blood glucose levels were 
determined following an overnight fasting period of 18 hours until five months of age. 
For this, a superficial ear vein was punctured with a blood lancet to gain a little drop of blood 
which was immediately applied on a Precision Xtra Plus blood glucose test stripe (Abbott, 
Wiesbaden, DE) and examined using a FreeStyle Precision® Xceed glucometer (Abbott, 
Wiesbaden, DE). 
3.3.3.3.2 Clinical chemical parameters 
Clinical-chemical parameters of INSC94Y transgenic MPHs and wild-type littermates were 
determined from EDTA-plasma at seven (not fasted) and 180 days (fasted overnight) of age 
using an AU480 autoanalyzer (Beckman-Coulter, Krefeld, DE) and adapted reagent kits from 
Beckman-Coulter, Randox or Wako Chemicals. 
3.3.3.3.3 Plasma insulin concentrations by radioimmunoassay (RIA)  
To determine plasma insulin concentrations of INSC94Y transgenic MPHs and their non-
transgenic littermates, a commercial porcine insulin RIA kit (MilliporeTM, Billerica, USA) was 
used. Non-fasting blood samples of the two animal groups were taken on day seven of age and 
fasting (18-hour overnight fast) blood samples were collected at the age of 180 days. Blood was 
collected in EDTA monovettes and immediately stored on ice until centrifugation. Samples 
were centrifuged within 30 minutes after sampling (15 minutes, 1500 x g, 4°C) followed by 
plasma separation and storage at -80°C until usage. The radioimmunoassays were performed 
according to the manufacturer’s instructions. The assay is based on the competitive binding of 
radiolabeled insulin (tracer) and unlabeled insulin in a defined volume of the respective plasma 
sample to a limited and constant quantity of antibodies specific for porcine insulin. When the 
amount of labeled antigen decreases, thus the concentration of unlabeled antigen increases. For 
the labeling the radioisotope 125I was used. Accordingly, tracer, test sample and antibody were 
added to a special assay buffer. Mixture was vortexed and incubated overnight at 4°C. The next 
day antibody-bound tracer was precipitated and separated from unbound tracer by 
centrifugation. The supernatant was carefully decanted. Afterwards the amount of antibody-
bound tracer was determined with a γ-counter (Berthold, Bad Wildbach). All samples were 
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measured in duplicate. Only duplicates with a coefficient of variance (CV) less than 10% were 
accepted. 
3.3.3.3.4 Plasma connecting peptide (C-peptide) concentrations by enzyme-linked 
immunosorbent assay (ELISA) 
Non-fasting and fasting levels of plasma C-peptide concentrations were measured in the same 
animals and at the same points in time as for the determination of plasma insulin concentrations. 
Blood samples were collected and processed as described in 3.3.3.3.3. A commercially 
available ELISA kit (Mercodia AB, Uppsala, Sweden) for porcine C-peptide was used 
according to the manufacturer’s protocol. The procedure is based on the antigen-antibody 
reaction of two monoclonal antibodies which are directed against separate antigenic 
determinants on the C-peptide molecule. The second antibody is enzyme conjugated, leading 
to a concentration-dependent color change after substrate supplementation that can be measured 
by a spectrophotometer. Before starting the assay, all reagents and blood plasma samples were 
brought to room temperature. Enzyme conjugate solution (containing mouse monoclonal anti-
porcine C-peptide antibody II) and wash buffer were prepared according to the manufacturer’s 
instructions. The plasma sample was pipetted into a well of the precoated plate (precoated with 
mouse monoclonal anti-porcine C-peptide antibody I). Assay buffer was added to each well and 
incubated on a plate shaker (500 rpm) for two hours at room temperature. Afterwards the 
reaction volume was discarded by inverting the microplate and then each well was washed six 
times with wash buffer, removing liquids by tapping firmly several times against absorbent 
paper between each washing step. Subsequently, enzyme conjugate solution was added, 
incubated for one hour on a plate shaker and washed again six times with the same 
specifications as described before. Then, the substrate tetramethylbenzidine (TMB) was added 
and incubated for 15 minutes at room temperature. The reaction was stopped by addition of the 
stop solution (0.5 M H2SO4) that was mixed with TMB on a shaker for five seconds. Finally, 
the optical density was read spectrophotometrically (450 nm) and results were calculated by 
comparing to the calibrator curve which originates from five different standard C-peptide 
concentrations using cubic spline regression. 
3.3.4 Morphological characterization of INSC94Y transgenic and non-transgenic MPHs 
3.3.4.1 Necropsy 
Routine necropsy was performed on INSC94Y transgenic MPHs, wild-type littermates and age-
matched non-transgenic DPs at the end of the observation period, i.e., at an age of six months. 
Anaesthesia was induced by intramuscular injection of azaperone (2 mg/kg BW) and ketamine 
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hydrochloride (20 mg/kg BW) in the animals familiar surroundings followed by intravenous 
injection of T61 (1 ml/10 kg BW) for euthanasia. After confirmation of death, body cavities 
were opened and organs were quickly inspected in situ before removal in order to their 
sensitivity towards fast autolysis (Albl, Haesner et al. 2016). All organs were macroscopically 
evaluated and selected organs were weighed. 
3.3.4.2 Absolute and relative organ weights 
Immediately after death and evisceration of the animals, organs were prepared like described 
in 3.3.4.1. For heavy-weight tissues (>2.5 kilogram, e.g., liver), a digital scale (Mettler PM 
6000, Mettler-Toledo GmbH, Gießen, DE) with the measuring unit kilogram and an inaccuracy 
of +/-200 gram was used. The weighing of light-weight tissues (<2.5 kilogram, e.g., pancreas) 
was performed with an analogue scale (Bizerba, August Sauter KG, Ebingen, DE) with the 
measuring unit gram. For the kidneys, the cumulative weight of the left and the right kidney 
was recorded. The stomach was weighed after removal of its content. Additionally, organ 
weights relative to the individual body weight of each animal were calculated. 
3.3.4.3 Pancreas preparation and systematic random sampling 
Due to the rapid autolysis of pancreatic tissue, this organ was eviscerated as fast as possible 
like described above (see chapter 3.3.4.1) and fat, blood vessels and connective tissue were 
removed. After weighing, the pancreas was cut at the intersection between splenic and 
connective lobe and laid out lengthwise over the working table. The organ was cut into parallel, 
equidistant, approximately 0.5 cm thick slices that were tilted to their left side. To avoid any 
more tissue damage due to manipulation, pancreas slices were prefixed in 4% neutral buffered 
formalin overnight. For a volume-weighted systematic random sampling of pancreas tissue 
locations, the pancreas slices were laid on a plane surface and superimposed by a one cm² point-
counting grid (Blutke and Wanke 2018). The number of points that hit pancreatic tissue was 
counted. A tenth of the total number of hitting-points defined hereby the total sample number. 
The quotient of total number of hitting-points and total sample number was calculated and 
termed as (Y). A random number (X) between one and (Y) was chosen for the selection of 
sample collection sites. Pieces with a volume of 0.5 cm³ were collected systematically at the 
sites X, X+Y, X+2*Y, X+3*Y, … An example is shown in Table 6. 
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Table 6: Example for systematic random sampling of pancreatic tissue 
Total number of hitting points 250
Sample number (by definition 1/10 of total number of points hitting 
pancreas
25
Y (Quotient of total number of hitting-points and total sample number) 10
X (random number) 3
Sites for sample collection 3, 13, 23, 33, …, 243
 
Selected samples were placed pairwise with the right cutting surface facing downwards into 
embedding cassettes and were routinely processed for paraffin embedding. For histologic 
examination, 1.5 mm thick slices were cut using a HM 315 microtome (Microm, Walldorf, DE) 
and mounted on Star Frost® glass slides for immunohistochemistry. Finally, sections were dried 
in a 37°C warm incubator overnight or until immunohistochemical staining. 
For qualitative morphological evaluation of exocrine and endocrine pancreatic tissue a 
hematoxylin and eosin staining (HE) was performed from a subset of pancreatic sections. For 
this, sections were deparaffinized, rehydrated in a descending alcohol series and washed in 
distilled water as described in 3.3.4.4. Subsequently, sections were stained for four minutes in 
Mayer´s Hemalum solution. Then, slides were washed for four minutes under running warm 
tap water. For differentiation, sections were placed shortly in 0.5% HCL-ethyl alcohol before 
being washed again for four minutes under running warm tap water. Finally, sections were 
counterstained with 1% eosin for two minutes and afterwards dehydrated in an ascending 
alcohol series, cleared in Xylol and mounted as described in 3.3.4.4. 
3.3.4.4 Immunohistochemical staining of pancreatic tissue 
Immunohistochemical staining was performed for quantitative stereological analyses of 
pancreatic β- and α-cells of six-month-old INSC94Y transgenic and non-transgenic MPHs. 
Details of the different stainings are summarized in Table 7. 
To identify insulin containing β-cells or glucagon containing α-cells the indirect horseradish 
peroxidase (HRP) method was implemented, whereby the secondary antibody was HRP-
labelled and 3,3′-Diaminobenzidine (DAB) was used as substrate (chromogene). Slides were 
processed as follows. First, they were deparaffinized in xylene for at least 20 minutes, followed 
by rehydration in a descending alcohol series with a total incubation time of 1–2 minutes in 
each ethanol dilution (2 x 100%, 2 x 96%, 1 x 70%) and finally washed in distilled water. 
Endogenous peroxidase activity was blocked by incubation of the sections using 1% hydrogen 
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peroxide in distilled water for 15 minutes. Next, sections were washed in 1:10 diluted tris-
buffered saline (TBS, pH 7.4) for 10 minutes. To reduce non-specific binding, normal rabbit 
serum for β-cell staining and normal goat serum for α-cell staining in a dilution of 1:10 with 
TBS was applied on each section and incubated at room temperature for 30 minutes. 
Afterwards, serum was dripped off and the primary antibody diluted in TBS was applied and 
incubated at room temperature for one hour followed by a TBS washing step. Subsequently, 
the secondary antibody diluted in TBS and additionally containing 5% pig serum was applied 
and incubated as well at room temperature for one hour followed by a TBS washing step. Then, 
DAB (incubation time five minutes) was applied on each slide. DAB was activated by adding 
2 µl 30% hydrogen peroxide per one milliliter DAB. After incubation with DAB, slides were 
washed shortly in distilled water and then for 5 minutes in tap water. For counterstaining 
Mayer´s Hemalum solution was prepared (1:10 with distilled water) and slides were incubated 
for 1–2 minutes. Then slides were washed again in distilled water and for five minutes under 
running tap water. Finally, slides were placed in distilled water and dehydrated in an ascending 
alcohol series (1 x 70%, 2 x 96%, 2 x 100%) with an incubation time of 1–2 minutes per ethanol 
dilution, followed by clearing in xylene and mounting using histokitt and cover slips. 
Table 7: Antibodies for immunohistochemical stainings 
Antigen Dilution Dilution ChromogenPrimary Antibody Secondary Antibody
1:100
1:100
DAB
DAB
Rabbit-Anti-Guinea      
Pig HRP-conjugated
Goat-Anti-Rabbit       
HRP-conjugated
Insulin
Glucagon
Polyclonal Guinea Pig 
Anti-Porcine Insulin
Polyclonal Rabbit Anti-
Human Glucagon
1:1000
1:300
 
3.3.4.5 Qualitative histological analyses of the endocrine pancreas 
For a qualitative evaluation of the endocrine pancreas, namely β- and α-cells, representative 
micrographs of immunhistochemically-stained pancreatic sections of paraffin embedded tissue 
samples of INSC94Y transgenic animals and their wild-type littermates were selected and 
displayed with an Olympus VisiomorphTM image analyses system (Visiopharm, Hoersholm, 
Denmark) coupled to a systemic light microscope (BX41, Olympus, Hamburg, DE) and a 
digital microscope camera (DP72, Olympus, Hamburg, DE). The stereology module was driven 
by newCAST™ (Visiopharm, Hoersholm, Denmark). Slides were scanned for cells of interest 
using a joystick controlled rotating object scanning stage (Märzhäuser, Wetzlar, DE). To show 
the magnification-dependent size of the image, an object micrometer (Carl Zeiss, Oberkochen, 
DE) was photographed at the same magnification, respectively. 
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3.3.4.6 Quantitative stereological analyses of the endocrine pancreas 
Quantitative-stereological analyses were carried out using the computer-assisted stereology 
module, microscope and video camera as described in 3.3.4.5 Point-counting measurements 
were performed in immunhistochemically-stained pancreatic sections (either stained with an 
anti-insulin or anti-glucagon antibody as described in 3.3.4.4) of paraffin embedded tissue 
samples of INSC94Y transgenic and non-transgenic littermates. While opening the software, the 
system automatically calibrated itself. After mounting the slides on the object stage the region 
of interest (ROI), i.e., the section profile of the tissue on each section was determined. For this, 
magnification 1.25 x was chosen at the microscope and *Lens Control* was chosen at the 
screen. Then, *Mask Properties* was selected on the program and the outline of pancreatic 
tissue on every single section, i.e., the ROI was manually surrounded with the cursor, as 
precisely as possible. When all ROIs were defined, the objective was changed to magnification 
40 x before the fields of view (sampling positions) were sampled by selecting *Setup Meander 
Sampling*. The section area fraction to be analysed was set on 20%.The number of sampling 
positions per section was dependent on the ROI size of each section. Two different layers of 
virtual point-counting grids (R) were used and simultaneously placed above all sampled fields 
of view. The first grid (setting 8x8/1x1) yielded 64 possible hitting points (R1) and the second 
one (setting 10x10/6x6) yielded 3600 possible hitting points (R2). All hitting points were 
allocated in equal distances respectively. The setup was consistent for all measurements. After 
confirming setup configuration, the program led through all randomly sampled positions. Per 
field of view, points hitting pancreatic tissue using R1 and points hitting 
immunohistochemically insulin-positive or glucagon-positive section profiles of β-, 
respectively of α-cells using R2 were counted. Subsequently, the number of points hitting 
pancreatic tissue by R1 per field of view was multiplied by the factor of 56.25, which is the 
quotient of 3600 divided by 64. This multiplication allows estimating the total number of points 
hitting pancreatic tissue in the examined section field when using R2 and is required for further 
calculations. All hitting points and their conversions were recorded in an excel sheet for further 
calculations. 
The volume of the pancreas (V(Pan)) before embedding was calculated by the quotient of the 
pancreas weight and the specific weight of the pig pancreas (1.07 g/cm³) (Renner, Fehlings et 
al. 2010) determined by the submersion method (Albl, Haesner et al. 2016, Blutke and Wanke 
2018). The volume density of β- or α-cells in the pancreas (Vv(β-cells/Pan); Vv(α-cells/Pan)) was 
calculated by dividing the total number of points hitting the target-cell population by the total 
number of points hitting pancreatic tissue. The product of (Vv(β-cells/Pan)) or (Vv(α-cells/Pan)) and 
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(V(Pan)) yielded the total volume of β- or α-cells in the pancreas (β/α-cell mass, i.e., V(β-cells, Pan); 
V(α-cells, Pan)). Additionally, the volume of β and α-cells in the pancreas in relation to the 
respective body weight of the animals was calculated (V(β-cells, Pan)/BW; V(α-cells, Pan)/BW). 
3.3.4.7 Examination of β-cell ultrastructural morphology by transmission electron 
microscopy (TEM) 
Ultrastructural morphology of pancreatic β-cells of six-month-old INSC94Y transgenic and non-
transgenic MPHs was examined using an EM 10 transmission electron microscope (Carl Zeiss 
AG, Oberkochen, DE). For this, pieces of approximately one mm³ were collected from the 
pancreas by systematic random sampling (Albl, Haesner et al. 2016, Blutke and Wanke 2018). 
For fixation and structural preservation samples were immersed in 6.25% glutaraldehyde in 
Sorensen’s phosphate buffer (pH 7.4) for 24 hours at 8°C (Herbach, 2007). To remove surplus 
glutaraldehyde after fixation, all samples were rinsed in Sorensen’s washing solution at least 
three times and afterwards post-fixed in an osmium tetroxide fixation solution for two hours at 
4°C, before rinsed another time in Sorensen’s washing solution. Afterwards, the tissue samples 
were prepared for embedding in a glycidyl ether mixture. For this, samples were dehydrated in 
an ascending acetone series (50%, 2 x 70%, 2 x 90%, 10 minutes per dilution; 3 x 100%, 20 
minutes per dilution) at 4°C and then incubated for one hour at room temperature in a solution 
containing 100% acetone and glycidyl ether-embedding mixture in equal parts. Subsequently, 
incubation in undiluted glycidyl ether-embedding mixture (twice for 30 minutes at room 
temperature) and final embedding in the same glycidyl ether-embedding mixture in gelatine 
capsules was performed. For polymerization, capsules were incubated at 60°C for at least 48 
hours. After embedding, the sample blocks were trimmed using a TM60 milling machine (Leica 
Microsystems GmbH, Wetzlar, DE) and semi-thin sections (0.5 μm nominal section thickness) 
were prepared using a Reichert-Jung Ultracut E microtome (Leica Microsystems GmbH, 
Wetzlar, DE). Finally, sections were transferred to microscope slides by a drop of water, dried 
at 60°C and fixated over a flame. 
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To identify pancreatic islets within the semi-thin sections, staining with toluidine blue was 
performed. For this, slides were stained with toluidine blue staining solution for 15 seconds at 
55°C on a heating plate, rinsed with aqua bidest. and dried. Then slides were counterstained for 
15 seconds using a safranin staining solution, rinsed and dried again. Finally, sections were 
mounted using histofluid mounting medium. Using a light microscope islets were located in the 
semi-thin sections and marked by drawing an outline of each piece of tissue and plotting the 
position of the “target-islet” on it. Based on these marked outlines, ultra-thin sections (70–80 
nm) were cut just at these previously marked localizations, also using a Reichert-Jung Ultracut 
E microtome. These sections were then mounted on copper rings for negative staining with 
uranyl acetate and lead citrate according to the method of Reynolds (Reynolds 1963).  
The evaluation of electron micrographs was kindly performed in cooperation with Dr. Elisabeth 
Kemter (Chair for Molecular Animal Breeding and Biotechnology).  
3.3.4.8 Qualitative histological evaluation of the kidneys 
At routine necropsy of INSC94Y transgenic and non-transgenic MPHs (see chapter 3.3.4.1), both 
kidneys were extracted, weighed, decapsulated and then fixed in 4% phosphate buffered 
formaldehyde for 24 hours. Kidney tissue locations were collected systematically and selected 
samples were routinely processed for paraffin embedding. Afterwards, sections of 
approximately 1.5 µm thickness were prepared with a HM 360 rotary microtome (Microm, 
Walldorf) and transferred on microscope slides before dried overnight at 37°C in an incubator. 
For HE staining, slides were routinely processed as described in 3.3.4.3. Qualitative histological 
analysis of the kidney tissue was performed using the same equipment as previously described 
in 3.3.4.5. Histopathological evaluation was performed in cooperation with Priv.-Doz. Dr. 
Andreas Parzefall, Institute of Veterinary Pathology, Ludwig-Maximilians-University, 
Munich.  
3.3.4.9 Qualitative histological evaluation of the eye lens 
During routine necropsy of INSC94Y transgenic and non-transgenic MPHs (see chapter 3.3.4.1) 
whole eye globes were dissected and fixated in Davidson's solution for a maximum of 24 hours. 
After fixation eye globes were cut longitudinally and routinely processed for paraffin 
embedding and HE staining as described in chapter 3.3.4.3. Qualitative histological 
examination of the lens was performed with the same equipment as previously described in 
chapter 3.3.4.5. 
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3.3.5 Statistics 
All data are presented as means ± standard error of means (SEM). Body weight gain and blood 
glucose concentrations were statistically evaluated by analysis of variance (ANOVA, Linear 
Mixed Models; SAS 8.2; Procedure MIXED), taking the fixed effects of Genotype (DP wt vs. 
MPH wt or MPH wt vs. MPH tg), Age and the interaction Genotype*Age as well as the random 
effect of Animal into account. Growth and clinical chemical parameters, concentrations of 
insulin and connecting peptide, body composition and organ weights were evaluated by the 
General Linear Model (GLM) procedure (SAS 8.2) including the fixed effects of Genotype (DP 
wt vs. MPH wt or MPH wt vs. MPH tg) and Age as well as the interaction Genotype x Age. 
For the parameters of body composition the fixed effects of Sex (female vs. male) and the 
interaction Genotype*Sex were also taken into account. Statistical significance of parameters 
evaluated by quantitative-stereological analyses was tested using an unpaired, two-tailed Mann-
Whitney-U test. P values less than 0.05 were considered significant. 
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4 RESULTS 
4.1 Generation of INSC94Y transgenic and non-transgenic domestic pig-
minipig hybrids (MPHs) 
For the generation of MPHs, two INSC94Y transgenic domestic pig (DP) sows (ID#1605/1611) 
were artificially inseminated on two consecutive days with semen from a non-transgenic black 
minipig boar. 
INSC94Y transgenic pigs on a DP background have been previously generated and characterized 
at the Chair for Molecular Animal Breeding and Biotechnology (Ludwig Maximilians 
University Munich) (Renner, 2013). Founder boars expressing the mutant insulin C94Y were 
generated using somatic cell nuclear transfer according to (Kurome, Ueda et al. 2006).  
Details of the mating and delivery management of MPHs are indicated in the Table 8: 
Table 8: Crossbreeding of INSC94Y transgenic domestic sows and a wild-type founder boar 
#1605 #MP10 25.02.2015 17.06.2015 19.06.2015 11 1 1
#1611 #MP10 26.02.2015 18.06.2015 19.06.2015 9 1 0
ID=identifier 
Mummy Stillborn
Wild type 
minipig sire 
ID
Transgenic            
domestic 
dam ID
Litter size   
total
Delivery    
date
Induction
Mating   
date
 
Prior to artificial insemination recipient gilts were estrus synchronized according to Kurome et 
al. 2015. Delivery was induced by a Prostaglandin F2α analogue (Estrumate®) two days prior 
to the calculated delivery date. Both dams delivered at the same day, following a normal 
gestation period (114/115 days). The total litter size of dam #1605 contained eleven piglets, 
including one stillborn and one mummy. Dam #1611 gave birth to nine piglets in total, 
including one stillborn. 
The inheritance of the INSC94Y transgene to the offspring is displayed in Table 9: 
Table 9: Inheritance of the INSC94Y transgene 
Dam Genotype %
ID ID Live piglets m (wt) m (tg) f (wt) f (tg) wt tg
#1605 #4136-4144 9 1 2 3 3 44.4 55.6
#1611 #4251-4258 8 4 1 2 1 75 25
Offspring
ID= identifier  
The litter with the piglets #4136–4144 contained four wild-type and five transgenic animals. 
Two piglets died within the first (#4137) and the third week (#4138) of life respectively. 
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Offspring #4251–4258 consisted of six wild-type and two transgenic piglets. Two piglets died 
within the first (#4251) and second week (#4252) after birth respectively. 
4.2 Genotyping by polymerase chain reaction (PCR) 
To identify which of the individuals of both litters had integrated the mutant INSC94Y transgene 
into their genome, transgene-specific PCR on genomic DNA isolated from tail biopsies of the 
neonatal piglets was performed. Proof for the INSC94Y transgene integration was the presence of 
a 500 bp band, this was detected in the transgenic MPHs whereas wild-type littermates did not 
show any bands.  
As a loading control, ACTB specific primers were used to amplify a 330 bp fragment. A visible 
band assured DNA integrity for each animal analysed. 
4.3 Physiological characteristics of INSC94Y transgenic and non-transgenic 
domestic pig-minipig hybrids 
4.3.1 Analyses of body weight gain and body measurements 
4.3.1.1 Body weight gain 
Body weight gain of INSC94Y transgenic MPHs (n=6), non-transgenic MPH littermates (n=7) 
and age-matched wild-type domestic pigs (DP) (n=5) and birth weight of wild-type MPHs 
(n=10) and wild-type DPs (n=31) born to INSC94Y transgenic DP sows are displayed in  
Figure 2. The body weight (BW) was determined at regular intervals to estimate the impact on 
weight gain by crossing in minipigs into a domestic pig line and additionally to evaluate the 
effect of the expression of the mutant insulin C94Y on body weight gain in the MPHs starting 
from the day of birth prior to first colostrum uptake until six months of age. 
Non-transgenic MPHs and non-transgenic DPs grew up matchable until week five of age 
(Figure 2 A). Starting at six weeks of age MPHs showed a significantly reduced body weight 
(6 ± 0.5 vs. 9.9 ± 0.8 kg; p<0.05). With increasing age, the differences in body weight gain 
increased. BW of wild-type MPHs was reduced by 39% compared to wild-type DPs at the age 
of six months (Figure 2 D, left picture).   
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INSC94Y transgenic MPHs showed significant body weight reduction starting at 11 weeks of age 
(Figure 2 B) in comparison to wild-type littermates (12 ± 0.3 vs. 16 ± 1.2 kg; p<0.01). With an 
age of six months INSC94Y transgenic MPHs reached a body weight reduction of 55% compared 
to non-transgenic littermates (Figure 2 D, right picture).  
Wild-type MPHs showed a significantly reduced birth weight compared to wild-type DPs 
(0.828 ± 0.06 vs. 1.168 ± 0.05 kg; p<0.001) that were also born to INSC94Y transgenic DP sows 
like wild-type MPHs (Figure 2 C). The separately evaluated birth weight also contained wild-
type MPHs (n=10) that died within the first week of life and consequently were excluded from 
the long-term evaluation (from birth up to six months of age) of BW gain of wild-type MPHs 
(n=7) versus wild-type DPs from non-transgenic sows. 
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Figure 2: Body weight gain of INSC94Y transgenic and non-transgenic MPHs 
and age-matched wild-type DPs 
(A, B) Body weight gain of wild-type MPHs (wt) vs. age-matched wild-type DPs (wt) (A) 
and of INSC94Y transgenic MPHs (tg) vs. non-transgenic MPHs (wt) (B) from birth up to six 
months of age. Birth weight of wild-type MPHs (wt) vs. wild-type DPs (wt) both from an 
INSC94Y transgenic DP sow (C) and body weight at six months of wild-type MPHs (wt) vs. 
age-matched wild-type DPs (wt) (D); Data are indicated as means ± SEM; *: p<0.05; **: 
p<0.01; ***: p<0.001 vs. controls; n: number of animals investigated. 
4.3.1.2 Growth parameters 
Additionally to the body weight gain displayed in Figure 2, selected growth parameters of 
INSC94Y transgenic MPHs (n=6), non-transgenic littermates (n=7) and of age-matched DPs 
(n=5) were evaluated to investigate the effect of minipig crossbreeding and of the expression 
of the mutant insulin C94Y on body shape. 
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Therefore, the following parameters were determined at regular intervals from birth until day 
153 of age for each animal: occipito-nasal length, biparietal diameter, crown-rump length, 
height and width of the shoulder, circumference of the forearm, the thorax, the abdomen and 
the shank, as well as height and width of the hip.  
Comparing wild-type MPHs and age-matched DPs, DPs revealed differences in body size 
starting at birth and getting more pronounced with increasing age (Figure 3 A-K, left side). At 
the latest time point measured (day 153 of age) DPs showed a significantly increased occipito-
nasal length of 17% (30.8 ± 0.4 vs. 26.4 ± 1 cm; p<0.001), biparietal diameter was increased 
by 18% (12.8 ± 0.4 vs. 10.8 ± 0.3 cm; p<0.001), crown-rump length by 29% (116.4 ± 3.2 vs. 
90.3 ± 1.6 cm; p<0.001), shoulder height by 34% (63.4 ± 1.3 vs. 47.3 ± 1.2 cm; p<0.001), 
shoulder width by 16% (25.0 ± 0.3 vs. 21.6 ± 0.5 cm; p<0.001), forearm circumference by 27% 
(23.6 ± 0.2 vs. 18.6 ± 0.9 cm; p<0.001), thoracic circumference by 12% (94.6 ± 0.9 vs. 84.7 ± 
2.2 cm; p<0.001) abdominal circumference by 8% (107 ± 2.3 vs. 99.2 ± 2.1 cm; p<0.001), hip 
height by 28% (66 ± 1.1 vs. 51.4 ± 0.8 cm; p<0.001), hip width by 19% (21 ± 0.7 vs. 17.6 ± 0.5 
cm; p<0.001) and shank circumference by 18% (25.8 ± 0.4 vs. 21.8 ± 0.8 cm; p<0.001) 
compared to wild-type MPHs. Several growth parameters of wild-type DPs were already 
significantly increased at the day of birth compared to parameters of the non-transgenic MPHs 
like shoulder height by 29% (19 ± 0.5 vs. 14.7 ± 0.4 cm; p<0.01) and hip height by 27% (18.7 
± 0.7 vs. 14.7 ± 0.5 cm; p<0.05). Representive pictures of wild-type DPs and MPHs are 
presented in Figure 4. 
The comparison of the same growth parameters between INSC94Y transgenic MPHs and wild-
type littermates mainly showed significantly altered values on day 153 of age (Figure 3 A-K, 
right side). On this last time point of measurement INSC94Y transgenic MPHs displayed 
significantly reduced mean values of all parameters compared to their non-transgenic 
littermates: occipito-nasal length was decreased by 18% (21.8 ± 0.4 vs. 26.4 ± 1 cm; p<0.001), 
biparietal diameter by 12% (9.5 ± 0.2 vs. 10.8 ± 0.3 cm; p<0.001), crown-rump length by 19% 
(73.3 ± 1.9 vs. 90.3 ± 1.6 cm; p<0.001), shoulder height by 20% (38 ± 0.7 vs. 47.3 ± 1.2 cm; 
p<0.001), shoulder width by 29% (15.3 ± 0.7 vs. 21.6 ± 0.5 cm; p<0.001), forearm 
circumference by 20% (14.9 ± 0.7 vs. 18.6 ± 0.9 cm; p<0.001), thoracic circumference by 21% 
(67.3 ± 1.9 vs. 84.7 ± 2.2 cm; p<0.001), abdominal circumference by 16% (83.5 ± 1.9 vs. 99.2 
± 2.1 cm; p<0.001), hip height by 16% (43.4 ± 1.2 vs. 51.4 ± 0.8 cm; p<0.001), hip width by 
29% (12.5 ± 0.3 vs. 17.6 ± 0.5 cm; p<0.001) and shank circumference by 20% (17.4 ± 0.5 vs. 
21.8 ± 0.8 cm; p<0.001). 
Results 81 
 
  
A 
B 
C 
0 20 40 60 80 100 120 140 160 180
0
10
20
30
40
MPH tg (n=6)
MPH wt (n=7)
***
**
*
Age (days)
 O
c
c
ip
it
o
-n
a
s
a
l 
le
n
g
th
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
10
20
30
40
MPH wt (n=7)
DP wt (n=5)
***
**
**
Age (days)
 O
c
c
ip
it
o
-n
a
s
a
l 
le
n
g
th
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
5
10
15
MPH tg (n=6)
MPH wt (n=7)
***
Age (days)
  
B
ip
a
ri
e
ta
l 
d
ia
m
e
te
r 
(c
m
)
0 20 40 60 80 100 120 140 160 180
0
5
10
15
MPH wt (n=7)
DP wt (n=5)
**
***
Age (days)
  
B
ip
a
ri
e
ta
l 
d
ia
m
e
te
r 
(c
m
)
0 20 40 60 80 100 120 140 160 180
0
50
100
150
MPH wt (n=7)
DP wt (n=5)
***
***
Age (days)
C
ro
w
n
-r
u
m
p
 l
e
n
g
th
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
50
100
150
MPH tg (n=6)
MPH wt (n=7)
***
Age (days)
C
ro
w
n
-r
u
m
p
 l
e
n
g
th
 (
c
m
)
Results 82 
 
  
D 
E 
F 
0 20 40 60 80 100 120 140 160 180
0
20
40
60
80
MPH tg (n=6)
MPH wt (n=7)
***
Age (days)
  
S
h
o
u
ld
e
r 
h
e
ig
h
t 
(c
m
)
0 20 40 60 80 100 120 140 160 180
0
20
40
60
80
MPH wt (n=7)
DP wt (n=5)
**
**
***
Age (days)
  
S
h
o
u
ld
e
r 
h
e
ig
h
t 
(c
m
)
0 20 40 60 80 100 120 140 160 180
0
10
20
30
MPH wt (n=7)
DP wt (n=5)
***
***
***
Age (days)
  
 S
h
o
u
ld
e
r 
w
id
th
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
10
20
30
MPH tg (n=6)
MPH wt (n=7)
***
Age (days)
  
 S
h
o
u
ld
e
r 
w
id
th
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
10
20
30
MPH tg (n=6)
MPH wt (n=7)
***
Age (days)
 F
o
re
a
rm
 c
ir
c
u
m
-f
e
re
n
c
e
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
10
20
30
MPH wt (n=7)
DP wt (n=5)
***
***
Age (days)
 F
o
re
a
rm
 c
ir
c
u
m
-f
e
re
n
c
e
 (
c
m
)
Results 83 
  
  
G 
H 
I 
0 20 40 60 80 100 120 140 160 180
0
20
40
60
80
100
MPH tg (n=6)
MPH wt (n=7) ***
*
Age (days)
T
h
o
ra
c
ic
 c
ir
c
u
m
fe
re
n
c
e
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
20
40
60
80
100
MPH wt (n=7)
DP wt (n=5)
***
*
Age (days)
T
h
o
ra
c
ic
 c
ir
c
u
m
fe
re
n
c
e
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
20
40
60
80
100
120
MPH tg (n=6)
MPH wt (n=7)
***
Age (days)
A
b
d
o
m
in
a
l 
c
ir
c
u
m
fe
re
n
c
e
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
20
40
60
80
100
120
MPH wt (n=7)
DP wt (n=5) ***
***
Age (days)
A
b
d
o
m
in
a
l 
c
ir
c
u
m
fe
re
n
c
e
 (
c
m
)
0 20 40 60 80 100 120 140 160 180
0
20
40
60
80
MPH tg (n=6)
MPH wt (n=7)
***
Age (days)
  
  
H
ip
 h
e
ig
h
t 
(c
m
)
0 20 40 60 80 100 120 140 160 180
0
20
40
60
80
MPH wt (n=7)
DP wt (n=5)
*
*
***
*
Age (days)
  
  
H
ip
 h
e
ig
h
t 
(c
m
)
Results 84 
 
Figure 3: Growth parameters of INSC94Y transgenic MPHs, wild-type littermates 
and age-matched wild-type DPs 
Occipito-nasal length (A), biparietal diameter (B), crown-rump length (C), shoulder height 
(D), shoulder width (E), forearm circumference (F), thoracic circumference (G), abdominal 
circumference (H), hip height (I), hip width (J) and shank circumference (K) of wild-type 
DPs (wt) compared to age-matched wild-type MPHs (wt) (left side) and of INSC94Y 
transgenic MPHs (tg) vs. non-transgenic MPHs (wt) (right side). (A-K) All parameters 
were determined from birth up to 153 days of age. Data are indicated as means ± SEM; *: 
p<0.05; **: p<0.01; ***: p<0.001 vs. controls; n: number of animals investigated. 
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Figure 4: Representative pictures of six-month-old male and female non-transgenic MPHs 
and age-matched DPs. 
Male (A) and female (B) wild-type MPHs (wt) (left side) and DPs (wt) (right side)  
4.3.2 Body composition 
Body composition of INSC94Y transgenic (n=6) and non-transgenic MPHs (n=7) and non-
transgenic DPs (n=5) was determined once at the age of six months by Dual-energy X-ray 
absorptiometry (DXA) to analyse the effect of crossing in minipig as well as the effect of the 
expression of the mutant insulin C94Y. Parameters that were measured are as follows: bone 
mineral density expressed in g/cm², total tissue, bone mineral content, fat mass and lean mass 
respectively expressed in kilogram. Additionally, the proportion of each parameter to total 
tissue was calculated in percent except for bone mineral density (Figure 5–Figure 9). 
Furthermore, possible gender-related differences in body composition were evaluated  
(Figure 10–Figure 12). 
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4.3.2.1 Bone mineral density 
Mean bone mineral density was equal in six-month-old wild-type MPHs and DPs (1.1 ± 0.04 
vs. 1.1 ± 0.04 g/cm²; p=0.99, Figure 5 A). However, INSC94Y transgenic MPHs revealed a 
significantly reduced bone mineral density (-27%) compared to non-transgenic littermates (0.8 
± 0.07 vs. 1.1 ± 0.1 g/cm²; p<0.001, Figure 5 B). 
 
Figure 5: Bone mineral density of six-month-old INSC94Y transgenic and non-transgenic MPHs 
and age-matched wild-type DPs evaluated by DXA. 
(A, B): Bone mineral density of six-month-old wild-type MPHs (wt) vs. age-matched wild-
type DPs (wt) (A) and of INSC94Y transgenic MPHs (tg) vs. non-transgenic MPHs (wt) (B). 
Data are indicated as means ± SEM; ***: p<0.001 vs. controls; n: number of animals 
investigated. 
4.3.2.2 Total tissue 
Mean total tissue of six-month-old non-transgenic MPHs showed a significant reduction of 39% 
compared to age-matched wild-type DPs (58.8 ± 2.2 vs. 95.8 ± 3.7 kg; p<0.001,  
Figure 6 A). The mean total tissue of INSC94Y transgenic MPHs was significantly decreased by 
55% in comparison to non-transgenic littermates (26.4 ± 3.9 vs. 58.8 ± 5.7 kg; p<0.001,  
Figure 6 B). 
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Figure 6: Total tissue of six-month-old INSC94Y transgenic and non-transgenic MPHs 
and age-matched wild-type DPs evaluated by DXA. 
(A, B): Mean total tissue of six-month-old wild-type MPHs (wt) vs. age-matched wild-type 
DPs (wt) (A) and of INSC94Y transgenic MPHs (tg) vs. non-transgenic MPHs (wt) (B). Data 
are indicated as means ± SEM; ***: p<0.001 vs. controls; n: number of animals 
investigated. 
4.3.2.3 Bone mineral content 
Total bone mineral content of non-transgenic MPHs was reduced by 38% compared to non-
transgenic DPs at an age of six months (1.3 ± 0.06 vs. 2.1 ± 0.1 kg; p<0.001, Figure 7 A, left 
panel). For the same animals, the proportion of bone mineral content to total tissue was equal 
(2.2 ± 0.07 vs. 2.2 ± 0.04 %; p=0.96, Figure 7 A, right panel). 
In six-month-old INSC94Y transgenic MPHs bone mineral content was significantly decreased 
by 46% compared to wild-type littermates (0.7 ± 0.1 vs. 1.3 ± 0.2 kg; p<0.001, Figure 7 B, left 
panel). However, a significant increase of bone mineral content/total tissue ratio (+14%) was 
detected for transgenic MPHs in comparison to non-transgenic MPHs at six months of age (2.5 
± 0.2 vs. 2.2 ± 0.2 %; p<0.01, Figure 7 B, right panel). 
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Figure 7: Bone mineral content of six-month-old INSC94Y transgenic and non-transgenic MPHs 
and age-matched wild-type DPs evaluated by DXA. 
(A, B): Bone mineral content in kilogram (left panels) and bone mineral content related to 
total tissue in % (right panels) of six-month-old wild-type MPHs (wt) vs. age-matched 
wild-type DPs (wt) (A) and of INSC94Y transgenic MPHs (tg) vs. non-transgenic MPHs (wt) 
(B). Data are indicated as means ± SEM; **: p<0.01; ***: p<0.001 vs. controls; n: number 
of animals investigated. 
4.3.2.4 Fat mass 
Total fat mass was slightly decreased in six-month-old wild-type MPHs compared to wild-type 
DPs (9.9 ± 1.8 vs. 11.1 ± 0.9 kg; p=0.60, Figure 8 A, left panel). However, the proportion of 
body fat to total tissue turned out to be decreased by 31% in non-transgenic DPs in comparison 
to non-transgenic MPHs (11.6 ± 0.7 vs. 16.7 ± 2.6 %; p=0.14) (Figure 8 A, right panel).  
Total fat mass of six-month-old INSC94Y transgenic MPHs was significantly reduced by 83% 
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compared to non-transgenic littermates (1.7 ± 0.2 vs. 9.9 ± 4.6 kg; p<0.001, Figure 8 B, left 
panel). Fat mass in relation to total tissue turned out to be decreased by 60% in INSC94Y 
transgenic MPHs compared to wild-type littermates (6.6 ± 1.1 vs. 16.7 ± 7 %; p<0.001, Figure 
8 B, right panel). 
 
Figure 8: Fat mass of six-month-old INSC94Y transgenic and non-transgenic MPHs 
and age-matched wild-type DPs evaluated by DXA. 
(A, B): Fat mass in kilogram (left panels) and fat mass related to total tissue in % ( right 
panels) of six-month-old wild-type MPHs (wt) vs. age-matched wild-type DPs (wt) (A) and 
of INSC94Y transgenic MPHs (tg) vs. non-transgenic MPHs (wt) (B) at six months of age. 
Data are indicated as means ± SEM; ***: p<0.001 vs. controls; n: number of animals 
investigated. 
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4.3.2.5 Lean mass 
Total lean mass was significantly reduced by 42% in wild-type MPHs compared to control DPs 
(47.6 ± 1.9 vs. 82.5 ± 2.9 kg; p<0.001, Figure 9 A, left panel). The proportion of total lean 
mass to total tissue was decreased by 6% in non-transgenic MPHs compared to wild-type DPs 
at six months of age (81.1 ± 2.6 vs. 86.2 ± 0.7 %; p=0.13, Figure 9 A, right panel).  
Measurement of total lean mass in INSC94Y transgenic MPHs revealed a significant decrease by 
50% (24.0 ± 3.4 vs. 47.6 ± 5.1 kg; p<0.001, Figure 9 B, left panel) while the lean mass/total 
tissue ratio was increased by 12% (91 ± 0.9 vs. 81.1 ± 6.8 %; p<0.001, Figure 9 B, right panel) 
in six-month-old INSC94Y transgenic MPHs compared to non-transgenic littermates. 
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Figure 9: Lean mass of six-month-old INSC94Y transgenic and non-transgenic MPHs 
and age-matched wild-type DPs evaluated by DXA. 
(A, B): Lean mass in kilogram (left panels) and lean mass related to total tissue in % (right 
panels) of six-month-old wild-type MPHs (wt) vs. age-matched wild-type DPs (wt) (A) and 
of INSC94Y transgenic MPHs (tg) vs. wild-type MPHs (wt) (B) at six months of age. Data 
are indicated as means ± SEM; ***: p<0.001 vs. controls; n: number of animals 
investigated. 
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4.3.2.6 Gender-related differences in body composition of INSC94Y transgenic and 
non-transgenic MPHs 
4.3.2.6.1 Total tissue 
The total tissue of six-month-old male (n=4) and female (n=3) wild-type MPHs revealed similar 
values compared to each other (58.8 ± 2.7 vs. 58.9 ± 3.2 kg; p=0.97), as well as male (n=2) and 
female (n=4) INSC94Y transgenic MPHs in comparison to each other (26.8 ± 3.9 vs. 26.2 ± 2.7 
kg; p=0.89, Figure 10). However, the comparison of both genders of wild-type MPHs with the 
respective gender of their transgenic littermates showed a significant decrease of the total tissue 
of male and female transgenic MPHs (males: -54% (26.8 ± 3.9 vs. 58.8 ± 2.7 kg; p<0.001); 
females: -56% (26.2 ± 2.7 vs. 58.9 ± 3.2 kg; p<0.001), Figure 10, see also chapter 4.3.2.2) 
 
Figure 10: Total tissue of six-month-old male and female INSC94Y transgenic 
and non-transgenic MPHs evaluated by DXA. 
Mean total tissue of male and female wild-type MPHs (wt) vs. male and female INSC94Y 
transgenic MPHs (tg) at six months of age. Data are indicated as means ± SEM; ***: 
p<0.001 vs. controls; n: number of animals investigated. 
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4.3.2.6.2 Fat mass 
Total fat mass displayed (Figure 11 A) was significantly increased by 112% (14.2 ± 1.1 vs. 6.7 
± 1.0 kg; p<0.001) in six-month-old female wild-type MPHs in comparison to male pigs of the 
same genotype. However, total fat mass of female animals of the transgenic group compared to 
male animals of the same genotype was just slightly elevated by 27% (1.9 ± 1.0 vs. 1.5 ± 1.4 
kg; p=0.8). Total fat mass measured in male and female six-month-old INSC94Y transgenic 
MPHs was significantly reduced in comparison to the respective genders of the non-transgenic 
MPHs (males: -78% (1.5 ± 1.4 vs. 6.7 ± 1.0 kg; p<0.05); females: -87% (1.9 ± 1.0 vs. 14.2 ± 
1.1 kg; p<0.001, see also chapter 4.3.2.4). 
The mean fat mass/total tissue ratio determined in percent (Figure 11 B) was significantly 
increased by 109% in six-month-old female wild-type MPHs in comparison to the male pigs of 
the same genotype (23.8 ± 1 vs. 11.4 ± 0.9 %; p<0.001) and was marginally elevated by 33% 
in female compared to male transgenic MPHs (7.2 ± 0.9 vs. 5.4 ± 1.3 %; p=0.3). The fat 
mass/total tissue ratio measured in male and female six-month-old INSC94Y transgenic animals 
in comparison to the respective genders of wild-type MPHs was significantly reduced by -53% 
in males (5.4 ± 1.3 vs. 11.4 ± 0.9 %; p<0.01) and with a decrease of -70% even more pronounced 
in females (7.2 ± 0.9 vs. 23.8 ± 1 %; p<0.001, see also chapter 4.3.2.4). 
 
Figure 11: Fat mass of male and female six-month-old INSC94Y transgenic 
and non-transgenic MPHs evaluated by DXA. 
(A, B): Fat mass in kilogram (A) and related to total tissue in % (B) of male and female 
six-month-old wild-type MPHs (wt) vs. male and female INSC94Y transgenic MPHs (tg). 
Data are indicated as means ± SEM; *: p<0.05; **: p<0.01; ***: p<0.001 vs. controls; n: 
number of animals investigated. 
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4.3.2.6.3 Lean mass 
Total lean mass in six-month-old male wild-type MPHs was significantly increased by 16% 
compared to female wild-type littermates (50.6 ± 1.9 vs. 43.5 ± 2.2 kg; p<0.05). However, total 
lean mass in male INSC94Y transgenic MPHs revealed only a slight elevation by 4% in 
comparison to female littermates of the same genotype ( 24.7 ± 2.6 vs. 23.7 ± 1.9 kg; p= 0.76). 
The total lean mass of male and female non-transgenic MPHs reached a significant increase 
compared to INSC94Y transgenic animals of the respective gender at an age of six months (males: 
+105% (50.6 ± 1.9 vs. 24.7 ± 2.6 kg; p<0.001); females: +84% (43.5 ± 2.2 vs. 23.7 ± 1.9 kg; 
p<0.001), Figure 12 A, see also chapter 4.3.2.5).  
The ratio of lean mass/total tissue was significantly elevated by 16% in male compared to 
female wild-type MPHs (86.2 ± 0.9 vs. 74.2 ± 1 %; p<0.001) and slightly increased by 2% in 
male compared to female INSC94Y transgenic MPHs (91.9 ± 1.3 vs. 90.5 ± 0.9 %; p=0.36). The 
lean mass/total tissue ratio measured in male and female wild-type MPHs was significantly 
reduced compared to INSC94Y transgenic MPHs of the respective gender (males: -6% (86.2 ± 
0.9 vs. 91.9 ± 1.3 %; p<0.01; females: -18% (74.2 ± 1 vs. 90.5 ± 0.9 %; p<0.001),  
Figure 12 B, see also chapter 4.3.2.5) 
 
Figure 12: Lean mass of male and female six-month-old INSC94Y transgenic 
and non-transgenic MPHs evaluated by DXA. 
(A, B): Lean mass in kilogram (A) and lean mass to total tissue ratio in % (B) of male and 
female six-month-old wild-type MPHs (wt) vs. male and female INSC94Y transgenic MPHs 
(tg). Data are indicated as means ± SEM; *: p<0.05; **: p<0.01; ***: p<0.001 vs. controls; 
n: number of animals investigated. 
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4.3.3 Blood parameters 
To evaluate a possible impact of minipig crossbreeding on relevant blood parameters, blood 
glucose, plasma insulin and C-peptide concentrations and clinical chemical parameters were 
determined in INSC94Y transgenic MPHs and non-transgenic littermates in regular intervals from 
birth up to 180 days of age. Animals were unfasted until day 40 of age. Afterwards all animals 
were fasted overnight prior to blood sampling starting at day 41 of age. 
4.3.3.1 Blood glucose levels 
Random blood glucose levels were determined at four and seven days of age followed by 7-
day-intervals until day 153 of age. Later on in intervals of one to three weeks until the age of 
five months. On day four of age, mean blood glucose levels of animals from both groups (MPH 
tg, n=6 vs. MPH wt, n=7) were not significantly different (185 ± 17.4 vs. 182 ± 32.1 mg/dl; 
p=0.9). At the second time of blood glucose determination, i.e., on day seven of age, transgenic 
MPHs revealed significantly higher mean blood glucose concentrations than non-transgenic 
littermates (226 ± 20 vs. 134 ± 11.7 mg/dl; p<0.001) that increased up to 306 ± 29.3 vs. 74 ± 
9.6 mg/dl (p<0.001) at day 153 of age (Figure 13). 
 
Figure 13: Blood glucose concentrations of INSC94Y transgenic MPHs 
and non-transgenic littermates. 
Significantly elevated blood glucose levels could be detected in INSC94Y transgenic MPHs 
(tg) compared to non-transgenic littermates (wt) within the observation period starting from 
day four until day 153 of age. Data are indicated as means ± SEM; **: p<0.01; ***: 
p<0.001 vs. controls; n: number of animals investigated. 
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4.3.3.2 Plasma insulin concentration 
Random plasma insulin concentrations were determined on day seven and fasting plasma 
insulin concentrations were measured on day 180 of age (Figure 14). On day seven wild-type 
MPHs (n=3–7, 14.5 ± 4.1 vs. 7.2 ± 3.6 µU/ml, p=0.15) as well as transgenic MPHs (n=5–6, 4.6 
± 1.7 vs. 2.6 ± 0.6 µU/ml, p=0.85) displayed higher mean insulin concentrations compared to 
the levels on day 180, respectively. Plasma insulin levels of wild-type MPHs revealed 
significantly higher concentrations in comparison to INSC94Y transgenic MPHs on day seven 
(14.5 ± 4.1 vs. 4.6 ± 1.7 µU/ml, p<0.05) and as a trend on day 180 of age (7.2 ± 3.6 vs. 2.6 ± 
0.6 µU/ml, p=0.67).  
 
Figure 14: Plasma insulin levels of INSC94Y transgenic MPHs and non-transgenic littermates. 
Higher mean plasma insulin levels could be detected in non-transgenic MPHs (wt) in 
comparison to INSC94Y transgenic MPHs (tg) within the observation time, i.e., on day seven 
and day 180 of age. Data are indicated as means ± SEM; *: p<0.05 vs. controls; n: number 
of animals investigated. 
4.3.3.3 Plasma levels of connecting peptide (C-peptide) 
Plasma C-peptide levels were determined at the same points in time and under the same 
conditions as plasma insulin concentrations (Figure 15). Mean C-peptide concentrations of 
INSC94Y transgenic MPHs (n=5–6) were significantly decreased compared to wild-type MPHs 
(n=3–7) at day seven (22.1 ± 6.1 vs. 85.8 ± 24.9 pmol/L, p<0.05) and day 180 of age (32 ± 6.3 
vs. 75.5 ± 43.5 pmol/L, p<0.05). Seven-day-old non-transgenic MPHs revealed higher C-
peptide concentrations compared to 180-day-old animals (85.8 ± 24.9 vs. 75.5 ± 43.5 pmol/L, 
p=0.75). INSC94Y transgenic MPHs revealed higher concentrations of C-peptide at day 180 
compared to day seven (32 ± 6.3 vs. 22.1 ± 6.1 pmol/L, p=0.73). 
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Figure 15: Plasma levels of connecting peptide of INSC94Y transgenic MPHs 
and non-transgenic littermates. 
INSC94Y transgenic MPHs (tg) revealed significantly lower connecting peptide 
concentrations than non-transgenic MPHs (wt) within the observation period (day seven 
and 180 of age). Data are indicated as means ± SEM; *: p<0.05 vs. controls; n: number of 
animals investigated. 
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4.3.3.4 Clinical chemical parameters 
Clinical chemical parameters were determined on day seven (not fasted) and on day 180 of age 
(fasted) (Figure 16). Mean triglyceride and cholesterol concentrations of wild-type MPHs 
(n=3–8) were significantly decreased on day 180 in comparison to day seven (27.4 ± 3.8 vs. 
54.3 ± 4.3 mg/dl; p=<0.05, triglycerides), (89.5 ± 5 vs. 207.3 ± 14.5 mg/dl; p=<0.001, 
cholesterol). A remarkable increase on day 180 compared to day seven was determined for 
albumin (3.6 ± 0.2 vs. 2.6 ± 0.1 g/dl; p=<0.001), total protein (6.9 ± 0.2 vs. 5.8 ± 0.2 g/dl; 
p=<0.01), creatinine (0.96 ± 0.18 vs. 0.46 ± 0.02 mg/dl; p=<0.001) and urea (33.5 ± 4.7 vs. 20.6 
± 2.5 mg/dl; p=<0.05) concentrations of wild-type MPHs.  
In INSC94Y transgenic MPHs (n=5–6) a significant decrease on day 180 in comparison to day 
seven was observed for the plasma cholesterol concentration (67.5 ± 5.1 vs. 181.7 ± 10.8 181.7 
± 10.8 mg/dl; p=<0.001). Other clinical chemical parameters were significantly increased in 
transgenic MPHs on day 180 compared to day seven: albumin (3.3 ± 0.1 vs. 2.4 ± 0.1 g/dl; 
p=<0.001), total protein (6.6 ± 0.2 vs. 5.7 ± 0.2 g/dl; p=<0.01) and urea (49 ± 4.4 vs. 24.2 ± 3.3 
mg/dl; p=<0.001). Triglyceride and creatinine levels were not remarkably altered in INSC94Y 
transgenic MPHs, comparing day 180 with day seven of age (55.7 ± 9.3 vs. 54.5 ± 5.5 mg/dl; 
p=0.89, triglyceride), (0.53 ± 0.03 vs. 0.42 ± 0.01 mg/dl; p=0.13, creatinine). 
On day 180 mean triglyceride levels were significantly higher in INSC94Y transgenic MPHs 
compared to non-transgenic littermates (55.7 ± 9.3 vs. 27.4 ± 3.8 mg/dl; p=<0.05). Creatinine 
concentration were significantly decreased in INSC94Y transgenic MPHs (0.53 ± 0.03 vs. 0.96 ± 
0.18 mg/dl; p=<0.001) while mean plasma urea concentration were significantly increased (49 
± 4.4 vs. 33.5 ± 4.7 mg/dl; p=<0.001) on day 180 of age. None of the other clinical chemical 
parameters (cholesterol, albumin, total protein) were significantly altered on day seven or day 
180 in INSC94Y transgenic MPHs. 
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Figure 16: Clinical chemical parameters of INSC94Y transgenic MPHs 
and non-transgenic littermates. 
Plasma triglyceride (A), cholesterol (B), albumin (C), total protein (D), creatinine (E) and 
urea (F) concentrations of INSC94Y transgenic MPHs (tg) vs. non-transgenic littermates (wt) 
(A-F) All parameters were determined once at seven days and 180 days of age. Data are 
indicated as means ± SEM; *: p<0.05; **: p<0.01; ***: p<0.001 vs. controls; n: number of 
animals investigated.  
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4.4 Morphological analyses of the pancreas 
Reduced β-cell mass is a hallmark of clinical diabetes. An altered islet composition can be the 
consequence of the expression of the mutant insulin C94Y. Therefore paraffin sections from 
pancreata of INSC94Y transgenic and non-transgenic MPH pigs were prepared for qualitative 
histological and quantitative stereological analyses of β- and α-cells in the endocrine pancreas. 
Additionally, ultrathin sections were processed for electron microscopy to investigate 
ultrastructural changes of the β-cell. 
4.4.1 Absolute and relative pancreas weight 
At necropsy of INSC94Y transgenic MPHs and non-transgenic littermates at an age of six months, 
pancreas was dissected and weighed. Absolute pancreas weight of INSC94Y transgenic pigs was 
significantly decreased by 32% (60.17 ± 4.18 vs. 88.67 ± 5.55 g; p<0.01,  
Figure 17 A). However, the relative pancreas weight of INSC94Y transgenic pigs revealed a 
significant increase of 60% (0.24 ± 0.02 vs. 0.15 ± 0.01 %/BW; p<0.05, Figure 17 B) compared 
to wild-type littermates. 
 
Figure 17: Absolute and relative pancreas weight of six-month–old INSC94Y transgenic 
and non-transgenic MPHs. 
(A, B): Transgenic MPHs (tg) revealed lower absolute pancreas weight as non-transgenic 
controls (wt) (A). Significantly higher relative pancreas weight was detected in INSC94Y 
transgenic MPHs compared to their wild-type littermates (B). Data are indicated as means 
± SEM; *: p<0.05; **: p<0.01; vs. controls; n: number of animals investigated. 
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4.4.2 Qualitative histological evaluation of the endocrine pancreas 
Wild-type MPHs displayed species-specific β-cell formations: islet section profiles differed in 
shape and size, almost round to oval with an uneven contour, mostly in a range of 25–100 µm 
in diameter (Figure 18 B, left side). The distribution of the islet section profiles was irregular 
within the exocrine pancreatic tissue (Figure 18 A, left side).  
Sporadically isolated β-cells, i.e., small β-cell cluster of one to five cell section profiles, were 
detected in the sections of the INSC94Y transgenic MPHs and wild-type littermates. Compared 
to islet section profiles from non-transgenic MPHs, striking histological alterations were 
observed in islet section profiles of INSC94Y transgenic MPHs. The observed islet section 
profiles were generally smaller, they mostly showed an irregular contour, leading to an 
amorphous appearance. Less insulin positive cell section profiles could be observed within the 
islet section profiles indicative of β-cell loss (Figure 18 B, right side). The distribution of islet 
section profiles within the exocrine pancreatic tissue was irregular but islet section profiles were 
observed less frequently in INSC94Y transgenic MPHs (Figure 18 A, right side) compared to the 
wild-type MPHs. 
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Figure 18: Immunohistochemistry for insulin containing β-cells in pancreatic tissue of six-
month-old INSC94Y transgenic MPHs and wild-type littermates. 
(A, B): Immunohistochemistry for insulin containing cells of wild-type MPHs (wt, left 
side) and INSC94Y transgenic littermates (tg, right side). 
Furthermore, wild-type MPHs displayed species-specific α-cell distribution within the islet 
section profiles. α-cell section profiles were detected in the center but also in the periphery of 
the islet section profiles, rarely forming an (un-)complete ring. Minor small fractions of α-cells, 
i.e., isolated α-cell section profiles sporadically appeared in the adjacent exocrine tissue section 
profiles (Figure 19 A and B, left side).  
α-cell section profiles appeared predominant and organized in clusters within islet section 
profiles of INSC94Y transgenic MPHs. (Figure 19 A and B, right side).  
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Figure 19: Immunohistochemistry for glucagon containing α-cells in pancreatic tissue of six-
month-old INSC94Y transgenic MPHs and wild-type littermates. 
(A, B): Immunohistochemistry for glucagon containing cells of wild-type MPHs (wt, left 
side) and INSC94Y transgenic littermates (tg, right side). 
4.4.3 Quantitative stereological analyses of the endocrine pancreas 
In addition to qualitative analyses of pancreatic sections from six-month-old INSC94Y transgenic 
(n=6) and non-transgenic (n=3) MPHs, quantitative stereological analyses were performed. 
Results from quantitative-stereological analyses confirmed the results from qualitative 
histological evaluation. The volume density of β-cells in the pancreas (Vv (β-cells/Pan)) of INS
C94Y 
transgenic MPHs was significantly lower by 79% compared to wild-type littermates (0.13 ± 
0.02 vs. 0.61 ± 0.15 %; p<0.05, Figure 20 A). Accordingly, the total β-cell volume (V (β-cells, 
Pan)) of INS
C94Y transgenic MPHs was significantly lower by 85% compared to wild-type 
littermates (75.07 ± 13.77 vs. 515.5 ± 146.7 mm3, p<0.05, Figure 20 B).  
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Likewise, the total β-cell volume to body weight ratio (V (β-cells, Pan)/BW) of INS
C94Y transgenic 
MPHs was significantly lower by 69% in comparison to their wild-type littermates (2.81 ± 0.44 
vs. 8.68  ± 2.38 mm3/kg, p<0.05, Figure 21) 
 
Figure 20: Quantitative stereological analyses of β-cells in the pancreas in six-month-old INSC94Y 
transgenic MPHs and wild-type littermates 
(A): The volume density of β-cells in the pancreas (Vv (β-cells/Pan)) was significantly lower  
(-79%) in INSC94Y transgenic MPHs (tg) compared to their non-transgenic littermates 
(wt).(B): The total volume of β-cells in the pancreas (V (β-cells, Pan)) was significantly lower  
(-85%) in INSC94Y transgenic MPHs (tg) compared to non-transgenic littermates (wt). Data 
are indicated as means ± SEM; *: p<0.05 vs. controls; n: number of animals investigated. 
 
Figure 21: Total β-cell volume related to body weight in six-month-old INSC94Y 
transgenic MPHs and wild-type littermates 
The total β-cell volume in the pancreas in relation to body weight (mm3/kg) of the animals 
was significantly lower (-69%) in INSC94Y transgenic (tg) MPHs compared to the wild-type 
littermates (wt). Data are indicated as means ± SEM; *: p<0.05 vs. controls; n: number of 
animals investigated.  
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The volume density of α-cells in the pancreas (Vv (α-cells/Pan)) of INS
C94Y transgenic MPHs was 
lower by 30% compared to wild-type littermates (0.058 ± 0.004 vs. 0.083 ± 0.019 %; p=0.16, 
Figure 22 A), whereas the total α-cell volume (V (α-cells, Pan)) of INS
C94Y transgenic MPHs was 
significantly lower by 57% in comparison to wild-type littermates (31.84 ± 1.77 vs. 73.68  ± 
20.94 mm3, p<0.05, Figure 22 B).  
However, the total α-cell volume to body weight ratio (V (α-cells, Pan)/BW) of INS
C94Y transgenic 
MPHs was similar compared to their wild-type littermates (1.23 ± 0.07 vs. 1.27 ± 0.38 mm3/kg, 
p= 0.55, Figure 23) 
 
Figure 22: Quantitative stereological analyses of α-cells in the pancreas in six-month-old INSC94Y 
transgenic MPHs and wild-type littermates. 
(A): The volume density of α-cells in the pancreas (Vv (α-cells/Pan)) was lower (-30%) in 
INSC94Y transgenic MPHs (tg) compared to their non-transgenic littermates (wt). (B): The 
total α-cell volume in the pancreas (V (α-cells, Pan)) was significantly lower (-57%) in INSC94Y 
transgenic MPHs (tg) compared to non-transgenic littermates (wt). Data are indicated as 
means ± SEM; *: p<0.05 vs. controls; n: number of animals investigated. 
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Figure 23: Total α-cell volume related to body weight in six-month-old INSC94Y 
transgenic MPHs and non-transgenic littermates. 
The total α-cell volume in the pancreas in relation to body weight (mm3/kg) of the animals 
was not altered in INSC94Y transgenic MPHs (tg) compared to wild-type littermates (wt). 
Data are indicated as means ± SEM; n: number of animals investigated. 
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4.4.4 Electron microscopic examination of β-cells 
Ultrastructure of β-cells from six-month-old INSC94Y transgenic MPHs and non-transgenic 
littermates were analysed by a transmission electron microscope. The chosen electron 
micrographs present intracellular structures of β-cells of a wild-type MPH (Figure 24 A) and 
an INSC94Y transgenic littermate (Figure 24 B). Beta-cells of healthy non-transgenic MPHs 
displayed a high amount of secretory insulin vesicles containing insulin and its pre-stages. 
Insulin vesicles are characterized by a round shape and are differed in size with an electron 
dense and irregular formed crystalline core surrounded by an electron lucent bright halo. β-cells 
of INSC94Ytransgenic MPHs showed alterations compared to their wild-type littermates. An 
untypical enlargement of the endoplasmic reticulum was notable, detectable at the cross-
sectional areas of the organelle. In addition, insulin vesicles were highly reduced in number but 
still roundly shaped. However, the content seemed less concentrated and differently arranged, 
such that less halo inside the vesicle was visible. 
 
β: insulin vesicle of a β-cell; ER: endoplasmic reticulum; ER*: cross-sectional areas of enlarged ER; N: 
nucleus; Nc: nucleolus 
Figure 24: Representative transmission electron micrographs of β-cells from a six-month-old 
INSC94Y transgenic MPH and a wild-type littermate 
(A): Beta-cell of a non-transgenic MPHs (wt) showed insulin containing vesicles (β) in a 
high quantity and abundant rough endoplasmic reticulum. (B): INSC94Y transgenic MPHs 
(tg) revealed β-cells with a severely dilated endoplasmic reticulum (ER*) and a low 
amount of insulin vesicles. 
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4.5 Evaluation of diabetes-related secondary alterations in organs 
4.5.1 Absolute and relative organ weights 
The comparison of mean absolute and relative (% of body weight) organ weights of six-month-
old non-transgenic MPHs (n=3) and DPs (n=5) is summarized in Table 10. Results of mean 
absolute and relative organ weights of six-month-old INSC94Y transgenic (n=6) and non-
transgenic (n=3) littermates are summarized in Table 11. 
Significantly reduced mean absolute weights of the majority of organs were detected in wild-
type MPHs compared to wild-type DPs. Absolute kidney weight (cumulatively calculated from 
the weights of both kidneys) and liver weight was reduced by 48% and by 51% respectively, 
and for the absolute heart weight a reduction of 58% could be detected. Only the spleen reached 
a larger decrease (-71%) while lower reductions could be detected for pancreas (-36%), lung (-
30%), brain (-26%) and stomach (-7%). 
Further, INSC94Y transgenic MPHs showed a significant reduction of mean absolute weights of 
most organs when compared to their non-transgenic littermates. Absolute organ weights of 
pancreas and liver were significantly decreased by 32% and 35% respectively while more 
pronounced reductions could be detected for the absolute weight of the stomach (-45%) and 
especially for the spleen (-73%). Lower reductions of absolute organ weights were found for 
the kidneys (-21%) and for the brain (-8%). 
A significant reduction of the mean relative weight of the spleen by 53% was detected for wild-
type MPHs compared to the wild-type DPs. Also, a decrease of the mean relative weight of 
kidneys, liver and heart by 16%, 18% and 32% could be detected respectively. In contrast, 
relative pancreas, brain, lung and stomach weight was increased by 4%, 18%, 21% and 53% 
respectively in non-transgenic MPHs compared to DPs. 
For INSC94Y transgenic MPHs, the brain revealed the largest increase of mean relative organ 
weight (+123%). Also, a significant increase of the mean relative weight was detected for the 
kidneys by 88%, the pancreas by 60%, the liver by 52% and the heart by 50%. Reduction of 
relative organ weight could be recorded for spleen (-34%) and carcass (-23%) comparing 
INSC94Y transgenic with non-transgenic MPHs. 
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Table 10: Absolute and relative organ weights of six-month-old wild-type MPHs 
and wild-type DPs 
Absolute organ weights (g)   Relative organ weights (% BW) 
Organ Genotype Mean SEM P-value   Mean SEM P-value 
liver 
wt MPH 1373.33 49.10 
***   
2.39 0.30 
0.1141 
wt DP 2784.00 91.30 2.92 0.14 
kidneys  
(cumulative) 
wt MPH 247.00 18.90 
***   
0.42 0.02 
0.1195 
wt DP 476.20 23.38 0.50 0.03 
pancreas 
wt MPH 88.67 5.55 
**   
0.15 0.01 
0.7716 
wt DP 139.60 9.11 0.15 0.01 
spleen 
wt MPH 223.33 29.06 
***   
0.38 0.05 
** 
wt DP 776.00 60.13 0.81 0.05 
heart 
wt MPH 153.33 45.31 
**   
0.26 0.07 
0.0835 
wt DP 360.80 14.24 0.38 0.02 
lung 
wt MPH 570.00 152.07 
0.0949   
1.03 0.35 
0.5181 
wt DP 816.40 42.01 0.85 0.03 
stomach          
(without content) 
wt MPH 685.00 101.53 
0.5043   
1.19 0.25 
0.0665 
wt DP 742.00 23.05 0.78 0.03 
brain 
wt MPH 77.00 3.51 
***   
0.13 0.01 
0.0733 
wt DP 104.40 2.25 0.11 0.00 
carcass 
wt MPH 46766.67 5112.19 
**   
79.09 1.13 
0.0928 
wt DP 72620.00 4316.41 75.55 1.17 
wt MPH: n=3 / wt DP: n=5; wt: wild-type; MPH: minipig hybrid; DP: domestic pig; n: number of investigated 
animals; BW: body weight; SEM: standard error of mean; p-value: level of significance **: p<0.01; ***: p<0.001. 
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Table 11: Absolute and relative organ weights of six-month-old INSC94Y transgenic MPHs 
and wild-type littermates 
Absolute organ weight (g)   Relative organ weight (% BW) 
Organ Genotype Mean SEM P-value   Mean SEM P-value 
liver 
wt 1373.33 49.10 
 **   
2.39 0.30 
 * 
tg 900.17 72.68 3.62 0.20 
kidneys  
(cumulative) 
wt 247.00 18.90 
*    
0.42 0.02 
 *** 
tg 195.00 9.22 0.79 0.03 
pancreas 
wt 88.67 5.55 
**   
0.15 0.01 
 * 
tg 60.17 4.18 0.24 0.02 
spleen 
wt 223.33 29.06 
***   
0.38 0.05 
 * 
tg 61.17 5.33 0.25 0.03 
heart 
wt 153.33 45.31 
0.1279    
0.26 0.07 
 * 
tg 98.17 8.11 0.39 0.02 
lung 
wt 570.00 152.07 
0.1737    
1.03 0.35 
 0.172 
tg 386.17 47.45 1.54 0.17 
stomach          
(without content) 
wt 685.00 101.53 
**   
1.19 0.25 
 0.1307 
tg 377.50 24.28 1.53 0.07 
brain 
wt 77.00 3.51 
 0.0919   
0.13 0.01 
 *** 
tg 70.67 1.56 0.29 0.02 
carcass 
wt 46766.67 5112.19 
 ***   
79.09 1.13 
 *** 
tg 15133.33 1002.22 61.01 1.65 
wt MPH: n=3 / tg MPH: n=6; wt: wild-type; tg: transgenic; MPH: minipig hybrid; n: number of investigated 
animals; BW: body weight; SEM: standard error of mean; p-value: level of significance *: p<0.05; **: p<0.01; 
***: p<0.001. 
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4.5.2 Absolute and relative organ weights of female INSC94Y transgenic MPHs 
and non-transgenic littermates. 
Due to the fact that the group of non-transgenic MPHs consisted only of female pigs, an 
additional analysis of absolute and relative (% of body weight) organ weights was performed 
only taking female INSC94Y transgenic and non-transgenic MPHs into account (Table 12). 
Female INSC94Y transgenic MPHs (n=4) showed a significant reduction of absolute weights of 
numerous organs in comparison to female non-transgenic littermates (n=3). Absolute organ 
weight of liver and pancreas were significantly decreased by 28% while more pronounced 
reductions could be detected in the absolute carcass weight (-68%), the absolute stomach weight 
(-42%) and especially the absolute spleen weight (-70%). Not significant or lower reductions 
of absolute organ weights were found for heart and lung with -27% and -36% respectively, 
followed by absolute kidney weight with -18% and absolute brain weight with -7% 
In contrast to absolute organ weights relative organ weights of INSC94Y transgenic female MPHs 
were predominantly increased compared to non-transgenic littermates. Relative pancreas 
weight was significantly increased by 40%. The relative liver and kdiney weight showed a more 
pronounced increase with 40% and 48% respectively. An even more significant elevation was 
detected for the relative brain weight with 53%. A lower relative organ weight increase was 
reached by the stomach with 24%, the heart with 32% and the lung with 37%. 
However, relative spleen and carcass weight were reduced by 29% and 25% respectively. 
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Table 12: Absolute and relative organ weights of six-month-old female INSC94Y transgenic 
MPHs and non-transgenic littermates. 
Absolute organ weight (g)   Relative organ weight (%BW) 
Organ Genotype Mean SEM P-value   Mean SEM P-value 
liver 
Female wt 1373.33 49.10 
**   
2.39 0.30 
** 
Female tg 983.50 57.37 3.99 0.18 
kidneys  
(cumulative) 
Female wt 247.00 18.90 
0.06   
0.42 0.02 
** 
Female tg 203.75 7.18 0.81 0.05 
pancreas 
Female wt 88.67 5.55 
*   
0.15 0.01 
* 
Female tg 63.75 4.77 0.25 0.02 
spleen 
Female wt 223.33 29.06 
**   
0.38 0.05 
0.1251 
Female tg 66.25 6.25 0.27 0.04 
heart 
Female wt 153.33 45.31 
0.2007   
0.26 0.07 
0.0996 
Female tg 97.00 4.26 0.38 0.02 
lung 
Female wt 570.00 152.07 
0.2678   
1.03 0.35 
0.1287 
Female tg 410.50 11.60 1.64 0.14 
stomach          
(without content) 
Female wt 685.00 101.53 
*   
1.19 0.25 
0.1736 
Female tg 396.25 17.49 1.57 0.10 
brain 
Female wt 77.00 3.51 
0.2179   
0.13 0.01 
*** 
Female tg 71.25 2.39 0.28 0.01 
carcass 
Female wt 46766.67 5112.19 
***   
79.09 1.13 
*** 
Female tg 15050.00 1050.00 59.28 1.88 
wt MPH: n=3 / tg MPH: n=4; tg: transgenic; wt: wild-type; MPH: domestic pig-minipig hybrid; DP: n: number of 
investigated animals; BW: body weight; SEM: standard error of mean; p-value: level of significance *: p<0.05; 
**: p<0.01; ***: p<0.001. 
4.5.3 Alterations of the kidneys 
In order to evaluate the influence of the expression of the mutant insulin C94Y in the kidneys 
of six-month-old transgenic MPHs compared to their non-transgenic littermates, the parameter 
absolute and relative kidney weight was used for interpretation (see chapter 4.5.1) and 
histopathological examination was performed.  
4.5.3.1 Absolute and relative organ weight of the kidneys 
In contrast to the mean absolute weights of organs like liver, pancreas or spleen of INSC94Y 
transgenic MPHs that revealed reductions of more than 30%, the mean absolute weight for the 
kidneys, cumulatively calculated from the weights of both kidneys, decreased only by 20% 
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compared to their non-transgenic littermates (195 ± 9.22 vs. 247 ± 18.90 g p<0.05, Figure 25 
A). However, the relative weight of the kidneys reached a significant elevation of more than 
46% (0.79 ± 0.03 vs. 0.42 ± 0.02 g p<0.05) which was a higher rate as detected for the other 
organs in comparison to wild-type littermates, excluding the brain (Figure 25 B). 
 
Figure 25: Mean absolute and relative kidney weight of six-month–old INSC94Y transgenic MPHs 
and non-transgenic littermates. 
(A, B): Mean absolute (A) and mean relative (B) kidney weight of INSC94Y transgenic 
MPHs (tg) and non-transgenic littermates (wt). Data are indicated as means ± SEM; *: 
p<0.05; ***: p<0.001; vs. controls; n: number of animals investigated. 
4.5.3.2 Histopathology of the kidneys 
Histopathological analyses of the kidneys from INSC94Y transgenic MPHs and non-transgenic 
littermates with an age of six months, was performed in hematoxylin and eosin (HE) stained 
sections of paraffin-embedded tissue samples. The representative micrographs show the 
appearance of glomeruli and tubular structures of INSC94Y transgenic MPHs (Figure 26 B) and 
wild-type littermates (Figure 26 A). Generally, sections of INSC94Y transgenic pigs did not 
reveal histopathological alterations pointing towards diabetic glomerulosclerosis. Three out of 
six diabetic pigs and one out of three non-diabetic pigs, revealed paucifocal glomerular 
mesangial hypercellularity. An additional diabetic pig showed a slight focal interstitial non-
purulent nephritis.  
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Figure 26: Representative micrographs of histological sections from the kidney of six-month-old 
INSC94Y transgenic MPHs and non-transgenic littermates. 
(A, B): Micrographs (inset) of an HE staining of renal cortical tissue of a non-transgenic 
(A) and INSC94Y transgenic MPH (B). 
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4.5.4 Alterations of the lens 
After necropsy of six-month-old INSC94Y transgenic and non-transgenic MPHs, eye globes were 
dissected, fixated and cut into slices followed by paraffin embedding and H.E. staining for 
histopathological evaluation regarding diabetes-associated cataract. The chosen micrographs 
represent alterations of the lenses of diabetic MPHs (Figure 27 B) compared to wild-type 
littermates (Figure 27 A). In INSC94Y transgenic MPHs multifocal hydropic degeneration, 
swelling and disarray of the lens fibres were detected. The lenticular cortex evolved cyst-like 
cavities and multifocal morgagnian globes were detected. Wild-type littermates did not reveal 
any evidence of lens alterations.  
 
C: cyst-like cavity; s: swelling of the lens fibres; Mg: morgagnian globe 
Figure 27: Representative micrographs of histological sections of the lens of six-month-old 
INSC94Y transgenic MPHs and non-transgenic littermates. 
(A, B): HE stained sections of INSC94Y transgenic MPHs (tg) showed alterations of the lens 
structure (B) compared to their wild-type littermates (wt) (A).  
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5 DISCUSSION 
5.1 Principles and objectives 
The aim of the present study was the development and characterization of a size-reduced 
porcine model for permanent neonatal diabetes mellitus (PNDM). Experimental animals were 
non-transgenic domestic pig-minipig hybrids (MPHs) and INSC94Y transgenic MPHs expressing 
mutant insulin C94Y that were generated by crossbreeding of genetically modified INSC94Y 
domestic pig (DP) sows (Renner, Braun-Reichhart et al. 2013) with a non-transgenic minipig 
boar. Firstly, phenotypic characteristics of non-transgenic MPHs were evaluated in comparison 
to age-matched wild-type DPs to identify differences of the minipig crossbreed compared to 
the pure DP breed (German Landrace-Swabian Hall background). Secondly, phenotypic 
characteristics of INSC94Y transgenic MPHs were evaluated and compared to non-transgenic 
littermates to specify phenotypic correlates of the INSC94Y transgene compared to the INSC94Y 
transgenic DP model. The INSC96Y mutation in humans causes mutant INS gene induced 
diabetes of youth (MIDY) a form of human PNDM and is homologues to the INS gene mutation 
in mice (Ins2C96Y) and in transgenic DPs (INSC94Y) (Yoshioka, Kayo et al. 1997, Stoy, Edghill 
et al. 2007, Renner, Braun-Reichhart et al. 2013).  
5.2 Physiological characteristics of non-transgenic and INSC94Y transgenic 
domestic pig-minipig hybrids 
5.2.1 Altered blood parameters in non-transgenic and INSC94Y transgenic MPHs 
Pig blood parameters can vary depending on multiple factors such as breed, diet, gender, age 
and body weight (BW) or the analytical method and instrument used. PNDM in swine is caused 
by the expression of the INSC94Y mutation (Renner, Braun-Reichhart et al. 2013), leading to a 
decreased insulin secretion and subsequently increased blood glucose levels. To investigate the 
impact of minipig crossbreeding on blood glucose, plasma insulin, C-peptide and other selected 
chemical parameters, their levels were determined in non-transgenic MPHs and INSC94Y 
transgenic littermates.  
INSC94Y transgenic and non-transgenic MPHs had similar non-fasting blood glucose levels four 
days after birth (185 vs. 182 mg/dl; p=0.9) before it started to increase to a hyperglycemic state 
(>200 mg/dl) in INSC94Y transgenic MPHs but decreased in non-transgenic MPHs within the 
next ten days. Since then, INSC94Y transgenic MPHs showed significantly higher blood glucose 
levels both non-fasting and fasting compared to their non-transgenic littermates, starting from 
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day seven of age (non-fasting, 226 vs. 134 mg/dl; p<0.001) until the end of the observation 
period at 153 days of age (fasting, 306 vs. 74 mg/dl; p<0.001). After the initial elevation the 
blood glucose levels of INSC94Y transgenic MPHs slightly decreased and at the age of 56 days 
animals started to reveal again fasting blood glucose (FBG) levels (212 mg/dl) indicative for a 
derailed glucose metabolism. FBG further increased when animals grew older with the highest 
value (347 mg/dl) reached at day 112 of age. In contrast, FBG levels of wild-type MPHs were 
in a much lower range within the observation period, showing a mean value of 60 mg/dl from 
day 41 to day 153 of age while the highest value reached was 79 mg/dl at day 56 of age. Starting 
at day 112 of age FBG of wild-type MPHs showed a slight tendency to increase with age. The 
results of INSC94Y transgenic MPHs were in line with the range of FBG with >200 mg/dl for 
minipigs considered diabetic in studies using chemical induction (Roberts, Sturek et al. 2001, 
Stanley, Dore et al. 2001, Hara, Lin et al. 2008). Accordingly, the FBG levels of non-transgenic 
MPH littermates were within the reference range of 50–80 mg/dl reported for normoglycemic 
minipigs, even though a high variance needs to be considered (Larsen, Rolin et al. 2001, 
Roberts, Sturek et al. 2001, McAnulty 2012). Besides possible reasons like diet, breed, gender, 
fasting time or the analysis protocol, blood glucose concentration in minipigs is affected by age 
and BW (Larsen, Rolin et al. 2001). Blood glucose is increasing with advanced age and BW 
gain, due to a slight loss of insulin sensitivity and consequently deceleration of glucose 
clearance as also described in humans (Rosenthal, Doberne et al. 1982, Rowe, Minaker et al. 
1983, Ahren and Pacini 1998). Other animal models expressing insulin mutants like the 
Ins2C96Y Akita mouse, the Munich Ins2C95S mutant mouse and the INSC94Y transgenic DP model 
share the hyperglycemic findings observed in INSC94Y transgenic MPHs and therefore confirm 
the diabetogenic effect of a mutant insulin gene affecting one of the three disulfide bonds 
(Yoshioka, Kayo et al. 1997, Herbach, Rathkolb et al. 2007, Renner, Braun-Reichhart et al. 
2013). However, INSC94Y transgenic and non-transgenic DPs showed higher FBG levels 
compared to INSC94Y transgenic and non-transgenic MPHs reaching 415 and 84 mg/dl at day 
115 of age, respectively (Renner, Braun-Reichhart et al. 2013). DPs are known to have a higher 
FBG level compared to minipigs. The reference range for normoglycemic DPs is between 70–
115 mg/dl, compliant to human levels (Barb, Cox et al. 1992, Ramsay and White 2000, Renner, 
Braun-Reichhart et al. 2013). In humans, a range of 70–99 mg/dl is defined as normal fasting 
plasma glucose (FPG), a range of 100–125 mg/dl is defined as impaired fasting glucose for 
patients considered prediabetic and a cut-off of ≥126 mg/dl FPG for patients considered diabetic 
according to the American Diabetes Association (ADA) (ADA 2020). The WHO defined its 
cut-off for normal FPG at <110 mg/dl, though the stricter cut-off is preferred by recent 
investigations (Raizes, Elkana et al. 2016). In case of monogenic diabetes, young and non-obese 
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children are considered affected when showing a mild fasting hyperglycemia of 100–150 mg/dl 
according to ADA (ADA 2020). Further test methods used to diagnose diabetes in humans like 
the 2-h plasma glucose value after an oral glucose load (oral glucose tolerance test) could be 
further investigated in the INSC94Y transgenic and non-transgenic MPHs to evaluate the 
remaining capability of glucose-stimulated insulin secretion. Though glucose gavage should be 
limited to the first days of life in pigs to avoid the risk of a hyperglycemic crisis. Tests based 
on HbA1c criteria are not advisable neither in minipigs nor domestic pigs, as their erythrocytes 
are impermeable to glucose (Higgins, Garlick et al. 1982). 
A disturbed glycemic control due to an insulin mutation is referred to as MIDY, resulting from 
expression of a misfolded mutant proinsulin that is retained within the endoplasmic reticulum 
(ER) of β-cells leading to reduced secretion of insulin and hypoinsulinemia (Liu, Hodish et al. 
2010). Plasma insulin concentrations of INSC94Y transgenic MPHs were reduced and are 
probably accountable for early hyperglycemia. Already seven days after birth, transgenic MPHs 
showed a significantly lower level of mean plasma insulin compared to their control littermates 
(4.6 µU/ml vs. 14.5 µU/ml). Random plasma insulin concentrations on day seven showed 
higher values for transgenic (4.6 µU/ml) and non-transgenic (14.5 µU/ml) MPHs compared to 
the determinations at day 180, due to the fact that piglets were still with the sow at that age and 
therefore not fasted. At 180 days of age mean fasting plasma insulin (FPI) concentration of 
INSC94Y transgenic MPHs was lower compared to non-transgenic littermates but not 
significantly altered (2.6 µU/ml vs. 7.2 µU/ml), probably due to the low number of animals in 
the wild-type group (n=3) and the high variance of FPI in both groups at day 180. However, 
the values of the control animals were within the reference range for normal FPI known for 
minipigs (between 3–14 µU/ml) (Hara, Lin et al. 2008, Li, Yin et al. 2010). The tendency of 
reduced FPI in INSC94Y transgenic MPHs compared to the non-transgenic littermates were in 
concordance with the results described for the INSC94Y transgenic DP model. Transgenic DPs 
revealed even significantly lower FPI levels compared to their non-transgenic littermates (2 ± 
vs. 5.1 ± µU/ml) (Renner, Braun-Reichhart et al. 2013). Just like FPG, the FPI in minipigs is 
known to be lower compared to domestic pigs and humans (Barb, Cox et al. 1992, Ramsay and 
White 2000, Larsen, Rolin et al. 2001). However, four and a half-month-old INSC94Y transgenic 
DPs showed slightly lower FPI concentrations in the transgenic as well as in the wild-type group 
in comparison to six-month-old INSC94Y transgenic and non-transgenic MPHs, respectively. 
The slightly younger age of DPs compared to MPHs at the time of blood sampling might have 
had an influence on the lower FPI levels in INSC94Y transgenic and non-transgenic DPs. With 
increasing age and BW a combined elevation of blood glucose and consequently plasma insulin 
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is suggested in pigs as well as in humans (Rosenthal, Doberne et al. 1982, Larsen, Rolin et al. 
2001). The measurments of plasma insulin were not always correlative to plasma C-peptide 
concentrations, determined from the same blood sample per pig at day seven and day 180 of 
age, respectively. C-peptide is a part of proinsulin and is released in parallel and equal amounts 
to insulin from secretory granules of the β-cell into the blood, after the transformation of 
proinsulin to insulin. Therefore, plasma C-peptide concentrations correlate to plasma insulin 
concentrations. In accordance with lower FPI levels lower random and fasting plasma C-peptide 
levels were observed in INSC94Y transgenic MPHs compared to control littermates at both points 
in time, as well as the tendency of lower C-peptide concentrations in wild-type MPHs on day 
180 compared to day seven of age. Opposed to insulin measurements in transgenic MPHs 
(insulin values were lower at day 180 compared to day seven) a higher concentration of plasma 
C-peptide was seen at day 180 (fasted) compared to day seven (non-fasted) in these animals. 
Probably, this discrepancy also resulted from the high variance of FPI and C-peptide within the 
respective group. Furthermore, the longer half-life of the plasma concentration of C-peptide 
might result in uncorrelated measurements of FPI and C-peptide. However, the majority of 
diabetic minipig models successfully achieved reduction of FPI due to chemical induction. 
Hereby, the destruction of β-cells has a direct, dose-dependent impact on FPI concentrations 
(Stanley, Hall et al. 1997, Larsen, Wilken et al. 2002). In case of diabetes induced by the 
expression of mutant insulin, it is hypothesized that the lack of insulin initially derives from 
impaired trafficking or secretion of proinsulin prior to absolute insulin deficiency due to β-cell 
apoptosis as a consequence of ER stress response (Liu, Haataja et al. 2010). This 
pathomechanism was demonstrated in the INSC94Y transgenic DP model (Renner, Braun-
Reichhart et al. 2013) and is considered the same in INSC94Y transgenic MPHs. To confirm that 
initial insulin deficiency precedes β-cell loss also in INSC94Y transgenic MPHs, pancreata of 
neonates should be examined by quantitative-stereological analysis in parallel to further insulin 
measurements.  
Effects of domestic pig-minipig crossbreeding and expression of mutant insulin on glucose 
homeostasis and insulin secretion were displayed by this size-reduced INSC94Y porcine model. 
On the one hand, relevant blood parameters of wild-type littermates were more consistent with 
the reference ranges for minipigs than with those of domestic pigs, reflecting the impact of 
minipig background. On the other hand, INSC94Y transgenic MPHs revealed hyperglycemia and 
hypoinsulinemia, as a consequence of the expression of mutant insulin, to consider them 
clinically diabetic compared to their control littermates and in accordance to existing references 
for minipigs. The early manifestation of a constant hyperglycemia and hypoinsulinemia within 
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a few weeks of life in INSC94Y transgenic MPHs is therefore compliant with the clinical 
characteristics defined for PNDM in humans (Stoy, Edghill et al. 2007, Klupa, Skupien et al. 
2012). However, since there is no population statistics of swine available and the current 
reference ranges are based on individual investigations instead, pigs in diabetes research should 
be considered diabetic when relevant blood parameters are remarkably altered compared to an 
appropriate control and fit in an existing reference range from a diabetic population of the breed. 
Due to the high metabolic resemblance between human and pigs, it is possible to compare to 
human criteria, but the lower levels of blood glucose, plasma insulin and C-peptide in minipigs 
have to be taken into account. 
Clinical chemical parameters of interest were evaluated in INSC94Y transgenic and non-
transgenic MPHs. Besides on blood glucose insulin has a strong impact on blood lipids, as 
dyslipidemia is associated with type 1 diabetes (T1D) and type 2 diabetes (T2D) (Biesenbach 
1989, Filippatos, Tsimihodimos et al. 2017). Blood lipid abnormalities in diabetes are generally 
defined by hypertriglyceridemia and can be accompanied by low levels of high-density 
lipoprotein cholesterol and high levels of low-density lipoprotein cholesterol, but the alterations 
of cholesterol patterns can vary (Gerrity, Natarajan et al. 2001). Different types of diabetes can 
all result in hypertriglyceridemia but insulin deficiency or insulin resistance and the chronic 
oversupply of blood glucose affect the fat metabolism in different ways (Reaven and Greenfield 
1981, Filippatos, Tsimihodimos et al. 2017). The pathogenesis based on insulin deficiency leads 
to a diminished degradation of triglyceride-containing lipoproteins due to a reduced activity of 
the lipoprotein lipase. This can be enhanced by increased free fatty acid concentrations in the 
blood due to the reduced lipolysis-inhibiting effect of insulin. In contrast, the crucial pathogenic 
factor of impaired insulin sensitivity and subsequent hyperinsulinemia is the increased secretion 
of triglyceride-containing lipoproteins due to elevated free fatty acid levels (Reaven and 
Greenfield 1981, Biesenbach 1989, Keller, Golay et al. 1990). INSC94Y transgenic MPHs 
showed significantly higher mean fasted triglyceride levels compared to control littermates 
(55.7 mg/dl vs. 27.4 mg/dl, p<0.05) at day 180 of age. Mean fasted total cholesterol levels of 
INSC94Y transgenic MPHs were slightly but not significantly lower compared to non-transgenic 
littermates (67.5 vs. 89.5 mg/dl, p=0.32). In the Yucatan and Ossabaw minipig breed, the 
defined reference range was 19–39 mg/dl for normal triglyceride concentrations, whereas diet-
induced obese pigs that were considered hypertriglyceridemic reached triglyceride levels of 41–
106 mg/dl (Boullion, Mokelke et al. 2003, Neeb, Edwards et al. 2010). The concentration for 
normal cholesterol of these minipigs was 51–157 mg/dl, in contrast an elevation within a range 
of 280–479 mg/dl was observed in the diet-induced obese groups (Boullion, Mokelke et al. 
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2003, Mokelke, Dietz et al. 2005, Neeb, Edwards et al. 2010). In line with these previous 
investigations was the observation that insulin deficiency due to the expression of the mutant 
insulin affected the lipid metabolism of INSC94Y transgenic MPHs by increasing the triglyceride 
concentrations, while those of control littermates remained normal. Reduced insulin levels 
decreasing the activity of lipoprotein lipase are probably the main reason for 
hypertriglyceridemia in these pigs. An impact on total cholesterol levels could not be detected 
in INSC94Y transgenic MPHs. Moreover, hypercholesterolemia is not that common in diabetic 
subjects suffering from insulin deficiency as hypertriglyceridemia and low high-density 
lipoprotein cholesterol (Biesenbach 1989, Hirano 2018).  
Furthermore, INSC94Y transgenic MPHs showed significantly reduced mean fasted creatinine 
concentrations compared to non-transgenic littermates (0.53 mg/dl vs. 0.96 mg/dl, p<0.001) at 
day 180 of age. A reference range of blood creatinine for miniature swine at a similar age was 
defined to be 0.98–1.05 mg/dl (Garthoff, Henderson et al. 2002). The blood concentration of 
creatinine is predominantly used to screen earliest stages of diabetic nephropathy by indirect 
determination of glomerular filtration rate (GFR) or creatinine clearance (Chantler, Garnett et 
al. 1969, Rehling, Moller et al. 1984). Recently it is suggested that low blood creatinine 
concentration is also an early predictor of diabetes risk in humans (Hu, Nakagawa et al. 2019). 
The blood level of creatinine is directly proportional to the muscle mass since creatinine is the 
metabolite of creatine phosphate in the muscle (Heymsfield, Arteaga et al. 1983, Baxmann, 
Ahmed et al. 2008). Muscle tissue is one of the major targets for insulin activity (glucose uptake 
and oxidation, glycogen synthesis) and inversely insulin has an anabolic effect on muscle 
development (Menon and Sperling 1996, Zierath, Krook et al. 2000). A reduced muscle mass 
could accelerate or even cause an insulin resistance (Srikanthan, Hevener et al. 2010) while a 
decreased insulin concentration can impair muscle growth (Menon and Sperling 1996). The 
significantly lower creatinine concentrations of INSC94Y transgenic MPHs compared to wild-
type MPHs might be associated to a diminished muscle development due to an insufficient 
insulin supply. This assumption is supported by the observed growth retardation in INSC94Y 
transgenic MPHs. Forearm and shank circumference of INSC94Y transgenic MPHs were 
remarkably reduced in comparison to non-transgenic littermates, indicative for poor muscle 
mass (see chapter 5.2.2). However, relative lean mass evaluated by Dual-energy X-ray 
absorptiometry (DXA) was significantly higher in INSC94Y transgenic MPHs compared to wild-
type littermates (see chapter 5.2.3). Though, the lean mass measured consisted of more than 
muscle tissue (e.g., skin and connective tissue) and is therefore not a direct parameter for muscle 
mass. 
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Furthermore, mean fasted urea concentrations of INSC94Y transgenic MPHs were remarkably 
higher than those of control littermates (49 vs. 33.5 mg/dl, p<0.05) at day 180 of age. A 
reference range for blood urea in miniature swine at a similar age was defined to be 6.8–10.3 
mg/dl (Garthoff, Henderson et al. 2002). Thus, transgenic and non-transgenic MPHs inclined 
to have higher urea levels than normal. Urea is used as a marker of GFR but it is less specific 
than creatinine. An elevated urea concentration can be associated with many factors 
independent of renal failure, like high protein diet, hypovolemia, excessive tissue breakdown 
or gastrointestinal hemorrhage that makes it a less reliable marker of GFR (Traynor, Mactier et 
al. 2006). Therefore, the elevated urea concentration of INSC94Y transgenic and non-transgenic 
MPHs compared to the reference range may result from other reasons than a decreased GFR. 
Further evaluation of the kidneys revealed neither any findings verifying for kidney failure (see 
chapter 5.3.3).  
5.2.2 Growth retardation in non-transgenic and INSC94Y transgenic MPHs  
Growth retardation was observed in INSC94Y transgenic and non-transgenic MPHs within the 
observation period of six months. Wild-type MPHs gained significant lower BW than wild-type 
DPs starting from week six of age, resulting in a mean BW of 58 kilogram at the age of six 
months, which was 39% lower compared to age-matched DPs with a mean BW of 95 kilogram. 
Apart from that, a significant lower birth weight was observed for wild-type MPHs compared 
to a group of wild-type DPs (0.828 ± 0.06 vs. 1.168 ± 0.05 kg; p<0.001) that were also 
descendants of INSC94Y transgenic domestic sows. The fact that the compared wild-type MPH 
and wild-type DP piglets came from a similar maternal background enhances the outcome of 
the altered birth weight. INSC94Y transgenic domestic sows were diabetic and tended to be 
smaller and to weigh less than wild-type domestic sows, therefore the comparison of non-
transgenic MPHs and DPs all born to INSC94Y transgenic domestic sows is more accurate. 
Nevertheless, the determination of birth weight and body weight gain within six months showed 
both a strong impact on the BW due to crossbreeding minipig with a domestic pig line. 
However, it has to be considered that in addition to the genetic background of a foetus, length 
and capacity of the uterus have a major impact on foetal development (McCance and 
Widdowson 1974, Rothschild, Messer et al. 2000). A greater uterine space has a positive effect 
on foetal length and weight. The bigger the organ is, the larger foetuses it can obtain (Chen and 
Dziuk 1993). Also, the total number of foetuses itself determines inversely the size of each 
individual within the litter (Litten-Brown, Corson et al. 2010). Domestic sows used for 
laboratory purposes tend to have an average litter size of 12–14 piglets (Rutherford, Robson et 
al. 2009, Rutherford, Piastowska-Ciesielska et al. 2014), whereas the average litter size of 
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Göttingen minipig sows is six and a half piglets (Ganderup, Harvey et al. 2012, McAnulty 
2012). The two INSC94Y transgenic domestic dams delivered a litter of nine and eleven MPH 
piglets, respectively. For the generation of INSC94Y transgenic and non-transgenic MPHs, 
INSC94Y transgenic domestic sows with a German Landrace-Swabian Hall background were 
crossbred with a non-transgenic black minipig boar. For this reason, the uterus of the INSC94Y 
transgenic domestic sow had an above-average size for the low number of size-reduced minipig 
crossbred foetuses it contained. Thus, proportionally more uterine space was offered for the 
development of INSC94Y MPH foetuses, which could enable an above-average growth compared 
to minipig foetuses born from a minipig sow. This assumption could contribute to the fact that 
no significantly lower birth weight was detected in wild-type MPHs compared to wild-type DPs 
from a non-transgenic sow. The achieved BW of the wild-type minipig crossbred pigs at six 
months of age is comparable to the BW gained by other minipig breeds like the Yucatan 
miniature swine at 12 months of age or fully grown Micro-Yucatan miniature swine and Sinclair 
miniature swine at 24 months of age for example (Ganderup, Harvey et al. 2012, Kim, Song et 
al. 2015). 
The transgenic group of MPHs exhibited impaired BW gain starting from 11 weeks of age 
compared to non-transgenic MPHs. The reduction of BW gain was progressive with increasing 
age of the animals. The growth retardation led to a mean BW of 26 kilogram of INSC94Y 
transgenic MPHs, a 55% lower BW compared to their wild-type littermates at the end of the 
observation period, i.e., at an age of six months. Lower BW was also observed in other animal 
models, expressing an equivalent mutant insulin gene or transgene. INSC94Y transgenic DPs for 
example started to exhibit lower BW rates after two months of age and revealed a decrease of 
41% of BW at an age of four and a half months compared to non-transgenic littermates (Renner, 
Braun-Reichhart et al. 2013). These results imply a major impact of insufficient insulin 
secretion on BW gain of INSC94Y transgenic MPHs similar to INSC94Y transgenic DPs. Due to 
the age difference of the animals and the fact that impaired insulin secretion increased with age 
the alteration of BW was more pronounced in six-month-old INSC94Y transgenic MPHs (-55%) 
than in 4.5-month-old INSC94Y transgenic DPs (-41%) compared to their wild-type littermates, 
respectively. Concordant with the reduced BW were the values measured for the absolute organ 
weights that showed a proportional decrease, comparing wild-type MPHs to wild-type DPs and 
transgenic MPHs to non-transgenic littermates. None of the relative organ weights (% of BW) 
of wild-type MPHs was significantly altered compared to age-matched wild-type DPs, except 
for the spleen that showed a distinctive lower weight in non-transgenic MPHs. In contrast, the 
relative weight of most organs of INSC94Y transgenic MPHs was increased in comparison to 
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control littermates. 
Besides body and organ weights, relevant growth parameters of INSC94Y transgenic and non-
transgenic MPHs were measured to evaluate the body size (BS) and body shape and 
characteristics of growth retardation. Wild-type MPHs were already born with a significant 
reduction of 23% in shoulder height (14.7 ± 0.4 vs. 19 ± 0.5 cm, p<0.01) and of 21% in hip 
height (14.7 ± 0.5 vs. 18.7 ± 0.7 cm, p<0.05) and at the age of five months all growth parameters 
measured were significantly reduced (-7% to -25% dependent on the growth parameter) 
compared to wild-type DPs (occipito-nasal length: 26.4 ± 1 vs. 30.8 ± 0.4 cm; biparietal 
diameter: 10.8 ± 0.3 vs. 12.8 ± 0.4 cm; crown-rump length: 90.3 ± 1.6 vs. 116.4 ± 3.2 cm; 
shoulder height: 47.3 ± 1.2 vs. 63.4 ± 1.3 cm; shoulder width: 21.6 ± 0.5 vs. 25 ± 0.3 cm; 
forearm circumference: 18.6 ± 0.9 vs. 23.6 ± 0.2 cm; thoracic circumference: 84.7 ± 2.2 vs. 
94.6 ± 0.9 cm; abdominal circumference: 99.2 ± 2.1 vs. 107 ± 2.3 cm; shank circumference: 
21.8 ± 0.8 vs. 25.8 ± 0.4 cm; hip height: 51.4 ± 0.8 vs. 66 ± 1.1 cm; hip width: 17.6 ± 0.5 vs. 
21 ± 0.7 cm; p<0.001, respectively). Thus, the lower BS correlated with the lower BW gained 
of wild-type MPHs in the observation period of five months, except for the first five weeks of 
life where shoulder and hip height were already lower but no significant reduction in BW was 
observed in wild-type MPHs compared to wild-type DPs. Fattening pigs generally tend to have 
the lowest BW gain in the first seven weeks of life in relation to the weight gain of their 
remaining growth phase (Kohn, Sharifi et al. 2007). Important aspects to consider when 
comparing the growth of pigs on a domestic background with pigs on a minipig background are 
the differences in growth patterns defined by breeding goals. While fattening pigs have a more 
sigmoid growth curve, minipigs generally tend to have a linear growth curve in the first six 
months of life (Kohn, Sharifi et al. 2007). In line with these growth patterns, significant 
alterations of the BW occurred in age-matched wild-type DPs and MPHs starting from week 
six of life. In other words, MPHs have a more constant and slower growth pattern then DPs that 
can be beneficial for laboratory purposes. Young MPHs can enter the laboratory with a lower 
initial BW and BS, maintain a slower BW gain during growth and obtain a lower final BW and 
BS compared to DPs of the same age. Besides the easier handling and manipulation of a smaller 
pig in the laboratory, one of the main advantages of a lower BW is the reduced amount (i.e., 
lower cost) of a compound required for preclinical studies, e.g., for the development of new 
pharmaceuticals. In addition, the slower growth pattern and the estimated final BW of wild-
type MPHs corresponded more to the growth pattern and BW of adult humans in comparison 
to that of DPs, which adds to the translational benefits of MPHs. 
The comparison of the same growth parameters between INSC94Y transgenic MPHs and wild-
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type littermates showed similar initial growth characteristics at birth but at an age of five months 
significant retardation of growth (-12% to -29% dependent on the growth parameter) was 
detected in transgenic MPHs (occipito-nasal length: 21.8 ± 0.4 vs. 26.4 ± 1 cm; biparietal 
diameter: 9.5 ± 0.2 vs.10.8 ± 0.3 cm; crown-rump length: 73.3 ± 1.9 vs. 90.3 ± 1.6 cm; shoulder 
height: 38 ± 0.7 vs. 47.3 ± 1.2 cm; shoulder width: 15.3 ± 0.7 vs. 21.6 ± 0.5 cm; forearm 
circumference: 14.9 ± 0.7 vs. 18.6 ± 0.9 cm; thoracic circumference: 67.3 ± 1.9 vs. 84.7 ± 2.2 
cm; abdominal circumference: 83.5 ± 1.9 vs. 99.2 ± 2.1 cm; shank circumference: 17.4 ± 0.5 
vs. 21.8 ± 0.8 cm; hip height: 43.4 ± 1.2 vs. 51.4 ± 0.8 cm; hip width: 12.5 ± 0.3 vs. 17.6 ± 0.5 
cm; p<0.001, respectively). In a study of human neonatal diabetes mellitus (NDM) investigating 
a large cohort of patients, newborns presented intrauterine growth retardation (IUGR) and 
reduced birth weight due to insufficient insulin supply in up to 74% of the cases with transient 
neonatal diabetes mellitus (TNDM) and 36% of the cases with PNDM (Metz, Cave et al. 2002). 
Due to the notable difference of apparent IUGR between these two forms of NDM it is implied 
that the appearance of IUGR has to be based on a distinct pathomechanism. IUGR in infants 
with NDM shows the important role of insulin as foetal growth factor and the point of time of 
its absence being a key element (Cave, Polak et al. 2000). In patients with TNDM β-cell failure 
manifests already in the late foetal or early postnatal period, whereas in the majority of PNDM 
cases impaired β-cell function occurs after birth (Metz, Cave et al. 2002, Polak and Cave 2007, 
Stoy, Edghill et al. 2007). When comparing the prenatal consequences of NDM of humans with 
other species like the pig, it needs to be considered that the peak of foetal growth rate is reached 
at different gestational ages. For humans foetal growth achieves its maximum between gestation 
weeks 30–36, in contrast to pigs where foetal growth starts to accelerate around birth (Litten-
Brown, Corson et al. 2010). Birth weight and size, BW gain and growth rate of newborn INSC94Y 
transgenic MPHs compared to non-transgenic littermates were not significantly but just slightly 
lower at or immediately after birth, i.e., no apparent IUGR was present in newborn INSC94Y 
transgenic MPHs. This indicates that foetal and newborn transgenic MPHs developed a less 
severe or slower impairment of insulin secretion or dysfunction of β-cells due to mutant INSC94Y 
compared to infants with neonatal diabetes mellitus. The non-significant retardation in birth 
weight and size of newborn INSC94Y transgenic MPHs suggest that the degree of intrauterine 
insulin deficiency was not sufficient to provoke IUGR as assumed for the majority of infants 
suffering from PNDM. However, as already mentioned length and capacity of the uterus of a 
sow have a positive effect on foetal growth that could maybe mask a slightly underlying growth 
restriction due to insufficient prenatal insulin supply (McCance and Widdowson 1974, 
Rothschild, Messer et al. 2000).  
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Besides being a pivotal foetal growth factor, insulin is a key hormone for many anabolic 
processes. It regulates the metabolism of carbohydrates, fats and proteins in target organs like 
liver, muscle or adipose tissue (Menon and Sperling 1996). Additionally to the growth hormone 
(GH), insulin stimulates the synthesis of insulin-like growth factor I (IGF1) to control the 
anabolic processes in different body compartments and therefore insulin also has an impact on 
the GH/IGF1 axis (Laron 2004). Insulin, GH and IGF1 are anabolic agents, which collectively 
are responsible for the induction of bone growth and bone formation and the maintenance of 
bone mass (Thrailkill, Lumpkin et al. 2005, Trobec, von Haehling et al. 2011). Adolescent 
diabetic patients are known to have an impaired linear bone growth and a decreased growth 
velocity due to the lack of insulin. The bones of these patients tend to be smaller, particularly 
when hypoinsulinemia has already occurred during childhood (Sellmeyer, Civitelli et al. 2016). 
This clinical feature in humans is consistent with the results obtained by growth evaluation at a 
state of puberty in INSC94Y transgenic MPHs. All INSC94Y transgenic animals showed 
remarkably altered growth parameters at the age of five months compared to their non-
transgenic littermates. Also, all wild-type MPHs obtained size-reduced growth parameters 
compared to wild-type DPs. Thus, the observed growth retardation in non-transgenic and 
transgenic MPHs can be explained by the minipig background and the expression of mutant 
INS. 
5.2.3 Body composition of non-transgenic and INSC94Y transgenic MPHs 
Besides other anabolic factors, insulin does not only regulate growth formation and growth 
velocity of the organism, but has also a crucial role when it comes to the composition of body 
tissues and its maintenance. Hence, whole body composition was analysed at the age of six 
months by Dual-energy X-ray absorptiometry (DXA). When correcting for the significant 
difference in total tissue (corresponding to reduced BW shown in 5.2.2) no significant 
differences could be detected by comparing the mean values of bone mineral density (BMD), 
relative bone mineral content (BMC), relative fat mass and relative lean mass in wild-type 
MPHs and wild-type DPs. However, tendencies of increased relative fat mass and reduced 
relative lean mass in non-transgenic MPHs compared to DPs were observed. In contrast, the 
INSC94Y transgenic MPHs revealed significantly decreased mean values of total tissue (-55%) 
(corresponding to reduced BW shown in 5.2.2) with reduced relative fat mass (-83%) and 
increased relative lean mass (+12%) compared to their control littermates. This could indicate 
a superior influence of the absence of insulin on adipose tissue rather than on other body tissues 
like muscle for example. A high sensitivity of the lipometabolism with increased lipolysis is 
also observed in humans with hypoinsulinemia and weight loss is a main characteristic for 
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diabetes associated with insulin deficiency (Nurjhan, Consoli et al. 1992, Camastra, Vitali et al. 
2017). The anti-lipolytic effect of insulin demonstrates the importance of this hormone besides 
its pivotal role for the glucose metabolism. Insulin diminishes the release of glycerol or fatty 
acids and thereby inhibits the action of lipolytic hormones like adrenaline or 
adrenocorticotropic hormone (Touabi and Jeanrenaud 1970). Inversely, enhanced lipolysis can 
be expected in an organism lacking insulin, as demonstrated by INSC94Y transgenic MPHs. The 
determination of lipolysis measured as the percentage change in glycerol rate, is even used to 
characterize the effect of insulin using novel protocols (Herring, Shojaee-Moradie et al. 2015).  
However, gender-related differences were detected in fat and lean mass (related to total tissue) 
within the group of non-transgenic MPHs. Male wild-type MPHs showed significantly higher 
lean mass (+16%) compared to female wild-type MPHs, whereas females revealed a markedly 
higher fat mass (+112%) compared to males. No significant differences in relative fat and lean 
mass were detected between male and female wild-type DPs or between male and female 
INSC94Y transgenic MPHs. This, however, could result from the low number of animals in the 
groups consisting of only three female and two male wild-type DPs and only four female and 
two male INSC94Y transgenic MPHs, respectively. In general, male DPs also tend to have a lower 
relative fat mass and higher relative lean mass compared to female DPs when fed the same diet 
as detected in wild-type MPHs. The non-significant differences in fat and lean mass of male 
and female INSC94Y transgenic MPHs may also be attributable to an enhanced lipolysis in both 
genders due to an insufficient insulin supply, as described before. However, the gender-related 
results of relative fat and lean mass of non-transgenic MPHs were concordant with the 
differences described by Christoffersen et al. (Christoffersen, Grand et al. 2007, Christoffersen, 
Golozoubova et al. 2013). By comparing male and female Göttingen minipigs they suggested 
a higher probability for females to become obese and to develop metabolic syndrome-related 
parameters due to a gender-related hormonal profile. They hypothesized that testosterone and 
estradiol can have a protective influence, by preventing overeating and the likelihood for the 
development of obesity in males. (Christoffersen, Golozoubova et al. 2013). When feeding a 
high-energy diet to Göttingen minipigs of both genders under the same conditions, notably 
higher levels of testosterone and estradiol were found in prepubertal and sexually mature male 
minipigs compared to females. Minipig sows tend to be more obese, insulin resistant and were 
achieving a more severe atherogenic plasma profile (composed of high plasma triglyceride and 
high-density lipoprotein cholesterol levels) in comparison to the minipig boars (Clapper, Clark 
et al. 2000, Christoffersen, Grand et al. 2007). A gender-related difference in estradiol 
concentrations was also observed in a study with exercised adult Yucatan minipigs. Female 
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Yucatan minipigs obtained lower estradiol concentrations than males that could not be 
influenced by treadmill training (Laughlin, Welshons et al. 2003). In accordance with these 
previous observations, especially female INSC94Y transgenic MPHs may be a suitable animal 
model for obesity-related diabetes or metabolic syndrome. Sex hormones have an impact on 
the development of obesity and metabolic syndromes in pigs as well as in humans (Kautzky-
Willer, Harreiter et al. 2016). However, it must be noted that there is a discrepancy concerning 
the sex hormone balance between pigs and humans. Male pigs achieve higher estradiol levels, 
while female pigs have lower estradiol levels compared to humans in a similar developmental 
stage (Laughlin, Welshons et al. 2003, Christoffersen, Golozoubova et al. 2013). Therefore, 
gender-related differences in the sex hormone pattern cannot be translated that easily from pig 
to human. 
Other body tissues probably facing an impact of the expression of the mutant INSC94Y are BMD 
and BMC. Osteopenia and osteoporosis are bone disorders associated with reduced bone quality 
and are frequent comorbidities of diabetes and related to insulin deficiency (Schwartz 2003). 
The underlying pathophysiology of reduced bone quality and bone fracture risk in diabetes 
patients is complex, differs between the different types of diabetes and is still not fully 
understood. For example, BMD is only decreased in T1D but increased in T2D patients 
compared to subjects without diabetes which probably is related to a compensatory effect due 
to a higher body mass index (BMI) in T2D patients. However, it is suggested that an increased 
risk of bone fractures exists in patients with T1D as well as with T2D, though the risk is higher 
in T1D and remains controversial in T2D (reviewed in (Vestergaard 2007)). It is assumed that 
the fracture risk increases through an elevated risk of falls due to diabetic complications but 
that the often increased BMI in T2D patients could be protective and reduce the risk of fractures 
by increasing BMD. In contrast, T2D patients with a high BMI have also an increased traumatic 
load in case of a fall due to a heavy BW which increases the risk of bone fractures (De Laet, 
Kanis et al. 2005). Decreased BMD is an indirect indicator and predictor of osteoporosis. 
Hypoinsulinemia is known to affect bone mineralization and results in reduced BMD and 
reduced bone strength, leading among other factors to an elevated risk of bone fractures and an 
impaired bone healing (Thrailkill, Lumpkin et al. 2005, Sellmeyer, Civitelli et al. 2016). The 
absence of an insulin stimulus also diminishes the synthesis of IGF1 and alters the GH/IGF1 
axis (see chapter 5.2.2) which has consequences on bone remodeling (Moyer-Mileur, Slater et 
al. 2008). Reduced blood serum levels of IGF1, alkaline phosphatase and osteocalcin were 
measured in diabetic humans and rodents with lower BMD and attributed to a decreased 
osteoblastic function (Kemink, Hermus et al. 2000, Sellmeyer, Civitelli et al. 2016). Besides 
Discussion 129 
this indirect influence of insulin on bone remodeling, also hypoinsulinemia and hyperglycemia 
may have a direct impact on bone cells expressing insulin receptors. Osteocytes, osteoblasts 
and osteoclasts are stimulated by insulin secretion, resulting in a positive bone formation and 
physiological bone turnover (Fulzele, Riddle et al. 2010). Inversely, hypoinsulinemia or insulin 
resistance diminishes the activity of bone cells (Lecka-Czernik, Stechschulte et al. 2015). It is 
hypothesized that hyperglycemia also directly affects the function of osteoclasts through 
increased expression of sclerostin which attenuates bone formation (Pacicca, Brown et al. 
2019). Another influence on BMD may result from microvasculopathies like peripheral 
nephropathy, peripheral vascular disease, retinopathy and neuropathy, all of them known 
comorbidity of diabetes mellitus (reviewed in (Hofbauer, Brueck et al. 2007)). A similar 
pathomechanism that is responsible for these microvasculopathies may also underlie the 
changes observed in trabecular microarchitecture (i.e., reduced BMD) of T1D patients. 
(Abdalrahaman, McComb et al. 2015, Shanbhogue, Hansen et al. 2015). However, INSC94Y 
transgenic MPHs revealed a significant reduction of 27% in BMD but an increase of 14% in 
BMC (related to total tissue) compared to wild-type littermates, respectively. It should be 
mentioned that a minor discrepancy in the accuracy of the measurement of BMD could exist. 
To calculate true BMD, mass should be divided by volume. Using DXA imaging mass has to 
be divided by area due to the missing depth value. Such measurement inaccuracy, however, 
should not have a relevant influence on the results. The calculation of relative BMC depended 
on the total tissue of the animals that was significantly reduced in transgenic MPHs compared 
to control. Reduced insulin secretion seemed to have a greater impact on soft tissue such as fat 
and muscle compared to BMC. Therefore, relative BMC was higher in transgenic MPHs 
compared to non-transgenic MPHs. Nevertheless, this transgenic porcine model acquiring 
lower BMD likely recapitulates the alterations of bone mineralization due to the absence of 
insulin as observed in diabetic humans. An interesting complement to BMD measurements by 
DXA would be the determination of bone formation markers like serum osteocalcin (Starup-
Linde, Eriksen et al. 2014) to support the outcome of the DXA measurement and to evaluate 
possible influences on osteocalcin levels like a reduced insulin concentration. Osteocalcin is an 
indicator for osteoblast number and maturation (Lee, Sowa et al. 2007) and its serum level is 
also associated to different metabolic parameters (e.g., fasting glucose, fat mass, BMI) 
including insulin concentration, possibly with a bi-directional influence on each other 
(reviewed in (Pramojanee, Phimphilai et al. 2014, Starup-Linde and Vestergaard 2016)). A 
decrease in serum osteocalcin levels going along with a decrease of serum insulin levels and 
BMD could be expected in transgenic MPHs as described in diabetic rodent models (Botolin 
and McCabe 2007). Studies in diabetic humans showed a relation between reduced osteocalcin 
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serum levels and reduced BMD but could not detect a correlation between osteocalcin and 
BMD. However, the patients in these studies possibly did not suffer severe enough 
hypoinsulinemia (Gunczler, Lanes et al. 1998, Kemink, Hermus et al. 2000, Lumachi, Camozzi 
et al. 2009). In addition to the sensitivity of BMD to insulin deficiency in INSC94Y transgenic 
MPHs, minipigs have further important traits of bone architecture and regeneration that are 
similar to humans, most importantly a cancellous and cortical bone with a well-established 
Haversian system and a comparable remodeling bone turnover (Martinez-Gonzalez, Cano-
Sanchez et al. 2005). The porcine Haversian system presents a bone structural unit after 
completion of bone remodeling based on bone multicellular units as described in humans 
(Mosekilde, Weisbrode et al. 1993, Kalu 1999, Martinez-Gonzalez, Cano-Sanchez et al. 2005). 
Another attribute is the similar BW of a minipig compared to the BW of an adult human (see 
chapter 5.2.2) and therefore bones of minipigs tend to have a similar degree of mechanical stress 
compared to humans (Mosekilde, Weisbrode et al. 1993). Generally, an animal model with a 
non-seasonal cyclic oestrus similar to women (Kalu 1999) and a small average litter size of six 
piglets (McAnulty 2012) may also be preferable as it is more comparable to human 
reproduction. Indeed, predominantly uniparous animal species like cows, sheep or non-human 
primates would even be closer to human characteristics (Kalu 1999). It is suggested that 
multiparity and lactation are positively linked to bone regeneration (Bowman and Miller 2001). 
Pigs and rodents are multiparous (Howard, Chakraborty et al. 1982) and therefore could have 
an innate higher potential for remodeling bone (Nespolo 2007). Moreover, rodents have a 
higher birth rate and lactation frequency than pigs and humans, therefore they are capable of 
regenerating lost bone mass due to calcium deprivation in a shorter time (Osterloh and Kelly 
1999). Another advantage of pigs compared to other species is that they are omnivorous like 
humans and gastrointestinal physiology is similar to humans providing similar nutrients and 
minerals to be used for bone metabolism (Reinwald and Burr 2008). However, it should be 
noted that minipigs tend to have a denser trabecular architecture and higher bone mass 
compared to humans (Kalu 1999). 
5.3 Morphological alterations in INSC94Y transgenic MPHs  
5.3.1 Reduction of β-cell mass and rearrangement of pancreatic islets in INSC94Y 
transgenic MPHs 
Reduced functional β-cell mass is a hallmark of diabetes mellitus and its preliminary stages. 
The expression of mutant insulin provokes an altered islet composition of the endocrine 
pancreas due to β-cell apoptosis as detected in other animal models (Yoshioka, Kayo et al. 1997, 
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Herbach, Rathkolb et al. 2007, Renner, Braun-Reichhart et al. 2013). The loss of β-cells is a 
crucial factor for the persistence of impaired insulin secretion. Therefore, β- and α-cell section 
profiles of pancreas tissue from INSC94Y transgenic and non-transgenic MPHs were evaluated 
by qualitative histological and quantitative stereological analyses using paraffin sections. 
Sections of pancreatic tissue from six-month-old INSC94Y transgenic MPHs and non-transgenic 
littermates were immunohistochemically stained for insulin containing β-cells and for glucagon 
containing α-cells, respectively. Wild-type MPHs revealed numerous islet section profiles of 
different sizes and shapes mainly consisting of insulin positive cells as well as isolated small β-
cell cluster section profiles. Glucagon staining showed α-cells located in the centre but also in 
the periphery of the islet section profiles. In contrast, islet section profiles of INSC94Y transgenic 
MPHs seemed to be reduced in number, smaller in size with less amounts of insulin (i.e., 
reduced staining intensity) inside the β-cells. Glucagon positive areas appeared predominant 
and α-cells were organized in clusters. These qualitative observations suggest a decrease of β-
cells in the pancreas and a consequent change in islet architecture of INSC94Y transgenic MPHs 
compared to the wild-type controls. These observations were in line with the results obtained 
from quantitative stereological evaluation. The volume density of β-cells in the pancreas (Vv (β-
cells/Pan)), the total β-cell volume (V (β-cells, Pan)) and the total β-cell volume to BW ratio (V (β-cells, 
Pan)/BW) of INS
C94Y transgenic MPHs were lower by 79%, 85% and 69% in comparison to wild-
type littermates, respectively. Concerning the severe reduction of insulin-positive area 
described above, the glucagon-positive area presented a greater proportion of the islet instead. 
The volume density of α-cells in the pancreas (Vv (α-cells/Pan)) and the total α -cell volume to BW 
ratio (V (α-cells, Pan)/BW) of INS
C94Y transgenic and non-transgenic MPHs showed no significant 
difference, respectively. Instead, the total α-cell volume (V (α-cells, Pan)) of the transgenic animals 
was reduced by 57% when compared to wild-type littermates. However, this was likely the 
result of a significantly decreased body weight associated with a reduced absolute pancreas 
weight in INSC94Y transgenic MPHs compared to non-transgenic littermates (see chapter 5.2.2). 
Quantitative-stereological analyses of the pancreas in the INSC94Y transgenic pig model on a DP 
background showed significant but less severe alterations compared to INSC94Y transgenic 
MPHs. The volume density of β-cells in the pancreas of INSC94Y transgenic DPs was diminished 
by 54%, the total β-cell volume was decreased by 72% and the total β-cell volume related to 
BW was reduced by 53% at an age of four and a half months compared to wild-type littermates, 
respectively (Renner, Braun-Reichhart et al. 2013). The lower reductions of β-cell mass may 
be explained by the younger age of INSC94Y transgenic DPs (4.5 months) compared to six-
month-old INSC94Y transgenic MPHs at the time of necropsy. Reduction of β-cell mass as a 
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consequence of β-cell apoptosis is progressive with increasing age. Analogous to INSC94Y 
transgenic MPHs the total α-cell volume related to BW was unaltered in INSC94Y transgenic DPs 
compared to control littermates (Renner, Braun-Reichhart et al. 2013). In addition, the results 
described by Renner et al. for the volume density of β-cells in the pancreas (Vv (β-cells/Pan)) and 
the total β-cell volume (V (β-cells, Pan)) were higher in wild-type DPs compared to wild-type MPHs 
of this study (Renner, Braun-Reichhart et al. 2013). This is in line with the fact that domestic 
races like German Landrace are known to have a greater amount of endocrine tissue relative to 
the pancreas compared to minipig races like Göttingen minipig (Ulrichs, Bosss et al. 1995, 
Larsen, Rolin et al. 2003).  
Similar alterations of β- and α-cell mass were detected in other animal models with insulin 
mutations. Seven and a half-month-old male Ins2C96Y Akita mice showed a severe decrease of 
90% in volume density of β-cells and an increase in the volume density of α-cells compared to 
their controls (Yoshioka, Kayo et al. 1997). Six-month-old male Munich Ins2C95S mutant mice 
revealed a reduction of 81% for the calculated total β-cell volume in comparison to non-
transgenic controls (with similar pancreas volume between the groups) and increased volume 
density and total volume of α-cells in male and female Munich Ins2C95S mutant mice compared 
to their controls (Herbach, Rathkolb et al. 2007). 
It was shown that the content of β-cells in the endocrine pancreatic tissue of minipig and 
domestic pig breeds is with 60–80% in the same range as for human (Larsen, Rolin et al. 2003, 
Renner, Dobenecker et al. 2016). Actually, more recent studies even claim a lower content with 
an average of only 50–55% of β-cells in human and comparatively 75–77% in mice (Cabrera, 
Berman et al. 2006, Rorsman and Ashcroft 2018). A notable difference is that the total β-cell 
volume to BW ratio was shown to be higher (1.5-fold) for the minipig in comparison to human, 
that could indicate a higher insulin secretory capacity of minipig (Maclean and Ogilvie 1955, 
Larsen, Rolin et al. 2003). 
However, comparable data on β-cell mass in humans are rare due to the restricted number of 
available sample specimen. Currently, measurements can only be done after necropsy, and 
therefore β-cell mass is estimated indirectly by the evaluation of β-cell function as a 
replacement marker (Larsen, Rolin et al. 2007). However, nowadays it is known that these 
parameters do not evolve parallel to each other during the development of diabetes. Thus, it 
cannot be traced back from one to the other but rather depend on the state and the type of the 
disease, respectively. In recent years, the spectrum of suitable modern in vitro and in vivo 
techniques to determine human β-cell mass and function has risen constantly (Chen, Cohrs et 
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al. 2017). Especially non-invasive in-vivo determination of β-cell mass in humans is of major 
interest for early detection and prevention of diabetes and its pre-stages. It is assumed that 
impaired glucose tolerance occurs in humans when 50% of β-cell mass is destroyed and a 
reduction of more than 80% leads to the onset of diabetes (Larsen, Rolin et al. 2007). Recent 
studies demonstrated that these are just relative values as remaining β-cell mass and function at 
the onset of diabetes are also influenced by other factors such as age (Barker, Lauria et al. 2014) 
or a chronic inflammatory state (Leete, Willcox et al. 2016).  
The relative pancreas weight of INSC94Y transgenic MPHs compared to wild-type MPHs was 
significantly elevated (+60%) while the total β-cell volume in the pancreas per se and in relation 
to BW were tremendously reduced. In humans, islets account only for 1–2% of pancreas 
volume, but the destruction of these endocrine cells comes along with atrophy of the exocrine 
pancreas (Williams, Thrower et al. 2012, Rorsman and Ashcroft 2018). Reasons for the atrophy 
of the exocrine pancreas in T1D might be the reduced trophic effect of insulin and the ongoing 
inflammatory processes linked to insulitis (Henderson, Daniel et al. 1981, Nakanishi, 
Kobayashi et al. 1993). However, using magnetic resonance imaging (MRI) in humans, a 
reduction of pancreatic volume of 48% was detected for patients with T1D (Williams, Chau et 
al. 2007) but less severe for patients with T2D or monogenic diabetes, although these 
tremendous decreases developed over several years (≥10 years). Further, patients of T1D that 
were just recently diagnosed showed a less severe reduction of relative pancreatic volume of 
only 26% (Williams, Thrower et al. 2012). Nevertheless, MRI results may still have a higher 
inaccuracy compared to quantitative stereological measurements or a simple characterization 
by determination of the organ weight. Unlike the increased relative pancreas weight, the 
absolute pancreas weight of INSC94Y transgenic MPHs was decreased by 32% in comparison to 
non-transgenic littermates at an age of six months. Hence, it can be assumed that mutant insulin 
C94Y in transgenic MPHs had an impact on both, pancreas weight and BW. 
5.3.2 Modified ultrastructural architecture of β-cells in INSC94Y transgenic MPHs 
The insulin mutation C94Y leads to the expression of misfolded proinsulin that retains within 
the ER and leads to its dilation and impaired function. Misfolded insulin accumulation in the 
ER leads to ER-stress, disturbed insulin production, further expansion of the ER and finally β-
cell apoptosis. Ultrastructural morphology of pancreatic β-cells was examined by transmission 
electron microscopy to evaluate alterations of cellular structures.  
Ultrathin sections of pancreata of six-month-old INSC94Y transgenic and non-transgenic MPHs 
were investigated. Sections of wild-type controls presented a high concentration of insulin 
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containing vesicles in the cytoplasm, roundly shaped and differing in size with a dense and 
irregular formed core surrounded by a bright halo. In contrast, sections of transgenic MPHs 
showed a diminished amount of vesicles that appeared smaller inside the cell. Cores were partly 
electron lucent and had a narrow halo. This suggests that β-cells of INSC94Y transgenic MPHs 
contained a reduced number of insulin-filled vesicles compared to non-transgenic controls. 
Another microscopic dissimilarity between the β-cells of INSC94Y transgenic and non-transgenic 
MPHs was the enlargement of the ER observed in transgenic MPHs, noticeable as a dilatation 
at the cross-sectional areas of the ER in the β-cells. Enlarged ER in the cytoplasm is indicative 
for ER stress in the β-cells of INSC94Y transgenic MPHs. ER stress initiates different signalling 
pathways, cumulatively called the unfolded protein response (UPR). The retention of unfolded 
proinsulin in the ER lumen creates stress. Subsequently, UPR is activated by an intracellular 
stress signal transduction in the ER as a safety mechanism of the β-cell (reviewed in (Ron and 
Walter 2007)). The key mechanisms of the UPR aim to attenuate the ER load and to remodel 
the secretory apparatus of the cell by decreased translation of new preproinsulin, increased 
degradation of misfolded proinsulin and activation of more ER-resident chaperones. These 
mechanisms are predominantly regulated through at least three ER transmembrane proteins: the 
ribonuclease inositol-requiring protein-1 (IRE-1), the PERK kinase homologue PEK-1 and 
activating transcription factor-6 (ATF-6) (Henis-Korenblit, Zhang et al. 2010). The visible 
expansion of the ER that was detected in the β-cells of INSC94Y transgenic MPHs is probably 
part of the ER stress response, as a further mechanism to improve the capacity of the ER to 
process the retained misfolded mutant proinsulin (Cox, Chapman et al. 1997). Overwhelming 
cell stress can ultimately induce β-cell death through different apoptotic pathways and would 
explain the striking loss of β-cells detected by quantitative-stereological analyses and 
ultrastructural changes observed by electron microscopy in INSC94Y transgenic MPHs and are 
also in accordance with the reduced insulin secretion detected in these animals (see chapter 
5.2.1). 
Correspondingly, reduction of insulin granules and alterations of the ER structure within the β-
cells were observed in other animal models with insulin mutation. Despite an irregular shaped 
core of β-cells in swine and roundly shaped core of β-cells in mice, ultrastructure of β-cells and 
characteristics of insulin containing vesicles were found similar in swine and mice (round 
vesicles with a dense core and a wide and lucent halo) (Kayo and Koizumi 1998, Herbach, 
Rathkolb et al. 2007, Renner, Braun-Reichhart et al. 2013). Electron microscopy in INSC94Y 
transgenic DPs showed a reduced amount of insulin granules at the age of four and a half months 
compared to wild-type littermates. Enlargement of the ER was already detected to a small extent 
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at the age of eight days and prior to β-cell mass reduction in these pigs. In four and a half-
month-old INSC94Y transgenic DPs ER revealed severe dilation in comparison to wild-type 
controls, respectively (Renner, Braun-Reichhart et al. 2013). Homozygous Akita mice also 
showed a reduced number and a smaller appearance of insulin granules after a few weeks of 
postnatal life (Kayo and Koizumi 1998) and almost no granules were left or seemed immature 
in β-cells of heterozygous Munich Ins2C95S mutant mice compared to wild-types, respectively 
(Herbach, Rathkolb et al. 2007). Both Akita and Munich Ins2C95S mutant mice showed enlarged 
ER and furthermore mitochondria were dilated or started to denature. However, mitochondrial 
alterations were not observed in INSC94Y transgenic DPs and MPHs. Other typical signs like 
chromatin condensation, nuclear fragmentation or apoptotic body formation were not found, 
although their presence is not required to prove β-cell apoptosis (Herrera, Harlan et al. 2000). 
Actually, their occurrence depends on the apoptotic pathway activated (Herrera, Harlan et al. 
2000). Besides β-cell death due to mutant proinsulin-mediated ER stress response as assumed 
in INSC94Y transgenic MPHs, it is suggested that ER stress-triggered apoptotic pathways can be 
activated by cholesterol accumulation and obesity, a state involved in the development of T2D 
(Ozcan, Cao et al. 2004, Marchetti, Bugliani et al. 2007). Another induction of β-cell apoptosis 
can be cytokine-mediated and contributes to the damage of β-cells in T1D in humans (Cardozo, 
Ortis et al. 2005, Marhfour, Lopez et al. 2012). Besides electron microscopy to visualize 
characteristics of apoptosis or ER alterations in β-cells, the determination of ER stress marker 
expression by antibody immunostaining intensity or Western blot are valid methods for 
quantitative and qualitative analysis of ER stress response. Relevant markers for ER stress, e.g., 
C/EBP homologous protein (CHOP), immunoglobulin heavy chain (BIP) and X-box binding 
protein 1 (XBP-1) are the downstream components of different ER transmembrane proteins 
(Bertolotti, Zhang et al. 2000, Yang, Diiorio et al. 2013). Further investigation of ER stress 
markers in INSC94Y transgenic MPHs could be informative about signalling pathways activated 
by UPR due to the expression of mutant proinsulin compared to humans and further clarify the 
role of β-cell apoptosis as pathophysiological basis and as a therapy target for diabetes disease. 
Diabetic β-cell apoptosis is multifactorial and yet insufficiently understood. Besides ER or 
cytoplasmic stress-mediated β-cell death, several processes including inflammation, DNA 
damage or accumulation of micro-RNAs are suggested to contribute to the demise of pancreatic 
β-cells and are currently under investigation (Robertson, Harmon et al. 2004, Halban, Polonsky 
et al. 2014, Belgardt, Ahmed et al. 2015). Another reason to elucidate β-cell apoptosis and 
counter-regulatory mechanisms is its importance for allogenic islet transplantation, a promising 
treatment for T1D (Sakata, Yoshimatsu et al. 2012, Sakata, Yoshimatsu et al. 2018). Pancreatic 
tissue is highly sensitive and the explanted organ has a short durability compared to other 
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abdominal organs. Major problems of many islet transplantation methods are severe tissue 
damage of the transplant and subsequent graft loss (reviewed in (Sakata, Yoshimatsu et al. 
2018)). A promising implantation site for pancreatic islets is the spleen, which is rich of 
mesenchymal stem cells that can contribute to the repair of implanted damaged tissue (reviewed 
in (Limana, Germani et al. 2005, Sakata, Yoshimatsu et al. 2018)).  
5.3.3 Diabetes-related secondary alterations in organs of INSC94Y transgenic MPHs 
Diabetes is a complex metabolic disorder that not only causes derailed blood glucose but can 
lead to secondary alterations in other organs of the body. Secondary alterations can occur when 
there is a persistent elevation of glucose concentration in the blood that starts to affect blood 
vessels and organ tissues but the exact triggers of diabetes-related secondary alterations are still 
poorly understood (Camera, Hopps et al. 2007). Prolonged disease duration is a crucial factor 
as most, but not all secondary lesions only appear after years of exposure to hyperglycemia. 
Atherosclerotic changes lead to macroangiopathies including cardio- and cerebrovascular 
diseases such as myocardial infarction and stroke. Alterations in the small vessels accompanied 
by disturbed blood flow and increased vascular permeability result in microangiopathies like 
nephro-, neuro- and retinopathies. Lesions within the cell membrane of the lens cause 
cataractogenesis. Since hyperglycemia is seen as a relevant trigger for diabetic secondary 
diseases (Brownlee 2001), kidney and lens of INSC94Y transgenic and non-transgenic MPHs 
were examined to evaluate the diabetic effect of the mutant insulin C94Y. Additionally, organ 
weights were evaluated. 
In non-transgenic MPHs all absolute organ weights were significantly reduced compared to 
wild-type DPs, besides of lung and stomach weight that was just slightly but not significantly 
decreased. The reduced absolute organ weight correlated with the lower BW in wild-type 
MPHs. Relative organ weights of non-transgenic MPHs did not reveal significant alterations, 
except of the spleen with a reduced weight of 53% in comparison to wild-type DPs. This 
discrepancy in weight likely results from different blood volumes that retained in the spleen 
after bleeding.  
The absolute organ weights of INSC94Y transgenic MPHs were all proportionally decreased for 
at least 30% (except of the kidneys and the brain) compared to control littermates due to general 
growth retardation as a consequence of impaired insulin secretion. Relative organ weights of 
INSC94Y transgenic MPHs showed an increase of more than 30% except of the relative weight 
of the spleen and the carcass which were diminished compared to non-transgenic MPHs. The 
kidneys showed the most pronounced alteration of relative organ weight with an increase of 
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88%. These results could indicate a renal hypertrophy or hypercellularity in INSC94Y transgenic 
MPHs. In humans, renal hypertrophy is one of the first structural alterations within the course 
of diabetic nephropathy. About 20–40% of patients with T1D or T2D develop diabetic 
nephropathy usually within 10–15 years of disease duration (Molitch, DeFronzo et al. 2004). 
There are characteristic changes that can be expected in a diabetic nephropathy at the 
histological level. Thickening of the glomerular basement membrane and an expansion of the 
mesangial matrix including the formation of nodular or diffuse glomerulosclerotic alterations 
were already described in 1936 by Kimmelstiel and Wilson (Kimmelstiel and Wilson 1936). 
Furthermore thickening of the intima and hyalinosis of arteries and arterioles, tubular atrophy 
and interstitial fibrosis are common histological changes that can be detected by a light 
microscope (Amann and Benz 2013). Therefore, histopathological analyses of the kidneys from 
INSC94Y transgenic MPHs and non-transgenic littermates at an age of six months were 
performed using a light microscope. The majority of the sections analysed did not reveal any 
histopathological alterations. Occasionally, single altered glomerular mesangia characterized 
by slight hypercellularity were detected in transgenic as well as in non-transgenic MPHs. These 
sporadic pathological findings do not verify a diabetes-associated kidney disease. Kidney 
alterations may not be expected within this short observation period of six months, whereas in 
humans it can take years until remarkable changes appear. In accordance with the results of 
INSC94Y transgenic MPHs, the INSC94Y transgenic DP line did neither show any 
histopathological findings nor clinical symptoms of renal damage like albuminuria, which 
could indicate diabetic nephropathy in an observation period of two years (Renner, Braun-
Reichhart et al. 2013, Blutke, Renner et al. 2017). Distinct lines of Akita Ins2C96Y mutant mice 
showed glomerular hypertrophy, but just in some of them additional pathological alterations 
like an increase of mesangial matrix were detected (Gurley, Mach et al. 2010). This indicates 
additional triggering factors that may or may not be involved depending on the genetic 
background. 
Diabetic patients have a probability of 66% to develop a cataract (Raman, Pal et al. 2010) which 
is recognized as one of the earliest secondary complications of diabetes mellitus (Stefek 2011). 
Cataract development is associated with chronic hyperglycemia inducing ER stress and 
subsequently activating the UPR in lenticular cells (Ikesugi, Yamamoto et al. 2006). For these 
reasons, eye globes of six-month-old INSC94Y transgenic and non-transgenic MPHs were 
histopathologically evaluated for diabetes-associated cataract. In transgenic MPHs multifocal 
hydropic degeneration, swelling and disarray of the lenticular fibres were detected. Hydropic 
degeneration of the lens is associated with an increased activity of the polyol pathway and the 
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excess production of advanced glycation end products (AGE) in the eye lens (Brownlee 1995). 
Transformation from glucose to sorbitol and fructose that is catalysed by aldose reductase (AR) 
and the non-enzymatic reaction of glucose with lipids or proteins to AGEs lead to the 
accumulation of these metabolites and initiates intracellular osmotic stress (Reddy, Giridharan 
et al. 2012). Besides non-enzymatic protein glycation and osmotic stress, oxidative stress is 
another main factor in cataract development and can be detected in lenticular cells (Spector 
1995). Together, these factors trigger the UPR and furthermore reactive oxygen species (ROS) 
and cell apoptosis emerge and result in cataract formation (Lee and Chung 1999, Mulhern, 
Madson et al. 2006). The lenticular cortex of INSC94Y transgenic MPHs developed cyst-like 
cavities and multifocal eosinophilic globules were detected. These globules are probably 
accumulations of protein released from the destruction of cortical cell walls, named morgagnian 
globules, and are characteristic for cataract (Aliancy and Mamalis 1995). These structural 
changes repeal the even architecture of the lens tissue. In contrast, the wild-type littermates 
showed a smooth arrangement of lenticular fibres in parallel lines. No alteration of the lens was 
detected in this control group. Based on these findings, it can be claimed that a diabetic 
cataractogenesis was present in INSC94Y transgenic MPHs. These findings in the lens are 
consistent with a progressive diabetic cataract observed in INSC94Y transgenic DPs (Renner, 
Braun-Reichhart et al. 2013). A cataract appears as a turbidity of the lens and leads to a decrease 
of visual acuity. Dissected lenses of 8-day-old INSC94Y transgenic DP piglets, slightly 
magnificated by a light microscope, showed already a lack of transparency at the edges of the 
lens which was reversible to some degree in transgenic littermates treated with exogenous 
insulin. In addition, lenses of four and a half-month-old INSC94Y transgenic DPs appeared 
completely tarnished, demonstrating a diabetes-induced progressive cataractogenesis (Renner, 
Braun-Reichhart et al. 2013) Similar results were found in rat models (Sai Varsha, Raman et al. 
2014) but not in mice, which are known to have lower levels of AR in their lenses and for this 
reason normally do not develop a diabetic cataract (Lee, Chung et al. 1995). 
5.3.4 Conclusions and outlook 
INSC94Y non-transgenic MPHs show a remarkable lower BW and BS due to minipig 
crossbreeding. Moreover, INSC94Y transgenic MPHs exhibit a severe growth retardation and 
alteration in body composition concerning fat and lean mass due to the expression of mutant 
INS. Like INSC94Y transgenic DPs, INSC94Y transgenic MPHs develop a progressive diabetic 
phenotype. Also, the impaired glycemic control likely is initially provoked by disturbed 
trafficking or secretion of proinsulin until the retention of misfolded mutant proinsulin in the 
ER induces apoptosis of insulin producing β-cells. This accelerating ER stress response leads 
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to a significant reduction of the total β-cell volume and consequently to an insufficient insulin 
supply in INSC94Y transgenic MPHs with advanced age. A diabetic cataract manifests in the 
lenses of INSC94Y transgenic MPHs. However, diabetes-related secondary alterations in the 
kidneys are not observed until the age of six months. Nevertheless, the aim to create a size-
reduced swine model expressing the C94Y mutant insulin that reflects phenotypic findings and 
basic disease mechanisms of the previously well investigated INSC94Y transgenic DP model and 
the Ins2C96Y mouse model was achieved. The results of INSC94Y transgenic MPHs complements 
previously captured data of the INSC94Y transgenic DP model and clinical and diagnostic 
findings in swine resemble the features found in humans with PNDM. Therefore, the INSC94Y 
transgenic MPH is a powerful translational model with the benefit of BW and BS of a smaller 
pig breed which is more similar to human dimensions. The reduced BW is providing a particular 
advantage regarding compound-related costs for the development of new drug treatments. 
Moreover, the decreased BS is an important attribute for long-scale or multigenerational studies 
in terms of easier handling of fully grown pigs and minimised maintenance costs. More long-
term studies are necessary to investigate diabetes-related secondary alterations in organs like 
kidneys, nerves or arterial vessels that occur in humans after several years of suffering from 
diabetes but are not present in up to two-year-old INSC94Y transgenic pigs yet. The Munich 
MIDY Pig Biobank contains a high number of tissue samples and body fluids of two-year-old 
female INSC94Y transgenic pigs so far but can benefit from additional samples from other age 
groups or other genetic backgrounds as the INSC94Y transgenic MPH model. The size-reduced 
INSC94Y transgenic MPH is also an appropriate model for questions of preconceptional diabetes 
mellitus or gestational diabetes mellitus, where multigenerational investigation is indispensable 
to evaluate intrauterine effects of maternal diabetes or later consequences on offspring. One of 
the promising approaches to treat severe diabetes is islet transplantation. Investigations in this 
field can be perfectly addressed using INSC94Y transgenic MPHs, serving as recipients of 
transplants. The BS of these pigs enables the use of standard surgical methods. For this, imaging 
diagnostics of current human medicine, new surgical techniques or image analysis can be tested. 
Moreover, the possibility of qualitative histological and quantitative stereological analyses of 
pancreatic tissue enables a detailed evaluation of islet grafts. 
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6 SUMMARY 
Establishment and characterization of a size-reduced, diabetic pig model by 
minipig crossbreeding 
In the last two decades many new mutations in the human insulin gene have been discovered 
and are accountable for a variety of forms of monogenic diabetes. The mutations are located at 
different regions within the insulin gene and have different effects on the individual steps of 
insulin biosynthesis in pancreatic β-cells. The majority of insulin mutations cause a misfolding 
of proinsulin that retains in the endoplasmic reticulum of the cell and can subsequently lead to 
different forms of non-autoimmune permanent neonatal diabetes mellitus. Probably the best 
investigated mutation in this group is the human INSC96Y mutation, which is analogous to the 
Ins2C96Y mutant mouse model as well as to the INSC94Y transgenic domestic pig (DP) model. In 
mice, pigs and humans, this mutation results in a diabetic phenotype named MIDY (mutant INS 
gene induced diabetes of youth) that can be diagnosed predominantly within the first weeks of 
life by an impaired insulin supply and subsequent hyperglycemia. The Ins2C96Y mutant mouse 
model already elucidated underlying pathomechanisms of the disease but rodents have 
limitations in translational research. To establish a size-reduced porcine model for preclinical 
trials, INSC94Y transgenic domestic pig-minipig hybrids (MPHs) were generated that mimic 
diabetic conditions in humans and correspond to the INSC94Y mutation of the previously 
established transgenic DP model. Therefore, physiological (body weight gain, growth 
parameters, body composition, absolute and relative organ weight and blood parameters) and 
morphological (volume density, total volume and total volume to BW ratio of β- and α-cells 
within the pancreas and ultrastructure of β-cells) parameters of INSC94Y transgenic MPHs and 
non-transgenic littermates were analysed in regular intervals up to an age of six months. Age-
matched wild-type domestic pigs served as controls to evaluate differences related to the genetic 
background but not the expression of the mutant insulin C94Y.  
Non-transgenic MPHs showed already at birth a reduced BW and body height and at the age of 
six months a remarkable reduction of BW, body length and body height by 39%, 22% and 25% 
compared to age-matched DPs, respectively. INSC94Y transgenic MPHs showed a significant 
reduction in BW starting from eleven weeks of age and after six months they reached a 
reduction of BW, body length and body height by 55%, 19% and 20% compared to non-
transgenic littermates, respectively. Moreover, body composition of six-month-old pigs was 
determined by Dual-energy X-ray Absorptiometry. Non-transgenic MPHs and DPs showed 
comparable results with a tendency of increased fat mass in MPHs. In contrast, INSC94Y 
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transgenic MPHs showed a 60% decreased relative fat mass (p<0.001), a 12% increased relative 
lean mass (p<0.001) and 27% reduced bone mineral density (p<0.001) compared to non-
transgenic littermates. Fasted blood glucose and plasma insulin levels of non-transgenic MPHs 
matched reference ranges defined for normoglycemic minipigs, that on average are lower than 
for DPs. INSC94Y transgenic MPHs revealed a hyperglycemic status and reduced insulin 
secretion within the first week of life. Clinical chemical parameters of six-month-old INSC94Y 
transgenic MPHs showed a hypertriglyceridemia and a significantly reduced creatinine level in 
comparison to non-transgenic controls. Quantitative-stereological analyses of pancreatic tissue 
of INSC94Y transgenic MPHs showed a 69% reduction of the total β-cell volume related to BW 
(p<0.05), though the relative pancreas weight of these pigs was increased by 60% (p<0.05) 
compared to non-transgenic littermates. Pancreatic islets of INSC94Y transgenic MPHs appeared 
to be smaller and with an altered architecture as a consequence of massive β-cell loss. 
Ultrastructural evaluation of β-cells from INSC94Y transgenic MPHs by electron microscopy of 
β-cells of INSC94Y transgenic MPHs showed a reduced appearance of insulin containing vesicles 
and an enlargement of the endoplasmic reticulum. Although relative kidney weight was 
significantly increased in INSC94Y transgenic MPHs, histological analyses of renal tissue of six-
month-old INSC94Y transgenic MPHs did not verify a diabetic nephropathy. However, the 
animals developed a diabetic cataract within six months of life. In summary, crossbreeding of 
minipig into the pre-existing INSC94Y transgenic DP model was successful. The obtained results 
verify a consistent diabetic phenotype of INSC94Y transgenic MPHs and a substantial BW and 
growth reduction of non-transgenic MPHs. Besides an easier handling of the animals, lowered 
BW has a great economic benefit. This is particularly true for testing of novel compounds. 
Further, a size-reduced porcine model is more suitable for long-term studies, e.g., to 
complement the evaluation on pathological alterations in secondary organs associated with 
prolonged disease duration or to facilitate multigenerational studies.  
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7 ZUSAMMENFASSUNG 
Etablierung und Charakterisierung eines größenreduzierten, diabetischen 
Schweinemodels durch die Einkreuzung einer Minipiglinie 
In den letzten zwei Jahrzehnten wurden viele neue Mutationen im humanen Insulingen 
entdeckt, die für eine Vielzahl von Formen des monogenen Diabetes verantwortlich sind. Die 
Mutationen befinden sich in verschiedenen Regionen innerhalb des Insulingens und zeigen 
unterschiedliche Auswirkungen auf die einzelnen Schritte der Insulinbiosynthese in den β-
Zellen des Pankreas. Die Mehrheit der Insulinmutationen bewirkt eine Fehlfaltung von 
Proinsulin, welches sich im endoplasmatischen Retikulum der Zelle ansammelt und 
nachfolgend zu verschiedenen Formen von nicht-autoimmunem permanenten neonatalen 
Diabetes mellitus führen kann. Die wohl am besten untersuchte Mutation dieser Gruppe ist die 
humane INSC96Y Mutation, welche analog ist zu der Ins2C96Y Mutation im Akita Mausmodell 
sowie zu der INSC94Y Mutation im transgenen Hausschweinemodell. In Mäusen, Schweinen und 
Menschen führt diese Mutation zu einem diabetischen Phänotyp, der sich MIDY (mutant INS 
gene induced diabetes of youth) nennt und oft bereits in den ersten Lebenswochen durch eine 
gestörte Insulinversorgung mit nachfolgender Hyperglykämie diagnostizierbar ist. Durch das 
mutante Ins2C96Y Akita Mausmodell konnten bereits wichtige zugrundeliegende 
Pathomechanismen der Krankheit erläutert werden. Nagermodelle weisen jedoch bestimmte 
Limitierungen im Hinblick auf die translationale Forschung auf. Um ein größenreduziertes 
Schweinemodel für präklinische Studien zu etablieren, das den diabetischen Zustand im 
Menschen wiederspiegelt und die Mutation des zuvor etablierten INSC94Y transgenen 
Hausschweinemodels trägt, wurden INSC94Y transgene Hausschwein-Minipig Hybriden 
(MPHs) generiert. Dazu wurden physiologische (Körpergewichtszunahme, 
Wachstumsparameter, Körperzusammensetzung, absolute und relative Organgewicht und 
Blutparameter) und morphologische (Volumendichte, Gesamtvolumen und Gesamtvolumen 
bezogen auf das Körpergewicht von β- und α-Zellen im Pankreas und die Ultrastruktur von β-
Zellen) Merkmale von INSC94Y transgenen MPHs und ihren nicht-transgenen Wurfgeschwistern 
in regelmäßigen Intervallen bis zu einem Alter von sechs Monaten ausgewertet. Wildtyp 
Hausschweine im gleichen Alter dienten als Kontrolle um Unterschiede bezogen auf den 
genetischen Hintergrund und nicht auf die Expression der Insulinmutante C94Y evaluieren zu 
können. 
Die nicht-transgenen MPHs zeigten bei Geburt ein reduziertes Körpergewicht und eine 
reduzierte Körperhöhe. Im Alter von sechs Monaten erreichten sie eine Reduktion von 
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Körpergewicht, Körperlänge und Körperhöhe von jeweils 39%, 22% und 25% im Vergleich zu 
Hausschweinen des gleichen Alters. Die INSC94Y transgenen MPHs zeigten ab Woche elf nach 
der Geburt eine signifikante Gewichtsabnahme und erreichten sechs Monaten post partum eine 
Reduktion von Körpergewicht, Körperlänge und Körperhöhe von jeweils 55%, 19% und 20% 
verglichen mit ihren nicht-transgenen Wurfgeschwistern. Darüber hinaus wurde die 
Körperzusammensetzung der sechs Monate alten Schweine mittels Dual-Röntgen-
Absorptiometrie ermittelt. Hierbei wiesen die nicht-transgenen MPHs vergleichbare Werte zu 
den Hausschweinen auf mit einer tendenziell erhöhten Fettmasse bei den MPHs. Im Gegensatz 
dazu zeigten INSC94Y transgene MPHs eine 60% geringere relative Fettmasse (p<0.001), eine 
um 12% erhöhte relative Magermasse (p<0.001) und eine um 27% verringerte 
Knochenmineraldichte (p<0.001) im Vergleich zu den nicht-transgenen Wurfgeschwistern. Die 
gefasteten Blutglukose- und Plasmainsulinwerte nicht-transgener MPHs entsprachen den 
Referenzwerten von normoglykämischen Minipigs, die durchschnittlich niedriger sind als bei 
Hausschweinen. INSC94Y transgene MPHs zeigten einen hyperglykämischen Zustand und eine 
reduzierte Insulinsekretion innerhalb der ersten Lebenswoche. Klinisch-chemische Parameter 
von sechs Monate alten INSC94Y transgenen MPHs zeigten eine Hypertriglyceridämie und 
signifikant reduzierte Kreatininwerte im Vergleich zu den nicht-transgenen Wurfgeschwistern. 
Quantitativ-stereologische Auswertungen des Pankreasgewebes von sechs Monate alten 
INSC94Y transgenen MPHs zeigten eine körpergewichtsbezogene Abnahme des Gesamt-β-
Zellvolumens von 69% (p<0.05), wobei das körpergewichtsbezogene Pankreasgewicht dieser 
Schweine gegenüber den Kontrolltieren um 60% (p<0.05) erhöht war. Die Langerhansschen 
Inseln der INSC94Y transgenen MPHs erschienen kleiner und als Konsequenz des massiven β-
Zell Verlusts zeigten sie eine veränderte Architektur. Die Ultrastruktur der β-Zellen von 
INSC94Y transgenen MPHs zeigte bei der elektronenmikroskopischen Untersuchung ein 
verringertes Vorkommen von insulingefüllten Vesikeln und ein dilatiertes endoplasmatisches 
Retikulum. Obwohl das körpergewichtsbezogene Nierengewicht hochgradig erhöht war 
erbrachte eine histologische Untersuchung des Nierengewebes von sechs Monate alten INSC94Y 
transgenen MPHs keinen Hinweis auf eine diabetische Nephropathie. Jedoch entwickelten die 
Tiere innerhalb von sechs Monaten einen diabetesbedingten Katarakt. Zusammenfassend kann 
man sagen, dass die Einkreuzung einer Minipiglinie in das bereits bestehende INSC94Y transgene 
Hausschweinemodell erfolgreich war. Die erhobenen Befunde bestätigten einen konstanten 
diabetischen Phänotyp der INSC94Y transgenen MPHs und eine erhebliche Gewichts- und 
Größenreduktion der nicht-transgenen MPHs. Neben einer einfacheren Handhabung der Tiere 
bringt ein verringertes Körpergewicht auch einen großen ökonomischen Vorteil mit sich. Vor 
allem bei der Testung von neuen Wirkstoffen ist dies ausschlaggebend. Außerdem bietet sich 
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ein kleineres Schweinemodell vor allem für Langzeitstudien an um die Untersuchung 
diabetischer Langzeitfolgen zu komplementieren oder um generationsübergreifende 
Studiendesigns besser umsetzen zu können.  
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